Form 10-Q MILESTONE SCIENTIFIC For: Mar 31

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

For the quarterly period ended March 31, 2016

Or

For the transition period from                      to                     

Commission File Number: 001-14053

 

MILESTONE SCIENTIFIC INC.

(Exact name of registrant as specified in its charter)

 

 

220 South Orange Avenue, Livingston, New Jersey 07039

(Address of principal executive offices)

(973) 535-2717

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Securities registered pursuant to section 12(g) of the Act:                    NONE

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    o  Yes    þ   No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     o  Yes    þ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.     þ  Yes    £  No

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     o  Yes    þ  No

As May 16, 2016, the Issuer had a total of 21,687,164 shares of Common Stock, $.001 par value, outstanding.

 

 

 

 

---

MILESTONE SCIENTIFIC INC.

TABLE OF CONTENTS

PART I—FINANCIAL INFORMATION

 

 

 

 

2

---

FORWARD-LOOKING STATEMENTS

When used in this Quarterly Report on Form 10-Q, the words “may”, “will”, “should”, “expect”, “believe”, “anticipate”, “continue”, “estimate”, “project”, “intend” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding events, conditions and financial trends that may affect Milestone Scientific’s future plans of operations, business strategy, results of operations and financial condition. Milestone Scientific wishes to ensure that such statements are accompanied by meaningful cautionary statements pursuant to the safe harbor established in the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and the actual results may differ materially from those included within the forward-looking statements as a result of various factors. Such forward-looking statements should, therefore, be considered in light of various important factors, including those set forth herein and others set forth from time to time in Milestone Scientific’s reports and registration statements filed with the Securities and Exchange Commission (the “SEC”). Milestone Scientific disclaims any intent or obligation to update such forward-looking statements.

 

Milestone Scientific has rights to the following trademarks: CompuDent^®, CompuMed^®, CompuFlo^®, The Wand^®, The Wand Plus^®, The SafetyWand^®, Dynamic Pressure Sensing Technology^®, and STA Single Tooth Anesthesia^™ (STA Instrument, instruments and handpieces).

3

---

MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

See Notes to Condensed Consolidated Financial Statements

 

 

4

---

MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

See Notes to Condensed Consolidated Financial Statements

 

 

5

---

MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

THREE MONTHS ENDED MARCH 31, 2016

(Unaudited)  

 

 

See Notes to Condensed Consolidated Financial Statements

 

 

6

---

MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

 

 

See Notes to Condensed Consolidated Financial Statements

 

 

7

---

MILESTONE SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

ORGANIZATION, BUSINESS AND BASIS OF PRESENTATION

Milestone Scientific Inc. and Subsidiaries, (collectively “Milestone Scientific”, “our”, “us” or “we”) was incorporated in the State of Delaware in August 1989. Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery instrument, through the use of The Wand®, a single use disposable handpiece. The instrument is marketed in dentistry under the trademark CompuDent®, Wand Plus® and STA (Single Tooth Anesthesia) ^TM and in medicine under the trademark CompuMed®. CompuDent® is suitable for all dental procedures that require local anesthetic. CompuMed® and Wand Plus are suitable for many medical procedures regularly performed in Plastic Surgery, Hair Restoration Surgery, Podiatry, Colorectal Surgery, Dermatology, Orthopedics and a number of other disciplines. The instruments are sold in the United States and in over 47 countries abroad. Milestone Scientific’s products are manufactured by a third-party contract manufacturer.

In July 2014, Milestone Scientific acquired all of the 750,000 outstanding shares of an inactive Florida corporation and changed its name to Wand Dental, Inc. (“Wand Dental”).  In September 2014, that corporation was merged into a Delaware corporation, retaining the same name and capitalization. On July 1, 2014, Wand Dental was capitalized with cash and received Milestone Scientific’s dental business and related dental assets including the exclusive license of Milestone Scientific’s, patents, trademarks, and technology for use in the dental marketplace. Wand Dental is consolidated into Milestone Scientific.

The unaudited consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2015 included in Milestone Scientific Annual Report on Form 10-K.

In the opinion of management, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present Milestone Scientific’s financial position as of March 31, 2016 and the results of its operations for the three months then ended.

The results reported for the three months ended March 31, 2016 are not necessarily indicative of the results of operations which may be expected for a full year.

Milestone Scientific has incurred operating losses and negative cash flows from operating activities since its inception, except for 2013. Milestone Scientific is actively pursuing the generation of revenue, positive operating income and net income. The capital raised in May 2014, provided Milestone Scientific with the opportunity to continue to develop and commercialize additional medical instruments and aggressively market the dental instruments throughout the world. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses. As of March 31, 2016 Milestone Scientific believes that with the new distribution agreement with Henry Schein Inc. (effective January 1, 2016), the world’s largest supplier of medical, dental and veterinary supplies and devices, that dental revenue is projected to improve in the upcoming 12 months. To further reduce our expenditures, Milestone Medical’s expenses related to USA FDA clearance for the epidural and intra-articular instruments can be controlled as required to meet Milestone Scientific’s budget. Milestone Scientific has completed a detailed cash flow projection for the upcoming 12 months and has concluded that by limiting the FDA related expenses and increasing the dental instrument revenue through the new distribution agreement, management believes that Milestone Scientific will have sufficient cash reserves to meet all of its anticipated obligations over the next twelve months.       

 

 

8

---

NOTE – 1 SUMMARY OF ACCOUNTING POLICIES

The accompanying consolidated financial statement have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including Wand Dental, as well as Milestone Medical Inc. (“Milestone Medical”) and Milestone Education LLC (“Milestone Education”), both variable interest entities for which Milestone Scientific is the primary beneficiary. All significant, intra-entity transactions and balances have been eliminated in the consolidation.   

A Variable Interest Entity (VIE) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE.

If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary, and if not, does not consolidate. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision making ability over key operational functions within the entity

Assets recognized as a result of consolidating VIEs do not represent additional assets that could be used to satisfy claims against Milestone Scientific’s general assets. Conversely, liabilities recognized as a result of consolidating these VIEs do not represent additional claims on Milestone Scientific’s general assets; rather, they represent claims against the specific assets of the consolidated VIEs.

Milestone Scientific is the primary beneficiary of Milestone Medical, and Milestone Education, as variable interest entities. Accordingly, the assets and liabilities of Milestone Medical and Milestone Education are included in the accompanying consolidated financial statements. Please refer to Note 4 for further details regarding the treatment of the variable interest entity.

Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. A majority of credit sales are due within ninety days from invoicing. There have not been any significant credit losses reported by Milestone Scientific.

 

Milestone Scientific does not accept non-defective returns from its customers. Product returns under warranty are accepted, evaluated and repaired or replaced in accordance with the Warranty Policy.  Returns not within the Warranty Policy are evaluated and the customer is charged for the repair.

Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.

 

9

---

Investments in which we have the ability to exercise significant influence, but do not control, are accounted for under the equity method of accounting and are included in the long term assets on the Consolidated Balance Sheet. Under this method of accounting, our share of the net earnings or losses of the investee is presented below the income tax line on the Consolidated Statement of Operations since the activities of the investee are not closely aligned with the operations of Milestone Scientific. We evaluate our equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments may be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period.

 

Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from five to seven years. The costs of maintenance and repairs are charged to operations as incurred.

Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. Although certain patents have not yet been approved, the costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. If the applicable patent application is ultimately rejected, the remaining unamortized balance will be expensed in the period in which Milestone Scientific receives a notice of such rejection. Patent applications filed and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries may be different from patent protection under United States laws and may not be favorable to Milestone Scientific Milestone Scientific also attempts to protect the proprietary information through the use of confidentiality agreements and by limiting access to the facilities. There can be no assurance that the program of patents, confidentiality agreements and restricted access to the facilities will be sufficient to protect the proprietary technology.

Milestone Scientific reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amounts may not be recoverable. The carrying value of the assets is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets. Milestone Scientific adjusts the net book value of an underlying asset if its fair value is determined to be less than its net book value. Milestone Scientific has reviewed long-lived assets for impairment and concluded no impairment exists as of March 31, 2016.

Revenue from product sales is recognized net of discounts and allowances to domestic distributors on the date of shipment for essentially all shipments, since the shipment terms are FOB warehouse. Milestone Scientific will recognize revenue on date of arrival of the goods at the customer’s location, where shipments are FOB destination. Shipments to international distributors are FOB warehouse, therefore revenue is recognized on shipment of the goods. In all cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone Scientific has no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific’s only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period 

Milestone Scientific includes shipping and handling costs in cost of goods sold. These costs are billed to customers at the time of shipment for domestic shipments. International shipments are FOB warehouse, therefore no costs are incurred by Milestone Scientific.

10

---

Research and development costs, which consist principally of new product development costs payable to third parties, are expensed as incurred.

Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The income tax provision or credit is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. The FASB continues to release guidance clarifying certain aspects of the revenue guidance.  We do not believe that this new accounting pronouncement will have a material impact on our financial statements.

In November 2015, the FASB issued guidance simplifying the balance sheet classification of deferred taxes. The new guidance requires that all deferred taxes be presented as noncurrent, rather than separated into current and noncurrent amounts. The guidance is effective for reporting periods beginning after December 15, 2016 and early adoption is permitted. In addition, the adoption of guidance can be applied either prospectively or retrospectively to all periods presented. As of March 31, 2016 and 2015 there are no deferred tax assets or liabilities recorded.

In February 2016, the Financial Accounting Standards Board issued a new standard ASU No.2016-02, “Leases “ (Topic 842): The new standard is intended to increase transparency and comparability among organizations to recognize lease assets and liabilities on the balance sheet and disclose key information about leasing arrangements. It will be effective for fiscal years beginning after December 15, 2019 and for interim periods within fiscal years beginning after December 15, 2020. Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows.

In March 2016, the Financial Accounting Standards Board issued a new standard ASU No.2016-07, “Investments - Equity Method and Joint Ventures” (Topic 323): The new standard is intended to eliminate the requirement that when an investment qualifies for the use of the equity method as a result of an in increase in the level of ownership or degree of influence, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect all of the previous periods that the investment was held. It will be effective for all entities for fiscal years and interim periods, beginning after December 15, 2016. Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows.

In March 2016, the Financial Accounting Standards Board issued a new standard ASU No.2016-09, “Compensation – Stock Compensation” (Topic 718): The new standard is intended to clarify certain reporting aspects relating to stock based compensation, relating primarily to forfeitures, tax impacts and cash flow presentation.  Certain attributes will be treated prospectively, while others will require a retroactive application. Generally, the changes will be effective for fiscal years and interim periods, beginning after December 15, 2016. Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows

11

---

 

 

NOTE – 2 Basic and Diluted Net INCOME (Loss) Per Common Share

Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of Statement of Financial Accounting Standards ASC Topic 260. Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is similar to that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options, warrants, and the conversion of debt were issued during the period.

Since Milestone Scientific had net losses for 2016 and 2015, the assumed effects of the exercise of potentially dilutive outstanding stock options and warrants were not included in the calculation as their effect would have been anti-dilutive.  

For the three months ended March 31, 2016 and 2015, Milestone Scientific calculated basic and fully diluted earnings per common share as described in the previous paragraph.

 

 

NOTE – 3 ACCOUNTS RECEIVABLE

Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. A majority of credit sales are due within ninety days from invoicing.  

 

NOTE – 4 CONSOLIDATION OF VARIABLE INTEREST ENTITY

Milestone Medical

 

Milestone Medical is 49.98% owned by Milestone Scientific as of March 31, 2016. Milestone Scientific has been established to develop and commercialize intra-articular and epidural drug delivery instruments, utilizing an exclusive royalty-free license to Milestone Scientific’s CompuFlo technology. The license was contributed by Milestone Scientific for our initial ownership in Milestone Medical.

 

Since our initial investment in Milestone Medical we have accounted for the investment in accordance with the equity method of accounting. However, during 2015, Milestone Scientific provided short term bridge financing to Milestone Medical in anticipation of the completion of a secondary stock offering in the Polish Market. In December 2015, Milestone Medical suspended their capital raise efforts meriting re-consideration of the initial accounting for the investment as an equity method investment. In April 2016, Milestone Medical cancelled the uplisting of its shares to the Poland Warsaw Stock Exchange.

 

As a result of the change in circumstances around the proposed offering in December 2015 by Milestone Medical, we reevaluated the relationship between the two entities and the status of Milestone Medical as a VIE. We have concluded that Milestone Medical does not have sufficient capital at risk to support its activities without additional financial support from Milestone Scientific. As a result of these factors, we have concluded that the line of credit extended to Milestone Medical constitutes a variable interest in Milestone Medical and therefore Milestone Medical is consolidated at March 31, 2016.

Since the factors giving rise to concluding that Milestone Medical is a VIE happened so close to the end of fiscal year 2015, the acquisition date for measuring the consolidation of Milestone Medical has been deemed to be December 31, 2015.

Subsequent to March 31, 2016 Milestone Scientific acquired equity and voting control of Milestone Medical as a result of the acquisition of an additional 37% of the outstanding common stock of Milestone Medical by exchanging Milestone Medical shares for shares of Milestone Scientific common stock at a rate of two shares of Milestone Medical for one share of Milestone Scientific.

12

---

Milestone Education LLC

Milestone Education is a 50% owned subsidiary of Milestone Scientific which began operations in 2013 to provide training and education to our dentists throughout the world. Milestone Scientific accounts for its investment in Milestone Education using the equity method of accounting through December 31, 2015. Approximately 80% of the revenue earned by Milestone Education is from services performed for Milestone Scientific. As a result of this relationship, we concluded that we have the power to direct the activities that most significantly impact Milestone Education’s economic performance, and that it is a variable interest entity and should be consolidated in the financials of Milestone Scientific. As of December 31, 2015, the impact of the consolidation was deemed not to be material to the consolidated financial statements.

 

The financial statements of Milestone Medical, and Milestone Education are included in the accompanying consolidated financial statements as of March 31, 2016.

 

The financial information in the table below summarizes the combined results of operations of Milestone Scientific, and its subsidiaries including Milestone Medical and Milestone Education (each a variable interest entity) on a pro forma basis as though the companies had been combined as of the beginning of the earliest period presented. The pro forma financial information is presented for informational purposes only and is not indicative of the result of operations that would have been achieved if the consolidation had taken place at the beginning of the period presented.

 

 

 

NOTE – 5 INVESTMENT IN UNCONSOLIDATED SUBSIDIARIES

Advance Ocular Science SA      

Advanced Ocular Sciences SA is an entity organized to develop an instrument that delivers injections into the eyes. The company is a shell company as of March 31, 2016. Milestone Scientific owns 25% of this entity. As of the balance sheet date, no equity has been contributed to the company by Milestone Scientific. During 2015, Milestone Scientific advanced $78,798 for marketing and strategy planning to Advanced Ocular Sciences SA. Advanced Ocular

13

---

Sciences SA., or their organizers are obligated to repay this advance once the public offering is approved and funded in Poland during 2016. Advance Ocular Science SA was not included in the consolidated financial statements at March 31, 2016 as no investment has been made by Milestone Scientific.  

Milestone China Ltd.

In June 2014, Milestone Scientific agreed to invest $1 Million through the contribution of 772 STA instruments (at a distributor price of approximately $1,295 per instrument) for a forty percent ownership in Milestone China Ltd. (“Milestone China”).  In 2014, the instruments were shipped and were recorded as an investment in Milestone China at the cost of the inventory contributed. In January 2016, Milestone Scientific contributed 308 STA instruments with a retail value of approximately $400,000 ($1,296 per instrument) to Milestone China Inc. as an increase in our investment in this subsidiary. The additional contribution increased the Company’s investment by approximately $165,000 which represents the costs of the instruments and it did not increase the company’s percentage of ownership since the contribution is proportionate to the other shareholder contribution. Milestone Scientific recorded a loss on its investment in Milestone China of $164,837 and equity earnings $96,674 for the three months ended March 31, 2016 and 2015, respectively. Milestone’s investment in Milestone China was $0 and $445,325, at March 31, 2016 and 2015 respectively. Milestone Scientific had suspended losses on its investment in Milestone China of $177,291, as of March 31, 2016.

Milestone Scientific sold $1,000,000 in instruments during quarter ended March 31, 2016 to Milestone China. Milestone China Ltd. owes $825,340 to Milestone Scientific for instruments shipped in 2016, which is included in accounts receivable at March 31, 2016

Milestone Scientific recognizes the total revenue and costs of goods sold at the time the shipment of instruments and handpieces. However, due to timing differences of when the inventory is sold to Milestone China and when Milestone China sells the acquired inventory to third parties, elimination of the intra-entity profit is required as of the balance sheet date. In accordance with Accounting Standard Codification (“ASC”) 323 – Equity Method and Joint Ventures, Milestone Scientific has deferred the gross profit associated with inventory shipped to Milestone China that has not been sold to third parties The deferred profit of $174,670 is included in the loss from the Milestone China within the Statement of Operations and presented as a reduction of the accounts receivable in the Consolidated Balance Sheet.

 

NOTE – 6 Stock Option Plans

Milestone Scientific recognizes compensation expense on a straight line basis over the requisite service period and in the case of performance based options over the period of the expected performance. For the months ended March 31, 2016 and 2015, Milestone Scientific recognized $134,505 and $82,124 of total employee compensation cost related to options that vested each year, respectively. As of March 31, 2016 and 2015, there was $1,026,024 and $949,780 of total unrecognized compensation cost related to non-vested options which Milestone Scientific expects to recognize over a weighted average period of 2.99 years and 3.10 years as of March 31, 2016 and 2015, respectively.

A summary of option activity for employees under the plans and changes during the three months ended March 31, 2016, is presented below:

 

 

     

14

---

A summary of option activity for non-employees under the plans and changes during the three months ended March 31, 2016, is presented below: 

 

 

The fair value of the options was estimated on the date of grant using the Black Scholes option-pricing model.  As of March 31, 2016, Milestone Scientific recognized $1,175 expense related to non-employee options that vested.   

In accordance with the provisions of FASB ASC 505-50-15, all other issuances of common stock, stock options or other equity instruments to non-employees as consideration for goods or services received by Milestone Scientific are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of any options or similar equity instruments issued is estimated based on the Black-Scholes option-pricing model and the assumption that all of the options or other equity instruments will ultimately vest. Such fair value is measured as of an appropriate date pursuant to the guidance, (generally, the earlier of the date the other party becomes committed to provide goods or services or the date of performance by the other party is complete) and capitalized or expensed as if Milestone Scientific had paid cash for the goods or services.

 

NOTE – 7 CONCENTRATION OF CREDIT RISK

 

Milestone Scientific’s consolidated financial instruments that are exposed to concentrations of credit risk consist primarily of cash, trade accounts receivable, and advances on contracts. Milestone Scientific places its cash and cash equivalents with large financial institutions. At times, such investments may be in excess of the Federal Deposit Insurance Corporation insurance limit. Milestone Scientific has not experienced any losses in such accounts and believes it is not exposed to any significant credit risks. Financial instruments which potentially subject Milestone Scientific to credit risk consist principally of trade accounts receivable, as Milestone Scientific does not require collateral or other security to support customer receivables, and advances on contracts.  

Milestone Scientific closely monitors the extension of credit to its customers while maintaining allowances, if necessary, for potential credit losses. On a periodic basis, Milestone Scientific evaluates its accounts receivable and establishes an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions. Management has provided a reserve that it believes is sufficient to record accounts receivable at net realizable value as of March 31, 2016, and 2015, respectively.

 

NOTE – 8 ADVANCES ON CONTRACTS

 

The advances on contracts represent funding of future STA inventory purchases. The balance of the advances as of March 31, 2016, and December 31, 2015, is $1,253,645 and $1,215,128, respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.   

 

NOTE – 9 INCOME TAXES

 

For the three Months ended March 31, 2016, and 2015 state tax liability was approximately $47,000 and $0, respectively. Due to Milestone Scientific’s history of past operating losses, which required a full valuation allowances for all of Milestone Scientific’s deferred tax assets at March 31, 2016 and 2015, no recognition was given to the utilization of the remaining Federal net operating loss carryforwards.  

 

15

---

NOTE – 10 SIGNIFICANT CUSTOMERS & GEOGRAPHICAL INFORMATION

Milestone Scientific has informal arrangements with the manufacturer of the STA, CompuDent® and CompuMed® instruments, one of the principal manufacturers for those instruments pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. Purchases from this supplier were $636,059 and $617,602 for the three months ended March 31, 2016 and 2015, respectively. Milestone Scientific has a manufacturing agreement with one of the principal manufacturers, which is a related party, of its handpieces pursuant to which they manufacture products under specific purchase orders but without minimum purchase commitments. A five percent shareholder of Milestone Scientific is also a shareholder of this vendor. Milestone Scientific owed $610,202 and $455,573 to this supplier as of March 31, 2016 and March 31, 2015, respectively.

 

For the three months March 31, 2016, Milestone Scientific had two customers (distributors) that respectively had approximately 21% and 35%, of its net product sales. Accounts receivable for the two major customers respectively amounted to approximately $505,670 and $228,148 of gross accounts receivable. For the three months March 31, 2015, Milestone had two customers (distributors) that respectively had approximately 27% and 18%, of its net product sales. Accounts receivable for the two major customers respectively amounted to approximately $761,413 and $170,536 of gross accounts receivable.       

Milestone Scientific’s sales by product and by geographical region are as follows:

 

 

NOTE – 11 PENSION PLANS

Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does not contribute to this plan, but does pay the administrative costs of the plan, which were not significant.

 

NOTE – 12 COMMITMENTS AND OTHER

(1) Lease Commitments

The headquarters for Milestone Scientific is located at 220 South Orange Ave, Livingston, New Jersey. Milestone Scientific leases approximately 7,625 square feet of office space. The lease term expires January 31, 2020 at a monthly cost of $12,522. Additionally, Milestone Scientific has other smaller insignificant leases ending through 2017. A third party distribution and logistics center in Pennsylvania handles shipping and order fulfillment on a month-to-month basis. For the three Months ended March 31, 2016 and 2015, rent expense amounted to $35,232, and $13,824 respectively.

(2) Contract Manufacturing Arrangement

Milestone Scientific has informal arrangements for the manufacture of its products The STA (single tooth anesthesia), and CompuDent® instruments are manufactured for Milestone Scientific by Tricor Systems, Inc. pursuant to

16

---

specific purchase orders. The STA and the Wand® Handpiece with Needle is supplied to Milestone Scientific by a contractor in the United States, which arranges for its manufacture with two factories in China.

The termination of the manufacturing relationship with any of the above manufacturers could have a material adverse effect on Milestone Scientific’s ability to produce and sell its products. Although alternate sources of supply exist and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, whether or not as a result of termination of such a relationship, would adversely affect Milestone Scientific.

(3) Other Commitments and Subsequent Events

Other Commitments

In March 2014, the Board of Directors approved the Compensation Committee’s request to amend the Chief Executive Officer of Milestone Scientific’s employment agreement to provide benefits to make payments of $203,111 per year for five years to the Chief Executive Officer, or as he directs such payments to a third party, to fund his acquisition of, or contribution to an annuity, pension, or deferred distribution plan or for an investment for the Executive and his family. For each the three months ended March 31, 2016 and 2015, approximately $51,000was charged to expense, respectively.

The technology underlying the SafetyWand and CompuFlo®, and an improvement to the controls for CompuDent® were developed by the Director of Clinical Affairs and assigned to us. Milestone Scientific purchased this technology pursuant to an agreement dated January 1, 2005. The Director will receive additional payments of 2.5% of the total sales of products using certain of these technologies, and 5% of the total sales of products using certain other of the technologies. The Director of Clinical Affairs is granted, pursuant to the agreement, an option to purchase, at fair market value on the date of the grant, 8,333 shares of the common stock upon the issuance of each additional patent relating to these technologies. If products produced by third parties use any of these technologies (under license from us) then the Director of Clinical Affairs will receive the corresponding percentage of the consideration received Milestone Scientific for such sale or license. Milestone Scientific expensed the Director of Clinical Affairs’ royalty fee of $190,626 and $111,484, during the three months ended March 31, 2016 and 2015, respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of $68,757 and $23,400 the three months ended March 31, 2016 and 2015, respectively.

Subsequent Events

 

Subsequent to March 31, 2016 Milestone Scientific acquired an additional 37% of the outstanding common stock of Milestone Medical by exchanging Milestone Medical shares for shares of Milestone Scientific common stock at a rate of two shares of Milestone Medical for one share of Milestone Scientific.

Milestone Scientific has evaluated subsequent events and has determined that there are no other events to be disclosed.

 

17

---

The following discussions of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Form 10-Q. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements.

OVERVIEW

Milestone Scientific Inc. (“Milestone Scientific”, “our”, “us” or “we”) was officially listed on the NYSE MKT on June 1, 2015.

In 2016, Milestone Scientific remains focused on advancing efforts to achieve our two primary objectives; those being:

STA Instrument Growth

Since its market introduction in early 2007, the STA Instrument and a prior computerized controlled local anesthesia delivery product have been used to deliver over 60 million safe, effective and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.

Global Distribution Network

United States and Canadian Market

In November 2012, Milestone Scientific entered an exclusive distribution and marketing agreement with a well-known U.S. domestic manufacturer and distributor, for the sale and distribution of the STA instruments and handpieces in United States and Canada. The exclusive distributor and marketing agreement was converted to a non-exclusive agreement as December 31, 2015. Henry Schein a global leader of distribution in the dental supplies was added as a non-exclusive distributor of the STA instruments and handpieces in the United State and Canada in January 2016. In August 2014, Milestone Scientific entered an exclusive distributor agreement (beginning October 1, 2014), with Henry Schein, for the sale and distribution of the legacy CompuDent® handpieces in the United States and Canada.

International Market

On the global front, we also have granted exclusive marketing and distribution rights for the STA Instrument to select dental suppliers in various international regions in Asia, Africa, South America and Europe. They include Istrodent in South Africa and Unident in the Scandinavian countries of Denmark, Sweden, Norway and Iceland.

In early October 2012, the State Food and Drug Administration (SFDA) of the People’s Republic of China approved Milestone Scientific’s Single Tooth Anesthesia System® (STA System). In May 2014, the CFDA, (previously the SFDA), granted registration approval of the STA handpieces in China.

Shortly before the end of the second quarter 2009, we announced that we were refining our international marketing strategy to gain greater access to and penetration of the international dental markets for the STA Instrument, CompuDent® and related disposable handpieces. The new sales strategy provides for increasing hands-on oversight and support of our existing international distribution network, while also attracting new distributors throughout Europe, Asia

18

---

and South America. To assist in this endeavor, in the spring of 2010, Milestone Scientific added an International Sales Director to focus on the growth of our products outside the USA and Canada.

In September 2014, Milestone Medical Inc., a subsidiary of Milestone Scientific (“Milestone Medical”), received CE clearance to distribute their instruments in European Community (EU). Milestone Medical is actively pursuing distributors for the instrument in the EU community. Milestone Medical signed a distribution agreement in March 2015, with a Polish Medical distributor for the distribution of the epidural instrument starting in April 2015.

The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by product category, and the percentage of product sales (net) by each product category:

 

Milestone Scientific earned gross profit of approximately $2.2 million and $1.8 million in the three months ended March 31, 2016 and 2015, respectively.  However, the revenues and related gross profits have not been sufficient to support overhead, new product introduction and research and development expenses.  Although Milestone Scientific anticipates expending funds for research and development in 2016, these amounts will vary based on the operating results for each quarter. Milestone Scientific has incurred annual operating losses and negative cash flows from operating activities since its inception, except for 2013. At March 31, 2016, Milestone Scientific has sufficient cash reserves to meet all of its anticipated obligations for at least the next twelve months, including a limited amount of financing for the operation of Milestone Medical until additional financing is consummated in 2016.  Milestone Scientific is actively pursuing the continued generation of positive cash flows from operating activities through increase in revenue, assessment of current contracts and current negotiations.

In 2016, Milestone Scientific plans to further support increased sales and marketing activity through our current distributors and newly appointed distributors of the STA instruments and handpieces in the international market. In the U.S. and Canada, Milestone Scientific will continue the utilization of independent hygienists for training individual practitioners and group practices domestically, refined and directed advertising to dental professionals, and support and broaden our global distribution network.  

19

---

Results of Operations

The following table sets forth for the consolidated results of operations for the three months ended March 31, 2016 compared to 2015 as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results:

 

Three Months ended March 31, 2016 compared to Three Months ended March 31, 2015

The following paragraphs will describe the results of 2016 compared to 2015.

Total revenues for the three months ended March 31, 2016 and 2015 were approximately $3.5 and $2.7 million, respectively. The total dental revenue increased by $799,170 or 29% which was primarily related to the increase in instrument sales worldwide. This increase in revenue is in both STA instruments and handpieces. It is important to note that in the first quarter of 2016 Henry Schein purchased their first order of instruments and handpieces as a non-exclusive distributor in USA and Canada. International Instruments sales increased by $590,000 over the same period in 2015 due to a shipment of STA instruments to China. Handpieces decreased by $630,000 for the same period in 2015 due to an incentive buyer program in 2015 for handpieces that did not occur in the first quarter of 2016. International sales decreased by approximately $17,000. In the USA, Milestone Scientific has modified its exclusive distributor and marketing agreement with Aseptico Inc.  This exclusive agreement was changed to a non-exclusive agreement in December 31, 2015. The term of this non-exclusive agreement expired on March 31, 2016. Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein, the leading distributor of dental products in the USA and Canada.

The gross margin in 2016 decreased to 62% versus 66% in 2015. This decrease in gross profit margin is due to price reduction in instruments in certain key markets to stimulate increased volume in 2016 by increasing marketing efforts by distributors. Although the gross margin percentage decreased 4%, gross profit dollars in 2016 increased to approximately $2.2 million from approximately $1.8 million in 2015 or, by approximately $364,000 over the same period year over year.

 

20

---

Selling, general and administrative expenses for the three months ended March 31, 2016 were approximately $3.0 million versus $1.9 million in 2015.  This increase of approximately $1.1 million is predominantly due to the consolidation of Milestone Medical in the first quarter of 2016. In 2015, Milestone Medical was accounted for under the equity method, as such their line item expenses were recorded as a one line entry in the Statement of Operations as a Loss on Earnings from Milestone Medical. The total operating expense for Milestone Medical for the quarter ending March 31, 2016 and 2015 was $851,000 and $890,000, respectively. The major reduction in the total operating expense for Milestone Medical was a reduction in Research and Development Expense of approximately $86,000, offset by an increase in various general expenses of $23,000.

 

On the consolidated basis, giving effect to the consolidation of Milestone Medical, Milestone Scientific and Wand Dental, expenses increased by approximately $400,000. Salaries and other compensation expense increased by $105,000 with the increase in personnel required to grow our business, a Senior Brand Manager, a Senior Manager of Project Management and an increase in our Clinical Hygienist staff to train our current and new customers. Other personnel benefits increased by $108,000 due to Medical Insurance increases and increased staff. Stock based compensation increased by $51,000 due stock option awards provided to executives at the end of 2015. Marketing and trade show expenses and travel and other expenses accounted for the remainder of the increase in the 1^st quarter 2016 versus the first quarter of 2015.

Research and development expenses for the three months ended March 31, 2016 and 2015 were $143,442 and $10,118, respectively. As previously stated, $47,000 of the increase is due to the consolidation of Milestone Medical in 2016. The remainder of the increase is due to other research and development projects that are in process.

The loss from operations for the three months ended March 31, 2016 and 2015 was $943,388 and $71,143, respectively. The additional loss of $911,000 is primarily the result of the consolidation Milestone Medical in 2016.

There was a loss on the China Joint Venture of $269,726 and profit of $96,674 for the three months ended March 31, 2016 and 2015, respectively. The China joint Venture is in its initial operating and expansion cycle in China, and as such will continue to have losses in 2016

 

For the reasons explained above, and after factoring in the positive effects of net loss attributable to non-controlling interest, the net loss for the three months March 31, 2016 was $750,059 as compared to the net loss for the three months ended March 31, 2015 of $419,375.

 

Liquidity and Capital Resources

Looking at the current balance sheet for Milestone Scientific and subsidiaries, current assets decreased by approximately $1.2 million. The reduction in current assets is primarily due to a decrease in cash of approximately $1.5 million and a decrease in inventories of approximately $360,000. The cash reduction is primarily due to the loss from operations and the financial support of Milestone Medical for the three months ended March 31, 2016.

Current liabilities decreased by approximately $402,000.

Working Capital decreased by $766,000, primarily due to the loss from operations for the three months ended March 31, 2016. However, Milestone Scientific believes that its cash on hand and revenues from the dental business will be sufficient to operate the ongoing business for at least the next 12 months. As noted above, the funding for Milestone Medical will be limited during 2016.

Milestone Scientific continues to take positive steps to maintain adequate inventory levels and advances on contracts to maintain available inventory to meet our domestic and international sales requirements. Cash flows from operating activities for the three months ended March 31, 2016 and 2015 were a negative $1,389,126 and $681,191, respectively.

 

Milestone Scientific has incurred annual operating losses and negative cash flows from operating activities since its inception, except for the year ended December 31, 2013. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through increases in revenues based upon management’s assessment of present contracts, and current negotiations and reductions in operating expenses. The consolidation of Milestone Medical

21

---

in December 2015 and the lack of capital raising activities by Milestone Medical in 2015 created a unique situation for Milestone Scientific advancing into 2016. However as noted previously, Milestone Scientific is not obligated to continue its financial support of Milestone Medical, but the timeline for Milestone Medical 510K FDA clearance is expected in 2016 (mid-year). Milestone Scientific expects that clearance to commercialize the epidural and intra articular instruments in 2016 will significantly improve the capital raising opportunities and financial picture.

 

Milestone Scientific believes that with the new distribution agreement with Henry Schein Inc. (effective January 1, 2016), the world’s largest supplier of medical, dental and veterinary supplies and devices, that dental revenues are projected to improve in the upcoming 12 months. To further reduce Milestone Scientific’s expenditures, Milestone Medical expenses related to USA FDA clearance for the epidural and intra-articular instruments can be controlled as required to meet Milestone Scientific’s budget. By limiting the FDA related expenses and increasing the dental instrument revenue through the new distribution agreement and performing a detailed cash flow projection of the consolidated company and its subsidiaries, management believes that Milestone Scientific will have sufficient cash reserves to meet all of its anticipated obligations over the next twelve months.

 

Item 3.Quantitative and Qualitative Disclosures about Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

 

Item 4.Controls and Procedures

Milestone Scientific’s management, including the Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the design and operation of Milestone Scientific’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report (the “Evaluation Date”). Based upon that evaluation, Milestone Scientific’s Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of the Evaluation Date are effective to ensure that information required to be disclosed in the reports Milestone Scientific files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Milestone Scientific’s management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding disclosure.

There were no changes in Milestone Scientific’s internal control over financial reporting identified in connection with the evaluation that occurred during Milestone Scientific’s last fiscal quarter ended March 31, 2016 that have materially affected, or that are reasonably likely to materially affect, Milestone Scientific’s internal controls over financial reporting.

 

 

 

22

---

PART II – OTHER INFORMATION

None.

As a smaller reporting company, we are not required to provide the information required by this Item.

None.

 

None.

Not applicable.

None.

 

 

 

 

 

 

23

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Date: May 16, 2016

24

Exhibit 31.1

Rule 13a-14(a)/15d-14(a) Certification

I, Leonard Osser, certify that:

Date: May 16, 2016

 

 

 

Exhibit 31.2

Rule 13a-14(a)/15d-14(a) Certification

I, Joseph D’Agostino, certify that:

Date: May 16, 2016

 

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Milestone Scientific Inc (“Milestone”) on Form 10-Q for the period ending March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leonard Osser, Chief Executive Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone.

Date:  May 16, 2016

 

A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Milestone Scientific Inc (“Milestone”) on Form 10-Q for the period ending March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph D’Agostino, Chief Financial Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone.

Date: May 16, 2016

 

A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request.

v3.4.0.3

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 16, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Trading Symbol	MLSS
Entity Registrant Name	MILESTONE SCIENTIFIC INC.
Entity Central Index Key	0000855683
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		21,687,164

v3.4.0.3

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 2,671,778	$ 4,194,384
Accounts receivable	2,269,154	1,793,801
Other receivable	58,140	58,140
Inventories	3,898,237	4,258,094
Advances on contracts	1,253,645	1,215,128
Prepaid expenses and other current assets	505,336	304,604
Total current assets	10,656,290	11,824,151
Furniture, fixtures & equipment net of accumulated depreciation	220,892	235,935
Patents, net of accumulated amortization of $663,926 as of March 31, 2016 and $646,388 as of December 31, 2015	712,448	715,540
Other assets	17,355	17,355
Total assets	11,606,985	12,809,327
Current Liabilities:
Accounts payable	1,866,352	2,088,268
Accrued expenses and other payables	1,375,171	1,555,567
Total current liabilities	$ 3,241,523	$ 3,643,835
Commitments and Contingencies
Stockholders’ Equity
Common stock, par value $.001; authorized 50,000,000 shares; 21,720,497 shares issued, 1,100,405 shares to be issued and 21,687,164 shares outstanding as of March 31, 2016; 21,720,497 shares issued, 963,451 shares to be issued and 21,687,164 shares outstanding as of December 31, 2015	$ 22,821	$ 22,685
Additional paid-in capital	79,076,752	78,632,383
Accumulated deficit	(68,185,043)	(67,434,984)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total Milestone Scientific Inc. stockholders' equity	10,003,021	10,308,575
Noncontrolling interest	(1,637,559)	(1,143,083)
Total Equity	8,365,462	9,165,492
Total liabilities and stockholders’ equity	11,606,985	12,809,327
Series A Preferred Stock [Member]
Stockholders’ Equity
Series A convertible preferred stock, par value $.001, authorized 5,000,000 shares, 7,000 shares issued and outstanding, respectively	7	7
Milestone Education LLC [Member]
Current Assets:
Investment in joint venture		16,346
Variable Interest Entities [Member]
Current Assets:
Cash and cash equivalents	72,967	1,222
Accounts receivable	45,075	45,075
Inventories	875,974	885,961
Advances on contracts	44,148	43,524
Furniture, fixtures & equipment net of accumulated depreciation	107,403	119,007
Current Liabilities:
Accounts payable	426,993	461,292
Accrued expenses and other payables	$ 324,815	$ 354,361

v3.4.0.3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Allowance for doubtful accounts	$ 5,000	$ 5,000
Accumulated depreciation on Furniture, Fixtures & Equipment	589,703	566,477
Accumulated amortization of patents	$ 663,926	$ 646,388
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	21,720,497	21,720,497
Common stock, shares to be issued	1,100,405	963,451
Common stock, shares outstanding	21,687,164	21,687,164
Treasury stock, at cost	33,333	33,333
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	7,000	7,000
Preferred stock, shares outstanding	7,000	7,000

v3.4.0.3

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Product sales, net	$ 3,569,374	$ 2,770,204
Cost of products sold	1,368,190	933,148
Gross profit	2,201,184	1,837,056
Selling, general and administrative expenses	3,001,130	1,898,081
Research and development expenses	143,442	10,118
Total operating expenses	3,144,572	1,908,199
Loss from operations	(943,388)	(71,143)
Interest expense	(1,237)
Interest income	302	1,210
Total other expenses, net	(935)	1,210
Loss before provision for income tax and equity in net earnings of equity investments	(944,323)	(69,933)
Provision for income tax	(46,834)
Loss before equity in net earnings of equity investments	(991,157)	(69,933)
Loss in equity investments	(269,726)	(357,701)
Net Loss	(1,260,883)	(427,634)
Net loss attributable to noncontrolling interests	510,824	8,259
Net loss attributable to Milestone Scientific Inc.	$ (750,059)	$ (419,375)
Net loss per share applicable to common stockholders—
Basic	$ (0.03)	$ (0.02)
Diluted	$ (0.03)	$ (0.02)
Weighted average shares outstanding and to be issued—
Basic	22,609,349	21,919,616
Diluted	22,609,349	21,919,616
Milestone Medical Inc. [Member]
Loss in equity investments		$ (450,160)
Milestone Education LLC [Member]
Loss in equity investments		(4,215)
Milestone China [Member]
Loss in equity investments	$ (164,837)	96,674
(Loss) Gain on earnings from China Joint Venture	$ (269,726)	$ 96,674

v3.4.0.3

Condensed Consolidated Statement of Changes in Stockholders' Equity - 3 months ended Mar. 31, 2016 - USD ($)	Total	Milestone Education [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Noncontrolling Interest [Member] Milestone Education [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2015	$ 9,165,492	$ 16,348	$ 7	$ 22,685	$ 78,632,383	$ (67,434,984)	$ (1,143,083)	$ 16,348	$ (911,516)
Beginning Balance, Shares at Dec. 31, 2015			7,000	22,685,160
Stock based compensation	134,505				134,505
Common stock to be issued to employee for bonuses	310,000			$ 136	309,864
Common stock to be issued to employee for bonuses, Shares				136,954
Net loss	(1,260,883)					(750,059)	(510,824)
Ending Balance at Mar. 31, 2016	$ 8,365,462		$ 7	$ 22,821	$ 79,076,752	$ (68,185,043)	$ (1,637,559)		$ (911,516)
Ending Balance, Shares at Mar. 31, 2016			7,000	22,822,114

v3.4.0.3

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (1,260,883)	$ (427,634)
Adjustments to reconcile net cash used in operating activities:
Depreciation expense	22,786	5,791
Amortization of patents	17,538	17,323
Common stock and options for compensation, consulting and vendor services	444,505	82,124
Equity loss (gain) on joint venture	269,726	357,701
Changes in operating assets and liabilities:
Increase in accounts receivable	(475,351)	(101,460)
Increase in other receivable		(268,914)
Increase in inventories	359,857	468,891
(Increase) decrease to advances on contracts	(38,517)	(236,644)
(Increase) decrease to prepaid expenses and other current assets	(200,732)
(Increase) decrease in other assets		(224,393)
Increase (decrease) in accounts payable	(237,853)
Increase in accrued expenses and other payables	(185,313)	(353,976)
Net cash used in operating activities	(1,389,126)	(681,191)
Cash flows from investing activities:
Notes receivable from Milestone Medical		(200,000)
Due from related party		(184,589)
Purchases of intangible assets	(14,442)
Purchases of property and equipment	(4,822)	(2,421)
Cash acquired from variable interest entity	50,621
Net cash used in investing activities	(133,480)	(455,397)
Cash flows from financing activities:
Capital contribution from noncontrolling interest		100,000
Net cash provided by investing activities		100,000
Net decrease in cash and cash equivalents	(1,522,606)	(1,036,588)
Cash and cash equivalents at beginning of period	4,194,384	10,367,993
Cash and cash equivalents at end of period	2,671,778	9,331,405
Supplemental disclosure of cash flow information:
Net Assets Acquired from Variable Interest Entity	20,472
Shares issued to employees in lieu of cash compensations	310,000
Milestone Medical Inc. [Member]
Adjustments to reconcile net cash used in operating activities:
Equity loss (gain) on joint venture		450,160
Cash flows from investing activities:
Investment in Milestone Medical		(68,387)
Milestone Education LLC [Member]
Adjustments to reconcile net cash used in operating activities:
Equity loss (gain) on joint venture		4,215
Milestone China [Member]
Adjustments to reconcile net cash used in operating activities:
Equity loss (gain) on joint venture	164,837	$ (96,674)
Cash flows from investing activities:
Investment in Milestone Medical	$ (164,837)

v3.4.0.3

Organization, Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization, Business and Basis of Presentation	ORGANIZATION, BUSINESS AND BASIS OF PRESENTATION Milestone Scientific Inc. and Subsidiaries, (collectively “Milestone Scientific”, “our”, “us” or “we”) was incorporated in the State of Delaware in August 1989. Milestone Scientific has developed a proprietary, computer-controlled anesthetic delivery instrument, through the use of The Wand®, a single use disposable handpiece. The instrument is marketed in dentistry under the trademark CompuDent®, Wand Plus® and STA (Single Tooth Anesthesia) TM and in medicine under the trademark CompuMed®. CompuDent® is suitable for all dental procedures that require local anesthetic. CompuMed® and Wand Plus are suitable for many medical procedures regularly performed in Plastic Surgery, Hair Restoration Surgery, Podiatry, Colorectal Surgery, Dermatology, Orthopedics and a number of other disciplines. The instruments are sold in the United States and in over 47 countries abroad. Milestone Scientific’s products are manufactured by a third-party contract manufacturer. In July 2014, Milestone Scientific acquired all of the 750,000 outstanding shares of an inactive Florida corporation and changed its name to Wand Dental, Inc. (“Wand Dental”).  In September 2014, that corporation was merged into a Delaware corporation, retaining the same name and capitalization. On July 1, 2014, Wand Dental was capitalized with cash and received Milestone Scientific’s dental business and related dental assets including the exclusive license of Milestone Scientific’s, patents, trademarks, and technology for use in the dental marketplace. Wand Dental is consolidated into Milestone Scientific. The unaudited consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2015 included in Milestone Scientific Annual Report on Form 10-K. In the opinion of management, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present Milestone Scientific’s financial position as of March 31, 2016 and the results of its operations for the three months then ended. The results reported for the three months ended March 31, 2016 are not necessarily indicative of the results of operations which may be expected for a full year. Milestone Scientific has incurred operating losses and negative cash flows from operating activities since its inception, except for 2013. Milestone Scientific is actively pursuing the generation of revenue, positive operating income and net income. The capital raised in May 2014, provided Milestone Scientific with the opportunity to continue to develop and commercialize additional medical instruments and aggressively market the dental instruments throughout the world. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses. As of March 31, 2016 Milestone Scientific believes that with the new distribution agreement with Henry Schein Inc. (effective January 1, 2016), the world’s largest supplier of medical, dental and veterinary supplies and devices, that dental revenue is projected to improve in the upcoming 12 months. To further reduce our expenditures, Milestone Medical’s expenses related to USA FDA clearance for the epidural and intra-articular instruments can be controlled as required to meet Milestone Scientific’s budget. Milestone Scientific has completed a detailed cash flow projection for the upcoming 12 months and has concluded that by limiting the FDA related expenses and increasing the dental instrument revenue through the new distribution agreement, management believes that Milestone Scientific will have sufficient cash reserves to meet all of its anticipated obligations over the next twelve months.

v3.4.0.3

Summary of Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Accounting Policies	NOTE – 1 SUMMARY OF ACCOUNTING POLICIES   1. Principles of Consolidation The accompanying consolidated financial statement have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including Wand Dental, as well as Milestone Medical Inc. (“Milestone Medical”) and Milestone Education LLC (“Milestone Education”), both variable interest entities for which Milestone Scientific is the primary beneficiary. All significant, intra-entity transactions and balances have been eliminated in the consolidation.      2. Variable Interest Entities A Variable Interest Entity (VIE) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary, and if not, does not consolidate. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision making ability over key operational functions within the entity Assets recognized as a result of consolidating VIEs do not represent additional assets that could be used to satisfy claims against Milestone Scientific’s general assets. Conversely, liabilities recognized as a result of consolidating these VIEs do not represent additional claims on Milestone Scientific’s general assets; rather, they represent claims against the specific assets of the consolidated VIEs. Milestone Scientific is the primary beneficiary of Milestone Medical, and Milestone Education, as variable interest entities. Accordingly, the assets and liabilities of Milestone Medical and Milestone Education are included in the accompanying consolidated financial statements. Please refer to Note 4 for further details regarding the treatment of the variable interest entity.   3. Cash and Cash Equivalents Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.   4. Accounts Receivable Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. A majority of credit sales are due within ninety days from invoicing. There have not been any significant credit losses reported by Milestone Scientific.     5. Product Return and Warranty Milestone Scientific does not accept non-defective returns from its customers. Product returns under warranty are accepted, evaluated and repaired or replaced in accordance with the Warranty Policy.  Returns not within the Warranty Policy are evaluated and the customer is charged for the repair.   6. Inventories Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.     7. Equity Method Investments Investments in which we have the ability to exercise significant influence, but do not control, are accounted for under the equity method of accounting and are included in the long term assets on the Consolidated Balance Sheet. Under this method of accounting, our share of the net earnings or losses of the investee is presented below the income tax line on the Consolidated Statement of Operations since the activities of the investee are not closely aligned with the operations of Milestone Scientific. We evaluate our equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments may be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period.     8. Furniture, Fixture and Equipment Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from five to seven years. The costs of maintenance and repairs are charged to operations as incurred.   9. Intangible Assets - Patents Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. Although certain patents have not yet been approved, the costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. If the applicable patent application is ultimately rejected, the remaining unamortized balance will be expensed in the period in which Milestone Scientific receives a notice of such rejection. Patent applications filed and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries may be different from patent protection under United States laws and may not be favorable to Milestone Scientific Milestone Scientific also attempts to protect the proprietary information through the use of confidentiality agreements and by limiting access to the facilities. There can be no assurance that the program of patents, confidentiality agreements and restricted access to the facilities will be sufficient to protect the proprietary technology.   10. Impairment of Long-Lived Assets Milestone Scientific reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amounts may not be recoverable. The carrying value of the assets is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets. Milestone Scientific adjusts the net book value of an underlying asset if its fair value is determined to be less than its net book value. Milestone Scientific has reviewed long-lived assets for impairment and concluded no impairment exists as of March 31, 2016.   11. Revenue Recognition Revenue from product sales is recognized net of discounts and allowances to domestic distributors on the date of shipment for essentially all shipments, since the shipment terms are FOB warehouse. Milestone Scientific will recognize revenue on date of arrival of the goods at the customer’s location, where shipments are FOB destination. Shipments to international distributors are FOB warehouse, therefore revenue is recognized on shipment of the goods. In all cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone Scientific has no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific’s only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period    12. Shipping and Handling Costs Milestone Scientific includes shipping and handling costs in cost of goods sold. These costs are billed to customers at the time of shipment for domestic shipments. International shipments are FOB warehouse, therefore no costs are incurred by Milestone Scientific.   13. Research and Development Research and development costs, which consist principally of new product development costs payable to third parties, are expensed as incurred.   14. Income Taxes Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The income tax provision or credit is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.   15. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. The FASB continues to release guidance clarifying certain aspects of the revenue guidance.  We do not believe that this new accounting pronouncement will have a material impact on our financial statements. In November 2015, the FASB issued guidance simplifying the balance sheet classification of deferred taxes. The new guidance requires that all deferred taxes be presented as noncurrent, rather than separated into current and noncurrent amounts. The guidance is effective for reporting periods beginning after December 15, 2016 and early adoption is permitted. In addition, the adoption of guidance can be applied either prospectively or retrospectively to all periods presented. As of March 31, 2016 and 2015 there are no deferred tax assets or liabilities recorded. In February 2016, the Financial Accounting Standards Board issued a new standard ASU No.2016-02, “Leases “ (Topic 842): The new standard is intended to increase transparency and comparability among organizations to recognize lease assets and liabilities on the balance sheet and disclose key information about leasing arrangements. It will be effective for fiscal years beginning after December 15, 2019 and for interim periods within fiscal years beginning after December 15, 2020. Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows. In March 2016, the Financial Accounting Standards Board issued a new standard ASU No.2016-07, “Investments - Equity Method and Joint Ventures” (Topic 323): The new standard is intended to eliminate the requirement that when an investment qualifies for the use of the equity method as a result of an in increase in the level of ownership or degree of influence, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect all of the previous periods that the investment was held. It will be effective for all entities for fiscal years and interim periods, beginning after December 15, 2016. Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows. In March 2016, the Financial Accounting Standards Board issued a new standard ASU No.2016-09, “Compensation – Stock Compensation” (Topic 718): The new standard is intended to clarify certain reporting aspects relating to stock based compensation, relating primarily to forfeitures, tax impacts and cash flow presentation.  Certain attributes will be treated prospectively, while others will require a retroactive application. Generally, the changes will be effective for fiscal years and interim periods, beginning after December 15, 2016. Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows

v3.4.0.3

Basic and Diluted Net Income (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Basic and Diluted Net Income (Loss) Per Common Share	NOTE – 2 Basic and Diluted Net INCOME (Loss) Per Common Share Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of Statement of Financial Accounting Standards ASC Topic 260. Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is similar to that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options, warrants, and the conversion of debt were issued during the period. Since Milestone Scientific had net losses for 2016 and 2015, the assumed effects of the exercise of potentially dilutive outstanding stock options and warrants were not included in the calculation as their effect would have been anti-dilutive.   For the three months ended March 31, 2016 and 2015, Milestone Scientific calculated basic and fully diluted earnings per common share as described in the previous paragraph.

v3.4.0.3

Accounts Receivable	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Accounts Receivable	NOTE – 3 ACCOUNTS RECEIVABLE Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. A majority of credit sales are due within ninety days from invoicing.

v3.4.0.3

Consolidation of Variable Interest Entity	3 Months Ended
	Mar. 31, 2016
Equity Method Investments And Joint Ventures [Abstract]
Consolidation of Variable Interest Entity	NOTE – 4 CONSOLIDATION OF VARIABLE INTEREST ENTITY Milestone Medical   Milestone Medical is 49.98% owned by Milestone Scientific as of March 31, 2016. Milestone Scientific has been established to develop and commercialize intra-articular and epidural drug delivery instruments, utilizing an exclusive royalty-free license to Milestone Scientific’s CompuFlo technology. The license was contributed by Milestone Scientific for our initial ownership in Milestone Medical.   Since our initial investment in Milestone Medical we have accounted for the investment in accordance with the equity method of accounting. However, during 2015, Milestone Scientific provided short term bridge financing to Milestone Medical in anticipation of the completion of a secondary stock offering in the Polish Market. In December 2015, Milestone Medical suspended their capital raise efforts meriting re-consideration of the initial accounting for the investment as an equity method investment. In April 2016, Milestone Medical cancelled the uplisting of its shares to the Poland Warsaw Stock Exchange.   As a result of the change in circumstances around the proposed offering in December 2015 by Milestone Medical, we reevaluated the relationship between the two entities and the status of Milestone Medical as a VIE. We have concluded that Milestone Medical does not have sufficient capital at risk to support its activities without additional financial support from Milestone Scientific. As a result of these factors, we have concluded that the line of credit extended to Milestone Medical constitutes a variable interest in Milestone Medical and therefore Milestone Medical is consolidated at March 31, 2016. Since the factors giving rise to concluding that Milestone Medical is a VIE happened so close to the end of fiscal year 2015, the acquisition date for measuring the consolidation of Milestone Medical has been deemed to be December 31, 2015. Subsequent to March 31, 2016 Milestone Scientific acquired equity and voting control of Milestone Medical as a result of the acquisition of an additional 37% of the outstanding common stock of Milestone Medical by exchanging Milestone Medical shares for shares of Milestone Scientific common stock at a rate of two shares of Milestone Medical for one share of Milestone Scientific. Milestone Education LLC Milestone Education is a 50% owned subsidiary of Milestone Scientific which began operations in 2013 to provide training and education to our dentists throughout the world. Milestone Scientific accounts for its investment in Milestone Education using the equity method of accounting through December 31, 2015. Approximately 80% of the revenue earned by Milestone Education is from services performed for Milestone Scientific. As a result of this relationship, we concluded that we have the power to direct the activities that most significantly impact Milestone Education’s economic performance, and that it is a variable interest entity and should be consolidated in the financials of Milestone Scientific. As of December 31, 2015, the impact of the consolidation was deemed not to be material to the consolidated financial statements.   The financial statements of Milestone Medical, and Milestone Education are included in the accompanying consolidated financial statements as of March 31, 2016.   The financial information in the table below summarizes the combined results of operations of Milestone Scientific, and its subsidiaries including Milestone Medical and Milestone Education (each a variable interest entity) on a pro forma basis as though the companies had been combined as of the beginning of the earliest period presented. The pro forma financial information is presented for informational purposes only and is not indicative of the result of operations that would have been achieved if the consolidation had taken place at the beginning of the period presented.     March 31, 2015 Pro Forma   Total revenue $ 2,791,103   Cost of products sold   933,148   Gross Profit   1,857,955   Selling, general and administrative expenses   2,683,757   Research and development expenses   143,685   Operating expenses   2,827,442   Loss from operations   (969,643 ) Other expenses   -   Interest expense   (369 ) Interest income   1,213   Loss before Provision for Income Tax   (968,643 ) Provision for Income Tax   -   Loss before equity in net earnings of equity    investments   (968,643 ) Loss on earnings from Milestone Medical Inc.   (450,160 ) Loss on earnings from Education Joint Venture   (4,215 ) Gain on earnings from China Joint Venture   96,674   Loss in equity investments   (357,701 ) Net loss   (1,326,344 ) Less: Net loss attributable to the    noncontrolling interests   (457,436 ) Net loss attributable to Milestone    Scientific Inc. $ (868,908 )

v3.4.0.3

Investment in Unconsolidated Subsidiaries	3 Months Ended
	Mar. 31, 2016
Equity Method Investments And Joint Ventures [Abstract]
Investment in Unconsolidated Subsidiaries	NOTE – 5 INVESTMENT IN UNCONSOLIDATED SUBSIDIARIES Advance Ocular Science SA       Advanced Ocular Sciences SA is an entity organized to develop an instrument that delivers injections into the eyes. The company is a shell company as of March 31, 2016. Milestone Scientific owns 25% of this entity. As of the balance sheet date, no equity has been contributed to the company by Milestone Scientific. During 2015, Milestone Scientific advanced $78,798 for marketing and strategy planning to Advanced Ocular Sciences SA. Advanced Ocular Sciences SA., or their organizers are obligated to repay this advance once the public offering is approved and funded in Poland during 2016. Advance Ocular Science SA was not included in the consolidated financial statements at March 31, 2016 as no investment has been made by Milestone Scientific.   Milestone China Ltd. In June 2014, Milestone Scientific agreed to invest $1 Million through the contribution of 772 STA instruments (at a distributor price of approximately $1,295 per instrument) for a forty percent ownership in Milestone China Ltd. (“Milestone China”).  In 2014, the instruments were shipped and were recorded as an investment in Milestone China at the cost of the inventory contributed. In January 2016, Milestone Scientific contributed 308 STA instruments with a retail value of approximately $400,000 ($1,296 per instrument) to Milestone China Inc. as an increase in our investment in this subsidiary. The additional contribution increased the Company’s investment by approximately $165,000 which represents the costs of the instruments and it did not increase the company’s percentage of ownership since the contribution is proportionate to the other shareholder contribution. Milestone Scientific recorded a loss on its investment in Milestone China of $164,837 and equity earnings $96,674 for the three months ended March 31, 2016 and 2015, respectively. Milestone’s investment in Milestone China was $0 and $445,325, at March 31, 2016 and 2015 respectively. Milestone Scientific had suspended losses on its investment in Milestone China of $177,291, as of March 31, 2016. Milestone Scientific sold $1,000,000 in instruments during quarter ended March 31, 2016 to Milestone China. Milestone China Ltd. owes $825,340 to Milestone Scientific for instruments shipped in 2016, which is included in accounts receivable at March 31, 2016 Milestone Scientific recognizes the total revenue and costs of goods sold at the time the shipment of instruments and handpieces. However, due to timing differences of when the inventory is sold to Milestone China and when Milestone China sells the acquired inventory to third parties, elimination of the intra-entity profit is required as of the balance sheet date. In accordance with Accounting Standard Codification (“ASC”) 323 – Equity Method and Joint Ventures, Milestone Scientific has deferred the gross profit associated with inventory shipped to Milestone China that has not been sold to third parties The deferred profit of $174,670 is included in the loss from the Milestone China within the Statement of Operations and presented as a reduction of the accounts receivable in the Consolidated Balance Sheet.

v3.4.0.3

Stock Option Plans	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Plans	NOTE – 6 Stock Option Plans Milestone Scientific recognizes compensation expense on a straight line basis over the requisite service period and in the case of performance based options over the period of the expected performance. For the months ended March 31, 2016 and 2015, Milestone Scientific recognized $134,505 and $82,124 of total employee compensation cost related to options that vested each year, respectively. As of March 31, 2016 and 2015, there was $1,026,024 and $949,780 of total unrecognized compensation cost related to non-vested options which Milestone Scientific expects to recognize over a weighted average period of 2.99 years and 3.10 years as of March 31, 2016 and 2015, respectively. A summary of option activity for employees under the plans and changes during the three months ended March 31, 2016, is presented below:       Number of Options     Weighted Averaged Exercise Price $     Weighted Average Remaining Contractual Life (Years)     Aggregate Intrinsic Options Value $   Outstanding, January 1, 2016     1,419,436       1.56       2.78       1,220,338   Granted     348,908       1.72       4.85       -   Exercised     -       -       -       -   Forfeited or expired     -       -       -       -   Outstanding, March 31, 2016     1,768,344       1.59       2.99       466,050   Exercisable, March 31, 2016     1,157,983       1.33       2.43       465,309           A summary of option activity for non-employees under the plans and changes during the three months ended March 31, 2016, is presented below:        Number of Options     Weighted Averaged Exercise Price $     Weighted Average Remaining Contractual Life (Years)     Aggregate Intrinsic Options Value $   Outstanding, January 1, 2016     8,333       2.70       4.83       -   Granted     -       -       -       -   Expired     -       -       -       -   Exercised     -       -       -       -   Outstanding, March 31, 2016     8,333       2.70       4.58       -   Exercisable, March 31, 2016     2,777       2.70       4.58       -     The fair value of the options was estimated on the date of grant using the Black Scholes option-pricing model.  As of March 31, 2016, Milestone Scientific recognized $1,175 expense related to non-employee options that vested.    In accordance with the provisions of FASB ASC 505-50-15, all other issuances of common stock, stock options or other equity instruments to non-employees as consideration for goods or services received by Milestone Scientific are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of any options or similar equity instruments issued is estimated based on the Black-Scholes option-pricing model and the assumption that all of the options or other equity instruments will ultimately vest. Such fair value is measured as of an appropriate date pursuant to the guidance, (generally, the earlier of the date the other party becomes committed to provide goods or services or the date of performance by the other party is complete) and capitalized or expensed as if Milestone Scientific had paid cash for the goods or services.

v3.4.0.3

Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2016
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	NOTE – 7 CONCENTRATION OF CREDIT RISK   Milestone Scientific’s consolidated financial instruments that are exposed to concentrations of credit risk consist primarily of cash, trade accounts receivable, and advances on contracts. Milestone Scientific places its cash and cash equivalents with large financial institutions. At times, such investments may be in excess of the Federal Deposit Insurance Corporation insurance limit. Milestone Scientific has not experienced any losses in such accounts and believes it is not exposed to any significant credit risks. Financial instruments which potentially subject Milestone Scientific to credit risk consist principally of trade accounts receivable, as Milestone Scientific does not require collateral or other security to support customer receivables, and advances on contracts.   Milestone Scientific closely monitors the extension of credit to its customers while maintaining allowances, if necessary, for potential credit losses. On a periodic basis, Milestone Scientific evaluates its accounts receivable and establishes an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions. Management has provided a reserve that it believes is sufficient to record accounts receivable at net realizable value as of March 31, 2016, and 2015, respectively.

v3.4.0.3

Advances on Contracts	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Advances on Contracts	NOTE – 8 ADVANCES ON CONTRACTS   The advances on contracts represent funding of future STA inventory purchases. The balance of the advances as of March 31, 2016, and December 31, 2015, is $1,253,645 and $1,215,128, respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.

v3.4.0.3

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	NOTE – 9 INCOME TAXES   For the three Months ended March 31, 2016, and 2015 state tax liability was approximately $47,000 and $0, respectively. Due to Milestone Scientific’s history of past operating losses, which required a full valuation allowances for all of Milestone Scientific’s deferred tax assets at March 31, 2016 and 2015, no recognition was given to the utilization of the remaining Federal net operating loss carryforwards.

v3.4.0.3

Significant Customers & Geographical Information	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Significant Customers & Geographical Information	NOTE – 10 SIGNIFICANT CUSTOMERS & GEOGRAPHICAL INFORMATION Milestone Scientific has informal arrangements with the manufacturer of the STA, CompuDent® and CompuMed® instruments, one of the principal manufacturers for those instruments pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. Purchases from this supplier were $636,059 and $617,602 for the three months ended March 31, 2016 and 2015, respectively. Milestone Scientific has a manufacturing agreement with one of the principal manufacturers, which is a related party, of its handpieces pursuant to which they manufacture products under specific purchase orders but without minimum purchase commitments. A five percent shareholder of Milestone Scientific is also a shareholder of this vendor. Milestone Scientific owed $610,202 and $455,573 to this supplier as of March 31, 2016 and March 31, 2015, respectively.   For the three months March 31, 2016, Milestone Scientific had two customers (distributors) that respectively had approximately 21% and 35%, of its net product sales. Accounts receivable for the two major customers respectively amounted to approximately $505,670 and $228,148 of gross accounts receivable. For the three months March 31, 2015, Milestone had two customers (distributors) that respectively had approximately 27% and 18%, of its net product sales. Accounts receivable for the two major customers respectively amounted to approximately $761,413 and $170,536 of gross accounts receivable.        Milestone Scientific’s sales by product and by geographical region are as follows:     Three Months Ended March 31,     2016     2015   DOMESTIC               Instruments $ 661,645     $ 448,965   Handpieces   988,143       432,062   Other   34,379       (13,467 ) Total Domestic $ 1,684,167     $ 867,560                   INTERNATIONAL               Instruments $ 1,268,156     $ 677,614   Handpieces   584,708       1,214,453   Other   32,342       10,577   Total International $ 1,885,207     $ 1,902,644                   Total Product Sales $ 3,569,374     $ 2,770,204

v3.4.0.3

Pension Plans	3 Months Ended
	Mar. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Pension Plans	NOTE – 11 PENSION PLANS Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does not contribute to this plan, but does pay the administrative costs of the plan, which were not significant.

v3.4.0.3

Commitments and Other	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Other	NOTE – 12 COMMITMENTS AND OTHER (1) Lease Commitments The headquarters for Milestone Scientific is located at 220 South Orange Ave, Livingston, New Jersey. Milestone Scientific leases approximately 7,625 square feet of office space. The lease term expires January 31, 2020 at a monthly cost of $12,522. Additionally, Milestone Scientific has other smaller insignificant leases ending through 2017. A third party distribution and logistics center in Pennsylvania handles shipping and order fulfillment on a month-to-month basis. For the three Months ended March 31, 2016 and 2015, rent expense amounted to $35,232, and $13,824 respectively. (2) Contract Manufacturing Arrangement Milestone Scientific has informal arrangements for the manufacture of its products The STA (single tooth anesthesia), and CompuDent® instruments are manufactured for Milestone Scientific by Tricor Systems, Inc. pursuant to specific purchase orders. The STA and the Wand® Handpiece with Needle is supplied to Milestone Scientific by a contractor in the United States, which arranges for its manufacture with two factories in China. The termination of the manufacturing relationship with any of the above manufacturers could have a material adverse effect on Milestone Scientific’s ability to produce and sell its products. Although alternate sources of supply exist and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, whether or not as a result of termination of such a relationship, would adversely affect Milestone Scientific. (3) Other Commitments and Subsequent Events Other Commitments In March 2014, the Board of Directors approved the Compensation Committee’s request to amend the Chief Executive Officer of Milestone Scientific’s employment agreement to provide benefits to make payments of $203,111 per year for five years to the Chief Executive Officer, or as he directs such payments to a third party, to fund his acquisition of, or contribution to an annuity, pension, or deferred distribution plan or for an investment for the Executive and his family. For each the three months ended March 31, 2016 and 2015, approximately $51,000was charged to expense, respectively. The technology underlying the SafetyWand and CompuFlo®, and an improvement to the controls for CompuDent® were developed by the Director of Clinical Affairs and assigned to us. Milestone Scientific purchased this technology pursuant to an agreement dated January 1, 2005. The Director will receive additional payments of 2.5% of the total sales of products using certain of these technologies, and 5% of the total sales of products using certain other of the technologies. The Director of Clinical Affairs is granted, pursuant to the agreement, an option to purchase, at fair market value on the date of the grant, 8,333 shares of the common stock upon the issuance of each additional patent relating to these technologies. If products produced by third parties use any of these technologies (under license from us) then the Director of Clinical Affairs will receive the corresponding percentage of the consideration received Milestone Scientific for such sale or license. Milestone Scientific expensed the Director of Clinical Affairs’ royalty fee of $190,626 and $111,484, during the three months ended March 31, 2016 and 2015, respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of $68,757 and $23,400 the three months ended March 31, 2016 and 2015, respectively. Subsequent Events   Subsequent to March 31, 2016 Milestone Scientific acquired an additional 37% of the outstanding common stock of Milestone Medical by exchanging Milestone Medical shares for shares of Milestone Scientific common stock at a rate of two shares of Milestone Medical for one share of Milestone Scientific. Milestone Scientific has evaluated subsequent events and has determined that there are no other events to be disclosed.

v3.4.0.3

Summary of Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	1. Principles of Consolidation The accompanying consolidated financial statement have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including Wand Dental, as well as Milestone Medical Inc. (“Milestone Medical”) and Milestone Education LLC (“Milestone Education”), both variable interest entities for which Milestone Scientific is the primary beneficiary. All significant, intra-entity transactions and balances have been eliminated in the consolidation.
Variable Interest Entities	2. Variable Interest Entities A Variable Interest Entity (VIE) is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary, and if not, does not consolidate. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision making ability over key operational functions within the entity Assets recognized as a result of consolidating VIEs do not represent additional assets that could be used to satisfy claims against Milestone Scientific’s general assets. Conversely, liabilities recognized as a result of consolidating these VIEs do not represent additional claims on Milestone Scientific’s general assets; rather, they represent claims against the specific assets of the consolidated VIEs. Milestone Scientific is the primary beneficiary of Milestone Medical, and Milestone Education, as variable interest entities. Accordingly, the assets and liabilities of Milestone Medical and Milestone Education are included in the accompanying consolidated financial statements. Please refer to Note 4 for further details regarding the treatment of the variable interest entity.
Cash and Cash Equivalents	3. Cash and Cash Equivalents Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Accounts Receivable	4. Accounts Receivable Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. A majority of credit sales are due within ninety days from invoicing. There have not been any significant credit losses reported by Milestone Scientific.
Product Return and Warranty	5. Product Return and Warranty Milestone Scientific does not accept non-defective returns from its customers. Product returns under warranty are accepted, evaluated and repaired or replaced in accordance with the Warranty Policy.  Returns not within the Warranty Policy are evaluated and the customer is charged for the repair.
Inventories	6. Inventories Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.
Equity Method Investments	7. Equity Method Investments Investments in which we have the ability to exercise significant influence, but do not control, are accounted for under the equity method of accounting and are included in the long term assets on the Consolidated Balance Sheet. Under this method of accounting, our share of the net earnings or losses of the investee is presented below the income tax line on the Consolidated Statement of Operations since the activities of the investee are not closely aligned with the operations of Milestone Scientific. We evaluate our equity method investments whenever events or changes in circumstance indicate that the carrying amounts of such investments may be impaired. If a decline in the value of an equity method investment is determined to be other than temporary, a loss is recorded in earnings in the current period.
Furniture, Fixture and Equipment	8. Furniture, Fixture and Equipment Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from five to seven years. The costs of maintenance and repairs are charged to operations as incurred.
Intangible Assets - Patents	9. Intangible Assets - Patents Patents are recorded at cost to prepare and file the applicable documents with the United States Patent Office, or internationally with the applicable governmental office in the respective country. Although certain patents have not yet been approved, the costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. If the applicable patent application is ultimately rejected, the remaining unamortized balance will be expensed in the period in which Milestone Scientific receives a notice of such rejection. Patent applications filed and patents obtained in foreign countries are subject to the laws and procedures that differ from those in the United States. Patent protection in foreign countries may be different from patent protection under United States laws and may not be favorable to Milestone Scientific Milestone Scientific also attempts to protect the proprietary information through the use of confidentiality agreements and by limiting access to the facilities. There can be no assurance that the program of patents, confidentiality agreements and restricted access to the facilities will be sufficient to protect the proprietary technology.
Impairment of Long-Lived Assets	10. Impairment of Long-Lived Assets Milestone Scientific reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amounts may not be recoverable. The carrying value of the assets is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets. Milestone Scientific adjusts the net book value of an underlying asset if its fair value is determined to be less than its net book value. Milestone Scientific has reviewed long-lived assets for impairment and concluded no impairment exists as of March 31, 2016.
Revenue Recognition	11. Revenue Recognition Revenue from product sales is recognized net of discounts and allowances to domestic distributors on the date of shipment for essentially all shipments, since the shipment terms are FOB warehouse. Milestone Scientific will recognize revenue on date of arrival of the goods at the customer’s location, where shipments are FOB destination. Shipments to international distributors are FOB warehouse, therefore revenue is recognized on shipment of the goods. In all cases the price to the buyer is fixed and the collectability is reasonably assured. Further, Milestone Scientific has no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific’s only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period
Shipping and Handling Costs	12. Shipping and Handling Costs Milestone Scientific includes shipping and handling costs in cost of goods sold. These costs are billed to customers at the time of shipment for domestic shipments. International shipments are FOB warehouse, therefore no costs are incurred by Milestone Scientific.
Research and Development	13. Research and Development Research and development costs, which consist principally of new product development costs payable to third parties, are expensed as incurred.
Income Taxes	14. Income Taxes Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The income tax provision or credit is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.
Recent Accounting Pronouncements	15. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. The FASB continues to release guidance clarifying certain aspects of the revenue guidance.  We do not believe that this new accounting pronouncement will have a material impact on our financial statements. In November 2015, the FASB issued guidance simplifying the balance sheet classification of deferred taxes. The new guidance requires that all deferred taxes be presented as noncurrent, rather than separated into current and noncurrent amounts. The guidance is effective for reporting periods beginning after December 15, 2016 and early adoption is permitted. In addition, the adoption of guidance can be applied either prospectively or retrospectively to all periods presented. As of March 31, 2016 and 2015 there are no deferred tax assets or liabilities recorded. In February 2016, the Financial Accounting Standards Board issued a new standard ASU No.2016-02, “Leases “ (Topic 842): The new standard is intended to increase transparency and comparability among organizations to recognize lease assets and liabilities on the balance sheet and disclose key information about leasing arrangements. It will be effective for fiscal years beginning after December 15, 2019 and for interim periods within fiscal years beginning after December 15, 2020. Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows. In March 2016, the Financial Accounting Standards Board issued a new standard ASU No.2016-07, “Investments - Equity Method and Joint Ventures” (Topic 323): The new standard is intended to eliminate the requirement that when an investment qualifies for the use of the equity method as a result of an in increase in the level of ownership or degree of influence, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect all of the previous periods that the investment was held. It will be effective for all entities for fiscal years and interim periods, beginning after December 15, 2016. Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows. In March 2016, the Financial Accounting Standards Board issued a new standard ASU No.2016-09, “Compensation – Stock Compensation” (Topic 718): The new standard is intended to clarify certain reporting aspects relating to stock based compensation, relating primarily to forfeitures, tax impacts and cash flow presentation.  Certain attributes will be treated prospectively, while others will require a retroactive application. Generally, the changes will be effective for fiscal years and interim periods, beginning after December 15, 2016. Milestone Scientific is in the process of determining what impact, if any, the adoption of this ASU will have on its financial position, results of operations and cash flows

v3.4.0.3

Consolidation of Variable Interest Entity (Tables)	3 Months Ended
	Mar. 31, 2016
Equity Method Investments And Joint Ventures [Abstract]
Pro Forma Financial Information	The financial information in the table below summarizes the combined results of operations of Milestone Scientific, and its subsidiaries including Milestone Medical and Milestone Education (each a variable interest entity) on a pro forma basis as though the companies had been combined as of the beginning of the earliest period presented. The pro forma financial information is presented for informational purposes only and is not indicative of the result of operations that would have been achieved if the consolidation had taken place at the beginning of the period presented.     March 31, 2015 Pro Forma   Total revenue $ 2,791,103   Cost of products sold   933,148   Gross Profit   1,857,955   Selling, general and administrative expenses   2,683,757   Research and development expenses   143,685   Operating expenses   2,827,442   Loss from operations   (969,643 ) Other expenses   -   Interest expense   (369 ) Interest income   1,213   Loss before Provision for Income Tax   (968,643 ) Provision for Income Tax   -   Loss before equity in net earnings of equity    investments   (968,643 ) Loss on earnings from Milestone Medical Inc.   (450,160 ) Loss on earnings from Education Joint Venture   (4,215 ) Gain on earnings from China Joint Venture   96,674   Loss in equity investments   (357,701 ) Net loss   (1,326,344 ) Less: Net loss attributable to the    noncontrolling interests   (457,436 ) Net loss attributable to Milestone    Scientific Inc. $ (868,908 )

v3.4.0.3

Stock Option Plans (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Option Activity for Employees and Non-Employees	A summary of option activity for employees under the plans and changes during the three months ended March 31, 2016, is presented below:       Number of Options     Weighted Averaged Exercise Price $     Weighted Average Remaining Contractual Life (Years)     Aggregate Intrinsic Options Value $   Outstanding, January 1, 2016     1,419,436       1.56       2.78       1,220,338   Granted     348,908       1.72       4.85       -   Exercised     -       -       -       -   Forfeited or expired     -       -       -       -   Outstanding, March 31, 2016     1,768,344       1.59       2.99       466,050   Exercisable, March 31, 2016     1,157,983       1.33       2.43       465,309   A summary of option activity for non-employees under the plans and changes during the three months ended March 31, 2016, is presented below:        Number of Options     Weighted Averaged Exercise Price $     Weighted Average Remaining Contractual Life (Years)     Aggregate Intrinsic Options Value $   Outstanding, January 1, 2016     8,333       2.70       4.83       -   Granted     -       -       -       -   Expired     -       -       -       -   Exercised     -       -       -       -   Outstanding, March 31, 2016     8,333       2.70       4.58       -   Exercisable, March 31, 2016     2,777       2.70       4.58       -

v3.4.0.3

Significant Customers & Geographical Information (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Sales by Product and by Geographical Region	Milestone Scientific’s sales by product and by geographical region are as follows:     Three Months Ended March 31,     2016     2015   DOMESTIC               Instruments $ 661,645     $ 448,965   Handpieces   988,143       432,062   Other   34,379       (13,467 ) Total Domestic $ 1,684,167     $ 867,560                   INTERNATIONAL               Instruments $ 1,268,156     $ 677,614   Handpieces   584,708       1,214,453   Other   32,342       10,577   Total International $ 1,885,207     $ 1,902,644                   Total Product Sales $ 3,569,374     $ 2,770,204

v3.4.0.3

Organization, Business and Basis of Presentation - Additional Information (Detail)	Jul. 31, 2014 shares
Wand Dental Inc [Member]
Organization Business And Basis Of Presentation [Line Items]
Number of outstanding shares acquired	750,000

v3.4.0.3

Summary of Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Due period for credit sales	90 days
Long-lived assets for impairment	$ 0
Deferred Tax assets	0	$ 0
Deferred Tax liabilities	$ 0	$ 0
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	5 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	7 years

v3.4.0.3

Accounts Receivable - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Due period for credit sales	90 days

v3.4.0.3

Consolidation of Variable Interest Entity - Additional Information (Detail)	May. 16, 2016	Mar. 31, 2016
Milestone Medical Inc. [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		49.98%
Milestone Medical Inc. [Member] | Subsequent Event [Member]
Schedule Of Equity Method Investments [Line Items]
Percentage of outstanding common stock acquired by exchange of shares	37.00%
Exchange terms	two shares of Milestone Medical for one share of Milestone Scientific
Milestone Education LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		50.00%
Percentage of revenue from services performed to variable interest entity		80.00%

v3.4.0.3

Consolidation of Variable Interest Entity - Pro Forma Financial Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Schedule Of Equity Method Investments [Line Items]
Loss in equity investments	$ (269,726)	$ (357,701)
Milestone Medical Inc. & Milestone Education LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Total revenue		2,791,103
Cost of products sold		933,148
Gross Profit		1,857,955
Selling, general and administrative expenses		2,683,757
Research and development expenses		143,685
Operating expenses		2,827,442
Loss from operations		(969,643)
Interest expense		(369)
Interest income		1,213
Loss before Provision for Income Tax		(968,643)
Loss before equity in net earnings of equity investments		(968,643)
Loss in equity investments		(357,701)
Net loss		(1,326,344)
Less: Net loss attributable to the noncontrolling interests		(457,436)
Net loss attributable to Milestone Scientific Inc.		(868,908)
Milestone Medical Inc. [Member]
Schedule Of Equity Method Investments [Line Items]
Loss in equity investments		(450,160)
Milestone Education LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Loss in equity investments		(4,215)
Milestone China [Member]
Schedule Of Equity Method Investments [Line Items]
Loss in equity investments	(164,837)	96,674
Gain on earnings from China Joint Venture	$ (269,726)	$ 96,674

v3.4.0.3

Investment in Unconsolidated Subsidiaries - Additional Information (Detail)	1 Months Ended		3 Months Ended
	Jan. 31, 2016 USD ($) Instruments $ / Instruments	Jun. 30, 2014 USD ($) Instruments $ / shares	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)
Schedule Of Equity Method Investments [Line Items]
Loss in equity investments			$ (269,726)	$ (357,701)
Cost of products sold			$ 1,368,190	933,148
Advanced Ocular Sciences SA [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investment, ownership percentage			25.00%
Advances for marketing and strategy planning					$ 78,798
Milestone China [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		40.00%
Investment in joint venture		$ 1,000,000	$ 0	445,325
Issue of purchase order | Instruments	308	772
Distributor price per instrument | $ / shares		$ 1,295
Loss in equity investments			(164,837)	$ 96,674
Suspended losses on investment			177,291
Purchase order	$ 400,000
Purchase order value per instrument | $ / Instruments	1,296
Additional investment in joint venture	$ 165,000
Deferred profit included in Statements			(174,670)
Milestone China [Member] | STA Instrument [Member]
Schedule Of Equity Method Investments [Line Items]
Cost of products sold			1,000,000
Accounts receivable			$ 825,340

v3.4.0.3

Stock Option Plans - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Milestone recognized total compensation cost	$ 134,505	$ 82,124
Total unrecognized compensation cost related to non-vested options	$ 1,026,024	$ 949,780
Milestone recognize cost over a weighted average period	2 years 11 months 27 days	3 years 1 month 6 days
Option Activity for Non-Employees [Member] | Vested Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Milestone recognized total compensation cost	$ 1,175

v3.4.0.3

Stock Option Plans - Summary of Option Activity for Employees and Non-Employees (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	1,419,436
Number of Options, Granted	348,908
Number of Options, Ending Balance	1,768,344	1,419,436
Number of Options, Exercisable	1,157,983
Weighted Averaged Exercise Price, Beginning Balance	$ 1.56
Weighted Averaged Exercise Price, Granted	1.72
Weighted Averaged Exercise Price, Ending Balance	1.59	$ 1.56
Weighted Averaged Exercise Price, Exercisable	$ 1.33
Weighted Average Remaining Contractual Life (Years), Outstanding	2 years 11 months 27 days	2 years 9 months 11 days
Weighted Average Remaining Contractual Life (Years), Granted	4 years 10 months 6 days
Weighted Average Remaining Contractual Life (Years), Exercisable	2 years 5 months 5 days
Aggregate Intrinsic Options Value, Beginning Balance	$ 1,220,338
Aggregate Intrinsic Options Value, Ending Balance	466,050	$ 1,220,338
Aggregate Intrinsic Options Value, Exercisable	$ 465,309
Option Activity for Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	8,333
Number of Options, Ending Balance	8,333	8,333
Number of Options, Exercisable	2,777
Weighted Averaged Exercise Price, Beginning Balance	$ 2.70
Weighted Averaged Exercise Price, Ending Balance	2.70	$ 2.70
Weighted Averaged Exercise Price, Exercisable	$ 2.70
Weighted Average Remaining Contractual Life (Years), Outstanding	4 years 6 months 29 days	4 years 9 months 29 days
Weighted Average Remaining Contractual Life (Years), Exercisable	4 years 6 months 29 days

v3.4.0.3

Advances on Contracts - Additional Information (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Advances To Contract Manufacturer [Abstract]
Advances on contracts	$ 1,253,645	$ 1,215,128

v3.4.0.3

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Line Items]
Amount of state tax expense	$ 47,000	$ 0
Federal [Member]
Income Tax Disclosure [Line Items]
Net operating loss	$ 0	$ 0

v3.4.0.3

Significant Customers & Geographical Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016 USD ($) Customer	Mar. 31, 2015 USD ($) Customer	Oct. 01, 2014
Entity Wide Information Revenue From External Customer [Line Items]
Number of customers | Customer	2	2
Customer One [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Accounts receivable	$ 505,670	$ 761,413
Customer Two [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Accounts receivable	228,148	170,536
Related Party Supplier [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Payable	$ 610,202	$ 455,573
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Number of customers | Customer	2	2
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Customer One [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Concentration risk percentage	21.00%	27.00%
Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member] | Customer Two [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Concentration risk percentage	35.00%	18.00%
Instruments [Member] | Supplier Concentration Risk [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Purchase from suppliers	$ 636,059	$ 617,602
Minimum [Member]
Entity Wide Information Revenue From External Customer [Line Items]
Rate of shareholder of the company			5.00%

v3.4.0.3

Significant Customers & Geographical Information - Sales by Product and by Geographical Region (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Product Information [Line Items]
Total Product Sales	$ 3,569,374	$ 2,770,204
Domestic [Member]
Product Information [Line Items]
Total Product Sales	1,684,167	867,560
Domestic [Member] | Instruments [Member]
Product Information [Line Items]
Total Product Sales	661,645	448,965
Domestic [Member] | Handpieces [Member]
Product Information [Line Items]
Total Product Sales	988,143	432,062
Domestic [Member] | Other [Member]
Product Information [Line Items]
Total Product Sales	34,379	(13,467)
International [Member]
Product Information [Line Items]
Total Product Sales	1,885,207	1,902,644
International [Member] | Instruments [Member]
Product Information [Line Items]
Total Product Sales	1,268,156	677,614
International [Member] | Handpieces [Member]
Product Information [Line Items]
Total Product Sales	584,708	1,214,453
International [Member] | Other [Member]
Product Information [Line Items]
Total Product Sales	$ 32,342	$ 10,577

v3.4.0.3

Commitments and Other - Additional Information (Detail)		1 Months Ended	3 Months Ended
	May. 16, 2016	Mar. 31, 2014 USD ($)	Mar. 31, 2016 USD ($) ft² shares	Mar. 31, 2015 USD ($)
Long-term Purchase Commitment [Line Items]
Area of office space | ft²			7,625
Lease expiration date			Jan. 31, 2020
Monthly cost			$ 12,522
Rent expense			35,232	$ 13,824
Employment benefits		$ 203,111
Number of years in providing benefits		5 years
Pension plan expenses			$ 51,000	51,000
Additional payment received by using technology			2.50%
Additional payment received by using other technology			5.00%
Milestone Medical Inc. [Member] | Subsequent Event [Member]
Long-term Purchase Commitment [Line Items]
Percentage of outstanding common stock acquired by exchange of shares	37.00%
Exchange terms	two shares of Milestone Medical for one share of Milestone Scientific
Director of Clinical Affairs [Member]
Long-term Purchase Commitment [Line Items]
Options to purchase common stock issued | shares			8,333
Director's royalty fees			$ 190,626	111,484
Professional fees			$ 68,757	$ 23,400

begin 644 Financial_Report.xlsx
M4$L#!!0    ( +*%L$CG?S$WN0$  )T7   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,V8RT[#,!!%?Z7*%C6N'=ZBW5"V@ 0_8))I8S6.+=M]_3UV"@BJ@EJ@
MTMWDT3N>>Y-QSJ(WSVM+OK?23>N'61V"O6;,ES5IZ7-CJ8W*Q#@M0[QU4V9E
M.9-38F(P.&>E:0.UH1]2CVQT\[ @YU1%O=N-D'H/,VEMHTH9E&G9HJVVNO;-
M9*)*JDPYUW%)'J(UG40]ZSU*%^ZECBW8JF&=L#GR/.GL?PR]=20K7Q,%W>0^
MK!ORN_PWRKOSF"9RWH2#C-_>7>ZHZ6I\K>R;U=TJ=O'QMV$65;^7P_;"GY(I
MG89FV^F7%>G^E\^R]1(7NAD[N51;!HNCC2F=::W?]W= [T;/N=$1(')1#@.0H0'*<@N0X \EQ#I+C B3')4B.*Y QW8OG*\M"_V/Z'D4X$G1H>)%]2-F Q+M*;V"^GH A3&^.R6:E((C
M-Z."N[_8_ )02P,$%     @ LH6P2 QUTFF. 0  J18  !H   !X;"]?&?/ODKC;671NJN@^S]^;:ANWP
M?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9L^-I
MG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ-?U28
MKPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z: T)VJ2#
M-I @RA49C-&;%;T9HSC-&;U;T9HS>
MK.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@MBMZ"
MT5L4O06CMTST#I7U[O0ID[:&AHZMC$:J:755JD;J-#N^7HQ
M<"*YB\Z7"/KKYR20AO;2TCR,%RZ./]O?9SO)4&%W,#$Z 6,E(%O'D<(!&<\Z
M2VN3@>>A6$+,\9A<%-V=:Q-S2Y=FX>GY7 JXU"*-05G/[W;['JPMJ!#"STD5
MM!,,\RSG21))P:W4*O@MA=&HYY9=K05$0^^Y0X&@R%,0J9%V$W1+G[JI\)D*
M'L&(<@5S'B&47D_&PF>DXX2KC5=>W4BUPKMDIB^YA3IJ_T89?2*]MA*!_ITN^4:4MK<8X2
MM";XJ\T*EP 6AUYE+(YUW_I9G@:]?N%!IWU/KV(6;&7;XYU;9M)&@./YA!O[
MGZ0H..V$Z/4[-?:[$(RKD%TI2^/(KE69BII7EZ0ZC33MA4((&9U01S*D,0O9
M!8^X$L!:8'KOP4PM_5'-+3!?6F#Z3LS8++B2CX5(G]A%BE(!8J'B!4?IQ$S3
M..9FP_22Q11+V449I7]0,KQMDGLJ%
MDK11M,-LE*(E;X/L X^3'^PGZ(7AB1,WH;%YBU4O3T;A5
MS2WT3PYL!SN:Y1C\V$X;W[V]KVZ(?_I^#7SW]CK&G7UFYR'-#F7F+73[V@+S
M[?WKXG\_M#\U.M'AF"5>4[H]W\]!IFX4U
MUL_>S=[^-V7P#U!+ P04    " "RA;!(IR.FW3X!  !I P  $0   &1O8U!R
M;W!S+V-O&ULS9--3\,P#(;_"NJ]2[NQ'JJN!T".%K?XZ48
M\&[O&X))P: !#08#RRCI-]\S<:UOT0_];QV2!M%Q4V
M<.%N22-IN?1)( E!>.5067,1CC!?Q 0+^_N;&-]=TK]B+Z]JOH34$L#!!0    ( +*%L$B97)PC$ 8  )PG   3    
M>&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;
MM)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+H
MAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J
M9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X
M.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-
M6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E
M0-,@ %AP=M;,[email protected]=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %
M#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU]
M.LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&
M)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CW
MJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"
MJ_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4
MOK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HX
MGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZA
MAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;
MQ@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=
MSU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ
M(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;
M.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE
M9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPY
MC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$
M%     @ LH6P2,XXE?5& @  >@H   T   !X;"]S='EL97,N>&ULS59;:]LP
M%/XK0AFCA1';"4WI:AM&(3#8RJ!YZ%N1;=D6Z.+)2_XCZ@OC;4
M7E^@.,P%'^NT@ Z(P_H9;!'5_H%Q3P45$BA]$%J#13ABV'G<(4H220R8(T9H
MY^"% >S9]7Z,<"%M;I?A,,_<'S/)(HF@W_].3Y>,['8PVR.4[F]/ W%8(:6P
MY&L] ;V]Z2J].2XX=B*MWPO>A41=L+B:!-A!YTV$S+ <,@=P!\4AQ;G2 9(4
MI1F5J(QTH91@VL@(*@1'U%#N(GI#TZ:8T@?SI3SF>]QM#IR/.6,? J-B9^I"
M].9X#6Q1O2F;XY[2OHT7M/F00$>CJJ+=)TH*SK 3ZZ"UZ&JO\%>FQ]3^-8M_TU-?[YJHQI]!?]U
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M/QZ/'T_WP4\?K+N_L_:>/5;:^*F;[email protected]<+_96ME\-G:NDH$'+K-
MP*[7(-6EE4VE3!CPX7 R<$J+ -;X+=0^V]/\K]!\[90H_5:I4.D.5@DPV<=,2U\^%1"4.4L&^'0/JC>#=?4%PWH.!@/Q]D@
MPIZ7>NV8M*7J8*LM^'_W#S)6JK5H=%AAL,_SSK*""@
M$P(Z.00MFZH2[@>S:W8NI6U0 +-AUQB:!.4)YY1P3@\Y<5;9SG\)NHF+^H;/
M%D;:2K%W7PGHC(#.#D'[*#R[45+!3D29B8-#*N$PF>%]7F,]P57="@<1@K'@
M2:6HGL\)H1=FAP6G/1M@V'=<"MVRAJ*HT7E"Z66P\IY=U6U0U^@QS6Q.-<[3
M'DN,POU_2:J^CW[K.S&B9KBJ+)YPMEK/$+)1%)'
M\X2DF4W)>EKN\1I[>746IZP]FB)XB.*HN+RA+A'T\YI_>5489Y0.%%>V)_L
MO,3SA'$*BJ)6\X35QW?PA**HT3QA]''4*451QWG"\:-5BY]1%+6=IVP_](JD
M2M,/,;6]2-B>1+UL*T51VXN$[ IJ?$&-+U+&OXJCUA?4^B+9=R0*7SIGU/IBLN\C7UI'[)[Q')>QL?;M--B9
MRMAMXT_W*1R-8QF-XW^P Y]EL4W&CKC1>H[WKLQ7*]IFLB,_]]
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M5)[= 3"X#8P]G+>'
MC_80[*&Q1[;\0+$#13P/B*R R-B3"0 HTGE ; 7$QKZ: ( "^?.$Q$I(P(\>
M$8V1Q(  "?;1@CJE5D@*$.M*B0#22Q8LE945L0)_.%&J7A+-(Y!O99AA%2&>
M@ R:9 $%V2G]KDPG?DFO2:,H3A>4#&$[";8GFEI?O08O6& HL%-@%V,T1>DU
M> '%OM<1;&4^W+39G
M]*<\SUIRH;\(OY2-< Y,JI/>',AGQB152?A/:L$7Z@8>.Q4]2_V:Z)T =Q)T
M)&N'*W:\Y_/_4$L#!!0    ( +*%L$BG^Q$QL@0  (,7   8    >&PO=V]R
M:W-H965T&ULE9A-;^,V$(;_BN%[UAQ^,W ,K%44[:' 8@_M
M68F5V%C;=[A>+]FE;'NKZ(
M,GZ\546UW_2_]U:&Z4_UBV55'O_]IMNFU4*^:S3?5<
MONZ[[_7YMPK;8/H"G^I]._R?/;VV77T80^:S0_DS?>Z.P^(%AM$!$@/D
M)0 T&Z P0'T(6"1E0[M^*;MRM6SJ\ZP]E?UHPWW$F[Z06/(L-J:-_324V0P]
MM5J^K:1>+M[ZOE5IGA[.UZ]C]+ !>4%
MW-9C2#TF5188/0DQ'K1@U%#4I!9+:K%#$8JI98V(#UXJ*T-%Z$C+%R
MI!Z7*@-&3T) &F6U8?2,'!BX&OM)/9[4XY,>R>A)B!%&*+D5,FJ SW
M J 5)?]3S-Q8(^- :LWX0G'AC,E98R!I1FQ1@:<,MRD)K%I/;1!0[)5
M;C6OD0&PP@;/2D)2QG6OKEQ_6M4'F\9M!S0:348)M+%",D3%.2LRX*U5AIV,
M:-/">VES--$&"VB+G,,B \H9<(SU%2-HXI_-Z6G:9,'AMLKLT,BHWATD:3BX
M18^@C5MTUJJEC18\;A]48J-1$S)JFBD^,]-* CT/DS/J#)>6M"?*Y&/T[H3]
M*T=/])(9AN*"69^3S]&.*).+:V*,EF9YEP(
MF3OKP1OQ<>#?RQI1IY4..=FBI-U18M+)Y8O(W 6(>R>WZT^ TYKH%%8F;]2<
MLR$#0@@EZ$DUBAI));QQ.?.*]EN)"2CG;P=5]*>*S%US>EK
MVBMEOEJ9*KY615BCXVJ_]Q;IXX.">S,)RA
M(!.7D\ZIB+83E0S Y'27H1MK\AM++U-EF6N"<> 3XV2P[.!C6B1EQ@I5] I5
M[O8M 3+:",%SD]B?'.!,?=6HR<-\%FG/04??A4X?;97(U^
M .RQ:L1B!IYSJT,[A\XX>2(#PFG!)0\C!T&(C$6A@5P4&K)/,)K.B;2\?8)!
M1DL; MLFY"S(G)U+TYZD%7-^P5P6F7A6\,#DO,7(&:T^SWT.QJ[-T\A-N9\?$81FZN?'X11\9D]#H.DUC'1RE/JR01VR,;
MJ7C@)S:I)WL^CU2JR_F0B-/,Z,X$C4.2(D22D?93W#;FWN/<-OPLAWYBCW,D
MSN-(Y[\;-O#K.L;Q[<93?SA*?2-IFV2)V_4CFT3/IVAF^W7\!:\Z7&C$$+]Z
M=A5WYY&6?^;\15_\V*UCI!W8P+92IZ#J<&$=&P:=28W\QR7]/Z8.O#^_9?]F
MIJOTGZE@'1]^]SMY5+8HCG9L3\^#?.+7[\S-P1AN^2#,?[0]"\G'6T@=
M1&6.U&2$JI/).9M*M@\;Y#4(!N+I'ZBM\:ME ?T&I6@4>DJ'#"R2(K+%.5U&3#R@%ZC"C2JK%$1,+((
MQ@CE*,!UEJM)EA>?6+(:U*G=FQK0J=V\257B4"4[#^@UP@A4,K>54V M-H[)
M]"]@!&)^'PS[N&[\F0QP)\6V!9(J\)$ZYJ.O%,3\/G _Q:ZA@JW]5N'L_@,,
MU1@&_4YP5\6V&9:A)K\P82& \MO 717;;EB"2W&S*3YE U#6)KG;&9SH@?VD
M\Z&?1/3,I=IDF+W GG/)5!;T4,3146W^EHN![:4^+=7Y;+=#]D+RTVUWMVPQ
MVW]02P,$%     @ LH6P2%),:7P)!   41(  !@   !X;"]W;W)K9B]YI.G(.&
M0Q9(9_;MUU F?9#'>&X".'^5/Y]^C->WMOO1G[0>HI]UU?1/\6D8+H])TN].
MNB[[A_:B&_//H>WJWK]JV(1L3[MJJGWZC
MW;4?VGH.B:.Z_$G7 =&HID4WM^J,<
MRLVZ:V]1?RG'T89'(^_&)"9S9!K3FWZ:#!"?)EB1P
M5R0FN;,&C%WA.(5[*BA(D?/E&OC'&E)J Z?X]&,5S23)"8(D/!.*^W0%Z3#/
M&;)TF2=U\J3$D[GJ$<1#$N!"@F*_UA6D4YQ#*I=Q,B=.1CC"@T,21 8@G=UC
M<4@'DNINC!
ML;*Q%Y=AI!-&$HSRP)#$S(@T^[QN/]"0SLPO,\?4,H]R\J@IB?0,PI8D*Y5R
M+CV=6%A=#J8?EW& .7FF8@,$'B"K60'R/* B<%=$MB<]/;RU&LY\PV!%@, "
M8- -0Q8IN0\&[3APC_$45A5(X_9;()?T.<76:LRL2#EZL(M9*)1QN0 DM^4"
M&:7T>:[5K%(A>8"W@]M-@3Q0^NS4:E9* 60>GRMF86CCW88*9(/2YZA6LT*A
MYQLF0D_&2R5
M/B.9IPK9[[F=$\GPE-,4E=T4DF;%'IASW)7=&;[),(#';9Z(=A/EX\$P'OPM
M'N[N87(\%3"/T>UVF'IZV,YCJT&SMA1//3.^F)6@0 D(V-:AVQDQ\_3S3)4%
M4V6_2^4V1R0_4R$KPFUEF'OLU2X^G TJ8R "WJSH-BBTYA,"Z[845(OO@@)G
MIT (J(B[-V+<^D3 R'"W3W!8[->MU:Q I)+[VF2%2H@\8%UQMU-PZQ1>(EQZ
MD&PO=V]R
M:W-H965T&ULE9;;;N(P$(9?)>)^&Q]BQZX :8$"K;12U8O=
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M!@)V$?@M<1#P7D"Y5Q"#(+[U&P0(Q"4#]0HD"&0OX-@K:&IN*X:A8\@PL^P8.LRL.B8:9M8=PX:9QX[AP\Q3Q\0]
M$YKE=]> ?*Y!9&M (,*7(A0M$]LB6$9BSB))AKDYQ.(T\D1;6"H>)AXL00@7
M;)A:0AS!*:&"#H,K"W[C<40C*:)A<@TDQA%%OI"/-WWI$X23&#/,;Z@0=5:(
M0H6D*Q.W:VJ9&'W=!-?0 [TL*^;H!C^1TT]D_6!/JADP-&)?6_P:6SJQ83_,
MZ8>!'^SQ8QEJAH1[A:#Q(!3E'L\0"DG!HQL\L*1<'>]!5< Q@PAYNG&-7#,3!5RBW7AM"[ NF?#SBPCJ)E,
MW#.9%N*?,T? YA#$V4)=*ZJA%7U;,N%O&6:R'[!R'6-K)_PZCQP3/;J1U+NTZ(*7G5M#A?M 6"G
M=:U,('1G3E('N!   ^!8  !@   !X;"]W;W)K_W=3UD/YOCJ;]=[(?A?+-:]0_[NJGZ+^VY/OF_
M/+9=4PW^9_>TZL]=7>VF1LUQ!7EN5DUU."TVZ^G9UVZS;I^'X^%4?^VR_KEI
MJNZ?;7UL+[<+M9@??#L\[8?QP6JS7EW;[0Y-?>H/[2GKZL?;Q9VZ*[R$&
MK[_/T7^=NNOMWU=]7;;'OPZ[8>_=YHML5S]6S\?A6WOYK>8^Z#'@0WOLI_^S
MA^=^:)NYR2)KJI_A\W":/B_A+Y:XF=P N %<&USSR V0&^!+@RG#*CB;^O5+
M-52;===>LOY']!&506/PX [[-$![>(7?"?AR W@:@$( X +XU>9HT
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M::@8AQ#!8GUV+N
M'8P%R?\\WZJ;,I1D7\)LUN?JJ?ZCZIX.ISZ[;X>A;::JY&/;#K7WEG_1BVQ?
M5[OKCV/].(Q?K?_>A<)L^#&TY[G.?"UV;_X%4$L#!!0    ( +*%L$@C1;Y.
MHP$  +$#   8    >&PO=V]R:W-H965T&ULC5/+;MLP$/P5
M@A\0RK*=M(8L($Y1I(<"00[MF996$A&2JY*4E?Y]^9 4.S"27L3=U+V!GO0_D^#1G'G4],RVQO@=20IR?(LNV6*
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MY' ].?R/_IM+@4T2V'PT8L(<9LQ[E^QL3Q68-EX=2RHB 0  L0,  !@   !X;"]W;W)K!I"3+DN0+4UP,M"I#[4E7)4Y6B@&>-#&34ES_/8+$
M^4!3NA:>1==;7V!5R39>(Q0,1N! -+0'>I_NCX5'!,!O ;.YB(GW?D)\\NB^=[2$R_C5?TQ3.OLK,7NL)$
MXG'!; CFU&^VR.@M>A;HV>?T_)J>1X?YXK#X7*"X%BBB0/&_$2/FN&)V'YJP
MBSU5H+MP=0RI<1ILW-*MNMW.^RRP2^N.S$8&PO=V]R:W-H965T&ULA5/;;J,P$/T5
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MN)XS)!(:%\(['YMTI5+BL)\?
MR/)*R[]02P,$%     @ LH6P2!@#,0ND 0  L0,  !D   !X;"]W;W)K&ULA5/+;MLP$/P5@A\0RO*CK2$+B!,$R:% D$-[IJ65
M1(3D*B1EI7]?/F3%#HSD(NZN9F9G^2A&-*^V W#D74EM=[1SKM\R9JL.%+#\@OH;D
MJ=[1+%@ "94+"MPO1[@#*8.0;_PV:7ZT#,3S^*3^$*?U[@_;
M45)#PP?I7G!\A&F$=1"L4-KX)=5@':H3A1+%W],J=%S']"=?3K3KA'PBY#/A
M9Q:-IT;1YCUWO"P,CL3V/)S=8NOA)HAX9>*]63]VU#1Q\+(XEHOUKX(=@] %
M)A'W$V9&,*]^M45.K]'S2,^_IR\OZ&PO=V]R:W-H965TU#I=4^M,\.#&"M[:&V"=N_KR_ )E74?<$SPSEG
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M#H?E@:ROM/H+4$L#!!0    ( +*%L$A]HP$  +$#   9    >&PO=V]R
M:W-H965TZ:EE42$Y*HD9:5_'SXDQ2Z,YB+NKF9F9_DH1C1OM@-PY%U);0^TZ(K.A5?1=BX46%FPA5<+!=H*U,1 Y/W,(CRM^B
M=ITWFU%20\,'Z5YQ_ G3"-L@6*&T\4NJP3I4,X42Q=_3*G19W[GA9&!R)[7DXN]7>PTT0\[-^[*AIXN!E<2Y7NVW!
MSD'H"I.(QPFS()A7O]DBI[?H>:3G7]/7U_1U'*Z_%MA<"VR2P.9_(R;,
M<<;L_FG"+O94@6GCU;&DPD&[M*5+=;F=#WD\DT]X6?2\A6=N6J$M.:'S)QL/
MH$%TX-MG=UM*.O]^ED1"XT+XS<C'U8I $  +$#   9    >&PO=V]R:W-H965T&+"!.$;2' D$.[9F65A(1DJN0E)7^??F0%#LPFHNX
MNYJ9G>6C&-&\V@[ D797=,<:%I6<3:LRD+')P4&IX-L8-2W/P]@,1Q3U=T+KR(MG.AP,J"+;Q:
M*-!6H"8&FCU]6.T.FX"(@-\"1GL6D^#]B/@:DI_UGF;! DBH7%#@?CG!(T@9
MA'SCMTGSHV4@GL>S^E.;$9)#0T?I'O!\0=,(]P&P0JE
MC5]2#=:AFBF4*/Z>5J'C.J8_VWRB72?D$R%?"/=9-)X:19O?N>-E87 DMN?A
M[%8[#S=!Q"L3[\WZL:.FB8.7Q:E*C!MO#J65#AHE[9T
MJ2ZW\R$>(ON ET7/6_C%32NT)4=T_F3C 32(#GS[[.:6DLZ_GR61T+@0;GUL
MTI5*B<-^?B#+*RW_ 5!+ P04    " "RA;!(O/1 MZ$!  "Q P  &0   'AL
M+W=O!OU]?DM"B"GB)9R;GG#GC2S&B>;8=@".O2FJ[HYUS
M_98Q6W6@N+W"'K3_TZ!1W/G4M,SV!G@=24JR/,M^,,6%IF41:X^F+'!P4FAX
M-,0.2G'SM@>)XXZNZ%QX$FWG0H&5!5MXM5"@K4!-##0[>KO:[C;,9)34T?)#N"%@9'8GL>SFZU]7 31+PR\=ZL'SMJFCAX61S+
MU4U6L&,0.L,DXG["+ CFU2^VR.DE>A[I^=?T]3E]G1RN)X??Z+\Y%]@D@/5L:3"0;NTI4MUN9VW>3R3=WA9]+R%!VY:H2TYH/,G
M&P^@073@VV=7UY1T_OTLB83&A?#&QR9=J90X[.<'LKS2\C]02P,$%     @ 
MLH6P2,<\H;"C 0  L0,  !D   !X;"]W;W)K&UL
MA5/;;J,P$/T5RQ]0$Z#M*B)(3:NJ?5BIZL/NLP,#6+49:IO0_?OU!6A21>T+
MGAG..7/&EV)"_68Z $L^E.S-CG;6#EO&3-6!XN8*!^C=GP:UXM:ENF5FT,#K
M0%*2I4ERPQ07/2V+4'O198&CE:*'%TW,J!37__8@<=K1#5T*KZ+MK"^PLF K
MKQ8*>B.P)QJ:';W;;/>Y1P3 'P&3.8F)]WY ?//)<[VCB;< $BKK%;A;CG /
M4GHAU_A]UOQLZ8FG\:+^&*9U[@_*\&3=VT-1A\+(XEIO;K&!'+W2&B<3]C%D1S*E?;)'22_0T
MT-.?Z=DY/8L.L]C])OE9(#\7R*- _MV($;-?,/F7)NQD3Q7H-EP=0RH<>QNW
M=*VNM_,N#6?R"2^+@;?PF^M6](8C 0  L0,  !D   !X
M;"]W;W)K&ULA5/;;J,P$/T5RQ]0$TB:5420FE95
M^[!2U8?=9P<&L&HSU#:A^_?K"]"DBMH7/#.<<^:,+_F(^LVT )9\*-F9/6VM
M[7>,F;(%QWJWVAW6'A$ ?P2,
MYBPFWOL1\)MX"2"BM5^!N.<$]2.F%7./W2?.SI2>>Q[/Z8YC6N3]R
M _E$2!?"KR08CXV"S0=N>9%K'(GIN3^[U<[!M1=QRL1Y,V[LH*G#X$5^
M*E;;3A8=9I/#VY\%UI<"ZRBP
M_F[$B#G,F.V7)NQL3Q7H)EP=0TH<.ANW=*DNM_,N#6?R"2_RGC?PF^M&=(8<
MT;J3#0=0(UIP[9.;#26M>S]+(J&V/MRZ6, *VE 0  L0,  !D   !X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK+2.(8L($X1M(<"00[MF996$A&2JY"4E?Y]^9 5
M.S":B[B[FIF=Y:.N6'+F*U[4-S>X #:_VG1*.Y\:CIF
M!P.\B20E69YEWYCB0M.JC+5G4Y4X.BDT/!MB1Z6X^;L'B=..KNBI\"*ZWH4"
MJTJV\!JA0%N!FAAH=_1AM=T7 1$!OP5,]BPFP?L!\34D/YL=S8(%D%"[H,#]
MT"AW7*?TI[F?:=4(^$_*%L,FB\=0HVOS.':]*
[email protected] P]GM]IZN DB7IEX;]:/'35-'+PJC]7J;E.R8Q"ZP"3B?L8L".;5K[;(
MZ35Z'NGYU_3U)7V='*YGA_=?"Q27 D42*/XW8L+L9\PF^]2$G>VI M/%JV-)
MC:-V:4N7ZG(['_)X)A_PJAQX![^XZ82VY(#.GVP\@!;1@6^?W=Q2TOOWLR02
M6A?".Q^;=*52XG X/9#EE5;_ %!+ P04    " "RA;!(-_O,SZ,!  "Q P  
M&0   'AL+W=OQ-W5S.PL'^6$YM7V (Z\
M*ZGM@?;.#7O&;-V#XO8.!]#^3XM&<>=3TS$[&.!-)"G)BBS[Q!07FE9EK#V;
MJL312:'AV1 [*L7-KR-(G XTITOA172]"P56E6SE-4*!M@(U,= >Z$.^/VX#
M(@)^")CL14R"]Q/B:TB^-0>:!0L@H79!@?OE#(\@91#RC=]FS8^6@7@9+^I?
MXK3>_8E;>$3Y4S2N]V8S2AIH^2C="TY?81YA%P1KE#9^23U:AVJA4*+X>UJ%
MCNN4_NRRF7:;4,R$8B7<1P)+C:+-)^YX51JLG,0NL(DXG'&K CFU6^V*.@M>A'IQ;_IFVOZ)CG2&D?MTI:NU?5V/A3Q3#[@53GP#KYS
MTPEMR0F=/]EX "VB ]\^N]M1TOOWLR826A?"SSXVZ4JEQ.&P/)#UE5:_ 5!+
M P04    " "RA;!(.ZP;T*,!  "Q P  &0   'AL+W=OP)$W);4]T-ZY8<^8K7M0W-[A -K_:=$H
M[GQJ.F8' [R))"59GF7W3'&A:57&VK.I2AR=%!J>#;&C4MS\/8+$Z4 W="F\
MB*YWH<"JDJV\1BC05J F!MH#?=SLCT5 1, O 9.]B$GP?D)\#&D6;
M7[GC56EP(G;@X>PV>P\W0<0K$^_-^K&CIHF#5^6YVCP4)3L'H2M,(AYGS(I@
M7OUFBYS>HN>1GG].WU[3M\GA=G:X^UR@N!8HDD#QOQ$3YKA@[C\T81=[JL!T
M\>I84N.H7=K2M;K>SL=XB.P=7I4#[^ G-YW0EIS0^9.-!] B.O#ML[L=);U_
M/VLBH74A_.)CDZY42AP.RP-97VGU#U!+ P04    " "RA;!(\(K8TFH"  !2
M"0  &0   'AL+W=OBD@OHNC*-H$_:H
M'8*Z4F.OM*[(E7?M@%\I8->^1_3?'G=DV@4PL -O[:7A1<\P^T>%E*B%+];/+&[-I#)'PAYEYV?IUT0R1QPAX]<6B#QN.$7W'72
M29#_&M-/I@R\;UOW[VJZ(OT#8OB%='_:$V]$ME$ 3OB,KAU_(],/;.:02<,C
MZ9CZ!<5)U<3KZE;#(J_"FS1ZT.C O=',BE"X.Q%QX J/
M57B\')X\ABR!6DRQ#"X5S],C<7&Q[&B-77@W@!@9BR\=6!%:^K O0= O+C6-'7#2>\._-Z3"_J:&?@2*X#
MUT?>/#I?'Y[5(1M^RNMJ1!?\"]%+.S!P(%R!'3UD &G'!F3L=
M/G/9S$6;ZB-?=S@9[0UFOD;5_P%02P,$%     @ LH6P2.B$[&VE 0  L0, 
M !D   !X;"]W;W)K&ULA5/;;IPP$/T5RQ\0 WM)
MM6*1LJFJ]J%2E(?VV0L#6+$]U#9+^O?U!\,QP+C.^E!.:-]L#./*N
MI+9'VCLW'!BS=0^*VP<<0/L_+1K%G4]-Q^Q@@#>1I"0KLFS/%!>:5F6LO9BJ
MQ-%)H>'%$#LJQU+_%
M:7WW9V[A&>5OT;C>-YM1TD#+1^E>?:?<)Q4PH5L*7+#:>C&*;7[GC56EP(G;@X>SR@X>;(.*5B>_-^K&C
MIHF#5^6E*O)=R2Y!Z :3B*>$R5<$\^IW+0IZCUXDB\_IFUOZ)G6X2>[[S><"
MVUN!;1+8SB/N[XV8,*<%\_B?";O:4P6FBU?'DAI'[=*6KM7U=CX5\4P^X%4Y
M\ Y^  MH@-OGSWL*.G]^UD3":T+X:./3;I2*7$X+ ]D?:75
M/U!+ P04    " "RA;!(IG\$Y:8!  "Q P  &0   'AL+W=O;0_@R(>2VNYH[]RP9*THSD]
M%5Y$U[M08%7)%EXC%&@K4!,#[8X^YMO].B BX%7 9,]B$GH_(+Z'Y'>SHUEH
M 234+BAPOQSA":0,0M[X[ZSY91F(Y_%)_6>4+Z)QO6^V8R2!EH^
M2O>"TR^81[@-@C5*&[^D'JU#=:)0HOA'6H6.ZY3^W!  MH@-O
MG]W<4M+[][,D$EH7PGL?FW2E4N)P.#V0Y956GU!+ P04    " "RA;!(9+>L
M$J4!  "Q P  &0   'AL+W=OM/_3H%'<^=2TS/8&>!U)2K(\R^Z9
MXD+3LHBU5U,6.#@I-+P:8@>EN/EW (GCGJ[H7'@3;>="@94%6WBU4*"M0$T,
M-'OZM-H=-@$1 ;\%C/8B)J'W(^)[2'[6>YJ%%D!"Y8("]\L)GD'*(.2-_TZ:
M9\M O(QG]9_^R"T\H_PC:M?Y9C-*:FCX(-T;CC]@&F$;!"N4-GY)-5B'
M:J90HOA'6H6.ZYC^;!\GVFU"/A'RA?"8Q<:346SS.W>\+ R.Q/8\G-UJY^$F
MB'AEXGNS?NRH:>+@97$J\WQ5L%,0NL(DXB%AS@CFU6]:Y/06/4\67]/7U_1U
MZG"=W!^^?2VPN1;8)('--&)^:\2$.&PO=V]R
M:W-H965TU>5$*]
MV+TV9$*LVI[4-H2^_?J09*%"(A?QC#W_-S,^E#V:#]L".')14ML-;9WKUHS9
M0PN*VR?L0/N5!HWBSKOFR&QG@-=1I"3+LVS)%!>:5F6QF:Q]N L23B:_-^K8CT\3&J_)H8LTQMIIC5(O/?MSSL:FL[?H0W;HY"6[)'YT\I;F:#Z,!CLJ<%):U_"Y,C
MH7'!7'G;I.N1'(?=>-FG%U?] U!+ P04    " "RA;!(QBW=9$Z+ !Z.M
M7$2U4MT\CN6V)@S+%]Z15C_9<\&PTDMQB&4G"-Y9$J,Q3)(\9KAIHZJT>Z^B
M*OE1T:8EKP+((V-8_%D1ROM%E$;#QEMSJ)79B*LR'GF[AI%6-KP%@NP7T3*=
MKU-D(!;QLR&]/)L#$W[#^;M9?-\MHL1D()1LE9' >CB1-:'4*&GGWU[TT],0
MS^>#^E=;KHZ_P9*L.?W5[%2MTR81V)$]/E+UQOMOQ-R [;/[M
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M%     @ LH6P2$0L9"^B 0  L0,  !D   !X;"]W;W)K&ULA5/;;J,P$/T5RQ]0$T):*2)(35=5^U"IZL/NLP,#6+4]U#:A^_?K
M2R#)*E)?\,QP+C.^E!.:3]L#./*MI+8[VCLW;!FS=0^*VSL<0/L_+1K%G4]-
MQ^Q@@#>1I"3+L^R>*2XTKS=5B:.30L.[(794BIN_>Y X[>B*SH4/T?4N
M%%A5LH77" 7:"M3$0+NCCZOMO@B("/@M8+(7,0F]'Q _0_+:[&@66@ )M0L*
MW"]'> (I@Y W_CIIGBT#\3*>U9_CM+[[ [?PA/*/:%SOF\TH::#EHW0?.+W 
M:81-$*Q1VO@E]6@=JIE"B>+?:14ZKE/ZLRE.M-N$_$3(%T+R8HN>)XN?Z>MK^CIUN$[N]]G/ L6U0)$$BN2_OCEBPNQGS/]=LHL]56"Z>'4L
MJ7'4+FWI4EUNYV,>S^0,K\J!=_#&32>T)0=T_F3C ;2(#KQ]=K>AI/?O9TDD
MM"Z$#SXVZ4JEQ.$P/Y#EE5;_ %!+ P04    " "RA;!(IW$V _@!  !J!@  
M&0   'AL+W=OJZ7L=[XO3C5IL7A@/>G4G8KQ%DNUY&=?])S@TI!:ZJ,@2/P6-YV79V;O
MA><9NTC:=.2% W%I6\S_'0AEP]Z#WK3QVIQKJ3?\//-G7MFTI!,-ZP GU=Y[
MA+L"(@TQB-\-&<3-'&CS1\;>].)GN?<"[8%0&!7F"DX7(5D[
M43S0XO=Q;#HS#N.=-+$T-P%9 OH@!-\20DL(9P*,3-+1FCR!8P<)ZE
MV5YYF! Z/4"XXJV90#%<4&ULE5?!CILP$/T5Q#T+'H-M5@G2)E75'BJM>FC/;.(D: &G0#;;OZ^Q33:I
M)L1[">"\F3RCYXKZNF6X3[OC\\1E&WWLNZZ![403;ZGZUJ
MZZ+7C^TNZ@ZM+#;&J*XBB&,6U479A/GZ+MJ_2UFI
MTR(DX;CPL]SM^V$ARN?1V6Y3UK+I2M4$K=PNPB?RN*(&8A"_2GGJ+NZ#(?@7
MI5Z'A^^;11@/,N5_5H$@9U\6ZO96.N
M)_N/B)T9;@#. ,X&9Q[<@#H#^F&0F$QM9":O+T5?Y/-6G8+N4 R[31XUO!V<
M:,^!3J;3=3(^6U.I?/Z60YK,H[?!T14&#&9I,>2,B+1WE )"S!PLQ6V"E45P
M>I^!7C/8Q2=J&1(/!\FU@\0Z2(P#P:]C; R$VRPL9 8LX\!NXU8.1U/.8X^2
MI6@\J=N5]+X#AE:$^5>$HQ%P%P&:*K.I.@S/"(D]B 1*).S>IQ,\%I)12A)Q
MGR9#:3*7#[K%CL=BB$AYYE-Y$J-,9EEG-,7D,, $Y14LXBDJBYEE+&,^+SG!=4^<\,D4U:AH
MEGGPX'HF5M "IG@LA@#QR8?A/$[W:39%Q,;:";_:X1V"6/F+J0[A,/Y4>(\@
M8J(_CU3B"M L8V,/6J.] L2;G6L <7
MWBO ]H%LDLIB9H*)+/9HM8 W"[!](/-H-X ?Z/")$QUP:SS*F9XMIE_MA17
M#HWO9KMTF!EAB3YF)\KB@!ECW$/+%-<7=5_2##U+W$>D ]W_BG1 +*3HXC._
MENW.C#]=L%;'IK>?X.?5\XCU!,.8\-_Z4H]>=E#Z<)//#\5._BC:7=ETP8OJ
M]1!B9H6M4KW4D<4/:1CL]7!X?JCDMA]NN;YO[;AD'WIU&*>_\PB:_P-02P,$
M%     @ LH6P2"3JXXM, P    X  !D   !X;"]W;W)K&ULE5=-CYLP$/TKB/LN^ ,;(H*T^5)[J+3JH3VSB9.@!9P"V6S_?8T]
ML$ED",TA@//FS?.,>;'CBZS>ZZ,0C?-9Y&4]=X]-^T
MXM^D?&\?ON_FKM]J$+G8-BU%JBX?8BGRO&52F?\ Z5?.-O#ZOF/?Z.DJ^6]I
M+98R_YWMFJ-2Z[O.3NS3<][\E)=O N:@%6YE7NMO9WNN&UET(:Y3I)_FFI7Z
M>C&_< 9A]@ , ;@/H'PT@$  ^0K HP$4 F@?@-%H0  !P=0 !@'L+L SQ=*E
M7J5-FL25O#CU*6T7()HI>-62*&9'U;=6K=.$G\DF.'8^VB);C!88Q8=
MA@QC5@:#>H2G%%AE8->6 D,*.IQBV6&"$1D=A@UCUAV&#V,V'29\/"%R.R%B
MZDH, 26/">@M 34$5!.$=R)+#>%FL@;RA%G$,1O&K0%' L[]"1T*K'H"3<*#
M$3T&@@@+4>3;<(9_;7 1(8A.J"^SRF'0H.@Q ;4*,AF3$,-< C!B[TCVL
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M    " "RA;!(OM]&(B4"  ",!@  &0   'AL+W=O^+?4TH%B^L)YUZ>5FPLVR;CKQR(,Z48OYO2UHVK#WHC8&W
MYE1+'?#+PI]XAX:23C2L YPH/C#CDUGQL&^27-'FR<@1T 3 25/
M":$CA%=":"JUSDQ=W[#$9<'9 $2/]=>&*P7G6D0I U6,4/MD-+G9J;*XE"B#
MA7_10G<89#!;B[DB?*4^FP)YP$;
MW$1.X L.XED'L1.([JOL#":U^V Q,(SB('X,JRPL0Q!%RVZ263>)<_,DS=9B
M8("2 #UQ75E<'N5I%BS[26?]I,Y/,G<&+&8[8M+'F&K$9,M&LEDCF1/(EP7R
MV8.2?_V@P@@DO'14'@C"-/R7R;RXY)?QDFI\ >W;NI+V 4W1JL!NDF\2G
M^%8W7M,\KC)ET>,3^87YJ>D$V#&I6I#I%$?&)%'&@I?8 [7Z-4R+EAREGJ9J
MSFVSM O)^K'W3S^@\C]02P,$%     @ LH6P2"_=@I!% P  G X  !D   !X
M;"]W;W)K&ULE5?;;IM $/T5Q >8O7"-L*6$JFH?
M*D5Y:)^)O;91@'5A':=_7_:&[72\WKX86,[,.0/>,TQYXL/;N&=,!!]=VX_+
M<"_$X2&*QO6>=?6XX ?63W>V?.AJ,5T.NV@\#*S>J*"NC0A":=3531^N2K7V
M/*Q*?A1MT[/G(1B/75&<5:UN9:6+^
M;9*>.67@Y;G-_E65.\E_K4=6\?97LQ'[22T*@PW;UL=6O/#3-V9J2&3"-6]'
M]1NLCZ/@G0T)@Z[^T,>F5\>3OI,C$P8'$!- Y@"[email protected]":#G "4LTLI475]J
M4:_*@9^"\5#+MXT?)O@@DTR9@ZF8<7I.*N>@GM2J?%^1 I71NTQTA2$*\Z0Q
M^#:BLEG.F&A2 ,H@(41!= ('A4$D]QGH-4.L"Z4Z/B?W$\37"?3B8VP2T/L)
M$E!!8A[2IRI[A4GU<] 8'.,BINE]HA0D2@T1=1!I#(WS N7W>3*0)S,\L8-'
M8W"6YC1VX*KL_PK/04&Y$90X!&D,QDE6^+S* B0J#%$*$16:2&/P(O$H!R.0
M1BU+G@SBD5:EMBW"JS/*IW("ZS';O7 0/1D0
M7E"/%XEA6\#:%R@"#3 V1-8\LMN@:L[D88(XAL7$)@5HA%:,!?D4#3L13DR*
MV,5C01Z6BV$CPL9E$+A/,L.C09@01*F'%V'8C'!FN,"]8C:_ <5IBA)T6U-E
MG0>"\JRS(,(=@@2>W0>"UKX
M\, .0>S'BK,?6-0"W'.F'0"@VVI@'R'VB\;5#2S(BP?V$&(]Q-4,+ @[0-4,
M\ODBALV#6/-PF;0%78C1/-'%,-"Q8:>&I#%8\V,O]"PPK\Z#V"-1P\09OBH/
M]8[]J(==TX_!*Q?32*(FARWG@DW\:)&$P7X:%>>+EFV%/,VF\T$/3_I"\(.=
M!>>!=/474$L#!!0    ( +*%L$@]PH[JH0$  +8#   9    >&PO=V]R:W-H
M965TI#]]D)
M0[#J"VL[H?OWZPNP2=3+"YX9GW-\9HRK49LWVP,X]"Z%LEO<.S=L"+'['B2S
M-WH Y7(W;UWO
MS688M="QHW O>GR"J84R".ZUL/&+]D?KM)PI&$GVGE:NXCJFG?5ZHGU,H!.!
M+H1\]26AF C%%8$D9[&O'\RQNC)Z1'9@X;+SC8>;(.*5D6_&^CE%31,G55>G
MNLAI14Y!Z )#(^8A8;Y -!.B7"#$&_C0!;UTD8KW=')1?"]07 JLDD Q"5QZ
M5!%RF[I(D)R6Q7I5?HYK9EQ>YO3NR@\Y&_' #O"+F0-7%NVT\[<5A]II[<#K
M9#YE>R/-7Z'U!+ P04    " "RA;!(/R[I
M6^P!  !(!0  &0   'AL+W=O?)L@5&Y!,?H-=?:BX84?HH&D\. DAE28QZH>]O
M/$:Z'N>9C;V(/..CHET/+P+)D3$B?A^ \FF' WP.O'9-JTS RS-OX54=@UYV
MO$<"ZAW>!]LB-0@+^-G!)*_VR'@_82TB,8,FIM+^H
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MLH6P2-R5[Q;_ @  #PT  !D   !X;"]W;W)K&UL
ME5?!;J,P$/T5Q <4>XR!1 2II5KM'E:J>M@]T\1)4 %GL=-T_WX!&]ITA\2Y
M!-MY\_SFR6.&]"3;5[470GOO==6HE;_7^K , K7>B[I0=_(@FNZ?K6SK0G?3
M=A>H0RN*S1!45P$0$@5U439^[email protected]\M9XZUG71_GT0E3RM?.J/
M"\_E;J_[A2!+@REN4]:B4:5LO%9L5_X]73Y"TD,&Q*]2G-2GL=>+?Y'RM9_\
MV*Q\TFL0E5CKGJ+H'F\B%U75,W4[_[&D'WOV@9_'(_NW(=U._DNA1"ZKW^5&
M[SNUQ/'76Q^5EO48XGMU\6Z>93,\3^:?A-@P
M/ !L $P!L+@8P&P ]49.W"V@[59^I8QNDB#MY[H# ,#YL%@Z(0(.G9T"_"Q<#!; )G?(A\Q
M=![S.&+@NA!V+H297)DE8-<)PG,"LW@?6H+P7&4S8"*3K<' /"+_BI@5P5$1
MW(K@UPDBU(;(W88851";!!(LQ]BX8""<\"@F\[#K'PMT/2E )P_*<(_9&
MJQ@K[M)1L:"($B!HV=BS8G$AYSQVD827,!UK>.% P7%C^ W&1+B*R.$FL:!+
M5\E_D'DA>"E34X&,$0>*!+BAVXF?1
M[LI&>2]2=TWMT'MNI=2BTT7NN._MNZ^3:5*)K>Z'<3=N3;]N)EH>QL^/Z1LH
M^P=02P,$%     @ LH6P2,/F)%$$ P  " T  !D   !X;"]W;W)K&ULE5=-WHM-/5K)O*Z67_3H9MKVHEB:H;1)(4YJT5=W%96'VGOJRD#O5U)UXZJ-A
MU[95_^]1-'(_BU$\;?RJUQLU;B1ED1SBEG4KNJ&67=2+U2Q^0/=SX"/$('[7
M8C^C^&8< T_O)_9O
MIEPM_[D:Q%PV?^JEVFBU:1PMQ:K:->J7W'\7K@8R$BYD,YC?:+$;E&RGD#AJ
MJS=[K3MSW=LG/'5A_@!P 7 (..3Q!V0N(#L&8%.I56;J^EJIJBQZN8^&;37^
MV^A>P_N11#-'NIA!^V0X>^-46;R6&49%\CH2G6' 8!XMYHA(-+LW!<2^<##A
M\'F"N46P['J&[#R#W7S(7!%PG0"?$V!+@!U!=BZR,QAFRW 80O.,X<]Q1/-P1E'HEF.UKGC@0I8B>:/WHB<-AS',:4!-"?DE3_]( "O#Z
M@N &8S*_BBS$& O*.4>7<'.'PQFD-$22OZ/1U-(L@(+XC2$W&$/]*FB(,0<0
MRR_Y8F%?D/ZS0XKRMS6:^IH'4'"_+_P&7W*_BCS$%PM"G!-(+QTO$S!/@8:<
MF.!O;YC:.P^@0%YK (5; ^!7 0'6.! "RA&A%ZQQ0,H812'.^/L;7'^3@-,;
ML-\9?(,S_G.XY]R:YAQ1GT7W(/>,W7RE P_3CQ!:]K
MPZ25?P/I/TT3>/GNV+_VY>KTWYGD"U'_JC9JK[.-PV##M^Q8JS=Q_L:AAM00
MKD4M^]]@?91*-"XD#!KV:9]5VS_/]I\LAC!_ (8 /#6 0  9 C :#4@@(!D"
MR+A""@'IC4)D:^]7;LD4*XM.G -Y8.8\H6<-[PR)9@[T%424,E\:V$Q2X?)'XND7I$4"&:^4C(K
M8C$(IQ@_EJ%>&6IE:#RR8M2=,H+O)[.R*$1RG#Q.)O,FDT$RZ+[,PF)P3!!"
MCW5RKTX..MZVL9B%Q6 R80-G7I$9B)"1#;28%,7QR/JO?*B[R:#8FTT_;=+Q
M-C .##"L^^SV2$07MXT#V_$?K-M5K0S>A=(7E_Y^L15"<4T3/^F$]_K*.@QJ
MOE7F-3.5V$N<'2AQ<'?2X6)<_@502P,$%     @ LH6P2+$C*&H&2   "QKK[_ZJIH^ILNDZA:K-(KGXJG]X>/S5,LGR7W_S^RK[YO?K;RZ*Z6:9YNLHR6?19;[.UL_15
M'4358U*FU>^_6G_S^Z]P#(\;1!^*?/U8P9A9.JL__9"4W6C0BZ/^8>^X^?"Y
M&_6.VQ^:]8S:U_/GT:1:E\ET_=^#(^^?5VG]8>_PX!_JOXW@[1F->+=('NI/
MY\FB:DQCOG&;EEF!"YQ%%\FZ\9[NO_.K7VW=Y+NLFB:+Z$]I4D;OX,<&F.MO
MRG=;W_V'7OV7^S*99?E#-'Y>3HI%8Y'OQ^/Z;P+QN_0A0S##AZ^397-[5^\O
MQ_71U?=X-3'<..RAA]5> *Y^COT^?Z^^=;\JR#H\0
M; \.>OV#06.O\JEWV2(MHW,8]U"4C>^,E\D"G]^EJZ)<(VC.B^4JR1LOZL*+
MY1*0;KPNIC_&T9AN0G2S65=KN"XPO+&/ G:85^D,1N95L&ER:(!XIOU(P I_/PJ_P0S%V76I NCV2?<:A4!V*9%
M3E>U\=)MF:Z2;!:EGU<(K8K67=!'I[++A';90.AB#>BQ_9UWFS+/UILRC:-Y
M]AG_J*+_DBQ7OR.@K.@VY>DZ*N91,H7;M5G0&%]7:V2:?IWOX9SJM+R4_KK;Z+&_<:+^E@L9FE9
M_=L__TMT"2>^;E(;OM45W^H5T!JX*ILT>M,]/.S]+DHVZT? [7^$;1\=QH>'
M]#]A@[^+^KWXI'\8#\].Y*M ON=PH'<^![I4#K1MNCI'63'WV9&*;7]-
M3M_BR4ZO,[+L]*I+A78:4(2EJ0"Y:)$F M?BQ3=?!$=H1/L&0V]OV6, B\=K
M^ ^S1L" FU5:$CILD1U=E:M!Q6_+ F[L.JI )&0QIKF.BD2;%;]91;"6QOZ^
M+8NJPE?F3=H^3HFTQA$P\!2%?20MR6R9Y:1)($4Q4D1][!TP=&)[.&:6 NTI
M6$X+#6!:7#!8@)Z'WGN/ZYV7Q5+?!1 VJ910')DD^#P#%M+4A60I)!+I,EHA
M3&N9I$!=D)(7G[(*[S<2&YXX6B>?"0#,0I!DHK@)@,EABX0'YHG2U1;)NGWB
M;8OYDN_1/##RY3>O86Y\N^WW!9M4V;2ATF6+S;I)*;Y/LX='(O; W9.'M%5"
M UQPR6G+)^T6/Z0S9' L$858IGW]_#'+D^![>WA0^]&W24;\S* $W20>^D?B
MYM^U<_.7B!KBUOEC K(^(<_8$^!8^@)"-XB6;&)*T<04>3:E,!VD^[B+Y!+:
M_*XBFFL;"+[DB,^W(CZ?L_@<'N*( A5<0\?4F^$>Z7"V*YY3E
MP$F1;UKXRJLGT"V$2$_3_C2K@6RK2=5_W877UF$["1]D6'H'PO$6X8/>F=,[
M+K=%(H:Z1,#V,/MA(\P"P08B-& G(""Q(;)B;7!I2(-VF>["E<(#O'ST>M&:
M5:052U]XHBYBQ:B?59O%6NDUJ# ?M$]FT>=Q"VXC9[#T >=U'^KI5,W+H
MI ,&,OC0%Q=;K#O #/"2IC@X>=GLY[Y>O&@"M.]F87/@GKZW#W*=C("S3G:Q
M$@;&KGZJ\;!M/K/3]B%FEWLZ8M^#9DQFC'=3>VR ?PY;A
MIJ@\W*HTL\E["H^16]."/JD=(3-2/5GR7P1Q&[A> O$T!S%
M4Q+.<7A P TNE90&E(0FSSLM%P>ZB#[=U4,0="4@0YD8[HSG1.ZH5XU/$?U#
M(\<;D+N)]0#$9EDU!4H)-!$'3!7XL!7C#FPB=*H.DFCD(4; P-2TU'GF,8>;
M$P5>9.G&+,9E!"V4P[5]O7BC;LJ')!?&%$=O-U66IQ73"E0KZ%+CZXOH[6A\-8YNWD6W=Y?CR^M[>F>+!1>W.=Y,JFR6)8!9)*H=W9ZUFU?,- H-5&@^D:D"M:\3LKGF% "
MU+WR0"\VF5AA$K(_PK@%;*C$ZPN0)L=N#&LIB\W#(ZT)J!&NZ![^_!Z \K>_
MQN2@W%S F_@/_#&Z76RJO_V5@78_BO;&\+X"IPVO2U*DOVH_L//!IP
M[F]_[;HS.;_;.>$LHC]N -P@*@[C]MT;:ILL%KA27/0)>TD\W575V3DL$W9+
M1"I%*;($M(ST,! ;B4Z0C ,G UB8)TMB\[2L"Z($,6/)'IRI\RL>;A?7/$Y7
M:W9B\,+7CV0HM)] #%BF)7TA1^G#'KGS&MJ^UR"2X?)Q6Q4NA%;#I(S(N%RQ
M;G0CL&+)>AB[ZZ4/F@'PU:<,3L:07V:WJ-&VXO2_('[1-!.7#"BKE6P^C6I:\ZHN2%/E:>*
M!"XD['>2ICE+AB7?(KS]C$ B;?AI>2H7DS&>N#E:,\GP#7^) #W+*
M )BCWN'!WQ/-P \4*[CLK IP1OB@M!B%M0M.X 23T:RO!0$T>E
MW4/ 92RDP2=R/.8%7GY04LAFC?)@6NV#N@N:4 7\ \G>/,E*.- 5,^PPB;!+
M6155QN@3"CC '<%\H*:R*([_L1X%A3?PH315DQO\D#/P^:+J\)+@B:!H&V4,
M==X*@,PB\NLVLP7R/Y2"B"?(/7#6YZSMZ3&#J9;),R(7:E!3_3:@\@8 CDBR
MA5$#FFS(E&PW0'\T4$M!B(2<9$-UTQRP"*"W_2BF"S@\!2
M@"HF*LNL-F6U48+--UBM$26(%?DFC>5($3AF(6+*YV6K+X+/1CA-5":9*#,?
M$F7B1F=H79>YFL4*CW63HW&"[-U(:S;$AT768298+(&.(-8!6P-D-[;-I5B?
MK5S#$$X>'N!@*]XY,PV7C;BOBQ@$0@2]\524B]F7@=- <:?C53&,Y!6K-,F9
MB%%QLX*I+;&@FXB-4\FJE
MSCZTDXG0)@,4YAGY&G_@2P^HF"T1G8TLLED!/B*P>GTA0' ?@()N2K%= 6@!
MM3?BEYN12[Z*F\H8[<389U30@@]^'(^B=Q>C:+H ,F-B TC26F6SC7HY,SSJ
M@Z0$$7\# /'0>@KX-$DC5Q]P6#M\8YFF6\C\9#-[2-=;*)PRL
MKBSP4X=@.]AH$SR9LE4Z#A \%MDR6^OU0E H=#QSEEP8?:]QN\V)NKI.&"]C
MYXK5L#I QH 3D!A8;>;H,*$+B# 09;4R@!;)*Z-[">>5K6@WQ621/K1^?G-Q^O[J^MOH]N;]U?G5Y?C3J_;N;5B(=KL/0O ?5VB
M>4FD^[\B4Z,Z]^UH=$M*NF 12<8;CXFB"ZGK 7HF(@?>5
MY9\0$T1  > ) 2< =41]^!MX!NRERAYR?#'!^\04BDVAJ.WE53*U3&C";J/*
M.?84+W[NFDNF+DIU._UN9TO,UBAH;XOVOKNZW"<6GD>Z(+S9:494>R_;%\G-
MN$**!:(:\)3I6NZ/(]@ =)<8WN.@!,K@0 ZF+BA_"YN&E0%S
MF"*<22\EYZ.H$)9(D@MG4A7E1,5IX2TE1C6(,P]M'++HM0A>[K&QD0;UQE6!
M9HB,2 :P2F>5.!.. ;"!UA:@!#,4+99H*.%)LS6!Q\I2#)\==U%?>, .YIQ@
MI4M$\A&XDFQ6R5 +A-LX*V 0JD3.+.TLGF0 0,$">-!2Q$I N/4&/ROG3GNN
M&B>LL!-X/Z%")Z#9Y#0-Z LY&92F'#&T3'XDF9C
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M-H"IZ.I<$JD50FVX">Q6R15_MG%@)S+\H!W9JB*(4>V
MXN)&ETEX0D)  A0@H0<8F5O6
M;\QHP/Q;K>.=(Q3I&7IW*1PF6X>_3TI,RFL?9/D*"][H8#Z8I:K*ES2-KMX%
M%5P$^92^L\D!_Z(G_1I%1(HP'T_1]_ZM$YV3])%$])N3?42675]7M''<[3K):Y/XM*@N)
M'6*J12288\#R(TSU4!2S2LU>*P UG"+&.51,0F;HS,9/+8@-$X. &?;F65FM
M#[(\B27@DBS7%/TJ']&&V+E2WI9
M/E]L4@I> U*@/%4DZE@Q$&^OG#*C*(D?O"H&LJ3GJ5ZJT*QSBD6!E!R(D>&=
M_'LXE:0+ZBM_$86MEF_%9&KB\&'A"GX\=6G$3'7](,Q2L7,1E\?S2-%NP\]-
M6#BH%&GK$KV06B=-@(W5-4V@_EVUS&.4!=I2$Y",Z=!B\4B,7J%1V!RT!2N">=(E
MNHU)L.=H/N]Z.2'3JCV+ 9C#7KJ=TVZGF27$.?@F2=7^Y4YN1ZH *&X'!";%;36#*?/%$2FF1&$,@T$FOCZQW/@2CU.#
MHSZ1_Z#"TR8_327N"EA]Q4XW%)9RHV,RS6;.J_0<)G"0T/'H=#MG2-I-4)DH
M'P>1Y.J:_S(M]8%GP@@%YG.,.J7=V+#_F63>5_8Z^/8K_D!T@U8*.$-U"^>B
M*L%],@.=:1\0KKE$.!4T5G'$IMY%1%/8DH,VC(?':)J6Y&44G[V5-IY3E3A6
M9!V?Q:($5&O/ELT*R\J!RB25^X0AL5^&$'-#\O@#=/-J.^L/RA<"PF:]:B,^+!*1!0.;Q,9,AJ,_F!K#*LCB^2)V;1<%@@
M*5%N(/L^LCEJ(2+9%C;DPL,ZLRX8OA;#?NNGA13RK#B )EXU!C,;]3';K!$G
M88DVFB>?@.!MRZQI-],NJ@(3 HB$Z 60'.7'BB2=
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MT]A)S%%1E*;I>,6=4\ T%06'NVR*8EA
MG0).0/&#S8H592,=QC*:!185E5!EM[8?LZJ9 :$%4#Z#V0**Y6%XRI83"BI4.4*^'L
M9FZ66CJ]?K>#J+)2S?4/\/\67*6H"M%YT6PK0@,S\E%'LAQ((7ELWV"DQNQN
M#?7C5T@B)+,810 9,YJ@/TAIS=MJ[K?!_R[[^PQZ-R]&*V[GA;,*$[05-([U
M!DB[G)SQ"R=G/)A,3E]0344M/JX5"*/TTB=#]!IC-6&'[U!6F](:HIY F?Y]\[email protected]:/S=?MIV6G& D^//8>[CFLZ-_BHZ&%MV*D+"DEWW
M-K^\W?(NYF!5#$ZF(_"=B28MA#[((4I$D,G!
M@E-6OR,*9RO5;6MO7:V@/)'>#VGB ]NQ$M9Y/#W-%6+H1.F2-%%!IV<06-,
M*$A*.+.W!?R'(BK>C<9O*?1"DG0>-MG,!&+T9O/WK^C#-G
MA=(64*36L7*;1 9)R&Y(>CWY6TG"XO#,&5#,\OG ^.1T57QH9HWF=CKA#X7(
M>T[0(.ITR#ZJ=;JJOHYZL%G20.;/ZN*C%T&8<*V,+X"
M,3(<96:(-&3]8%:OQY24&5DL2%*UH.-D"^O;N#)9/1@Y+K@&*-1 'S:@T$>!
MLJ0'%(#."(_>3W&/LWU$MFD#)1GWM*J@$AJ;+,>RA@EDQX7 6K
M&><92Y0+!::AR/+3YC[F8Z&M:D"O)%JSV]-L?+H 4,[9:2IFIH1,44:-4I!;
MI/X^51N]!.BI=IA5A E>;)AS\9U@O03=E+ 9C)'A6!0D9)LRX*R%<[P&S5(3
M?;:=9 7S+61')!B*U8C*H.)VJXK\#AHI[%(U,130)IJWEC:)8K4_!*FT->&3
M_)N+R3<6ASYK@14:'6UFC$E8IBR(W/R3>5Z-=*"N_(7XQOD -6S+*HMPK#9(
M_((XZ_4]%!X-RK 1A5@L1H-R\!:QFQG[?V$+!6 I\LU( N$.5,5.TSW
M($E1_!6M/ B=*[4HCG(FVWF73DH*8L8Y7\%KM$2:3]E&XX^ AUV"O:.^^6 'Q/QWV][]N4L6L(NV/LB1($]2L=J2U:(W.I\_&XPAX(N(=
MH /FD#@IGJ9@ M-AOL^AJ(J\Y0Z0;,RT.*4@'R\/:8).RX5$])*2\F!NX=K:
M7CUDG'/I5C+TOXB'9Y+K9%.I%"5$/7K-;/W#<("+FH71V%I5?->9$>)T3Q0[
M1;0G1A4.E-(FSA-)PU.WE*M@J<[
M7!L1M(R491FXREML_T:QI9#R,\UJ1K%]BV/W,N:L@ KS5)-C;[= 63"/)" DG%FRPI'9O05-AS3VMK[=;Z3U<&Q^.>9-N[(R7
M^S-]I&YW,[86.DDO[N8%PC,:GT=,)?K'(*HP?%]<(89J)(NIQ'9,T SW*2-M
MV>9_:DS1#MN9L.'@J5YW,-_0O2$7J_WZ]D*$:AI*$Z"_$M$BKCY>L*I5@C]F
MKVV;!%TMPZ0Y G-"\)SX$*J/,EFWAG_.4LQ: 'FD*/F*LZR@0K;)*K*;=4.T
MO7VS_$+1YC8;Q@4&XAVJ,$[2 NV3PS:ZDS%JMK0.LQL,D' ]:-QCJ!9:9E_4BLM:X;C[-,U/E.602;:N2@$>=49*7*4_6CP=C)
M _UR%[/\V7KU0^('FD,XCNXNSR^OOAN]?7_Y2XCWUA#OELJ)3H(E
M3+QK?:EP".VHH9;]Y!,>1NCNBL[YZOK^\NYR?!]A
MWY;[/[5D7#1_ 9HZ/.N>G?Y&DBH#CKGV2(.PDY@S#1V7R=9R _4L:[)D:1KV
MK-P\M)57 @(*E '&,Q]S*N24Q7.R6#\?S)%0:+F<0&P3>8^I9-*[1>&&YQ#7
MT\%/G$$M^Q'3-4TS$*._
M)9JZ&_VA>,)0H5C9S18":BI/5(^86DFQUI,RFSVD3MT\#]X&VW*;FVTD[E0S
MW>47H$F8K#A+M#P\!E.F)?MBZ'W,'0#Y^H,)N+=:0GW9^N5J4ZU$62.>XU76
M0 Y48/@_EM(A$:],#S17QUNI'I-C V^!?U)MBT!FOP7H=PO1<)NKG>+!L<,>
MS2D@ 9IB,QE5Y=&"_ (-22"IDB?192\_LQY&UE?7Y.)X 6N1V4@T84\S$[-6
MD!_6 ;T'9/\.F$2R)[09V;@OMB$QPZ=[X'J9UT^%M7:H,(1^@4TH80SW0AFC
MW\LUJ)4U: XQB3/-(@*, #"JS"HJ]:NYPB\G&S?SBVO5-=TP^N8)5!1!B"PS
M-A>ZMA,RA%%J@.%LZ6=K;FA!&2=]-&E)6FNE)@)T"=5HY0Y>KAU7'?98P-C$
M;LF6HH>,/&UE5HG*XA0R:SVC3(X5 +&"2XJ$I>#,!9OI.N,$'F,]<&59+%PG
MA9(HW MOY)(J6*O:802H:D6-\E1=JF8(5UL"/7>IWF(JZPE%
MH*HIQ5HR&3$+9@NZ^U?7W2L;4!VL')S\1M]SY7179VS_$%SEE D&OM]"/)G>
M(%QM];] @J-;7GF-ZY< /+SL;8/U&\0Z\]1FV;1?IE ]AK;?":^.#G]3KQ?Q
M'%P^AXY,THP!)0$]B+OBRC%6C7HU'P2DQHV)95)R:K7E3[RXX0H
M4*!=%+ ;M&']VQ*E-.:Z!9='Z!?_K%'ZIX<&?]0KC(I07=[Q $QT3VMB:YB"
M2"4[DL.L\E@$D<0:-733S;ZL)D)KS8Y_:2^/H!HZ5Q[(VNFJ1'K@F[987JU0
MHA]3M27C:M3>N8OIG'K2ZZG@6@=3"!Q@C-.N9G=
M\]KWR*H61J)]]DK!E8QH7]8E)9E"*BLG>48E7<0E93:6&$..5\J9"$128F6N
MM8D-L_[Y>Y;WY)L!Z+IYC.S<-0_1)+XI45R4.%P"6"7VG_9J@#78MYKF %@8
M?3)3AYR/\;C[=?(CUC'"Q&0-9FULO+'?CH=31QB\1A4DDP[W^Q'2UWG3Z<G<1G1T>=U[1-@F\=GP[BDZ,3
M/_JUK6-2IS<[T-$>C
MGTU[Q:?.WO#H,.X='P;'V2OK66U@(.S]"(;MW#ZG3
MPQY,JRU#.GN]>- _C@?#(:XQK:JOHV O) YN;V^HA%L%=!@<.Y/OWDP)KL#>
M*8#X[/"TL]^PD_EET#_F'DEW2WZ_SL!U%%U=?W7T/?T8?KZW!Z_(B
M&G]\.[ZZN!K=75V.(^E(&]VPV8B6CTG=(WTRJSVJ\)E7H$I";^H6*L?.%$G]
M0C) X2%*'F'%<5Y$7)]3DP%++(Z%A>H1*X_I3Z^PH(&\6D7]H]\8^8@7J_)!
M,^8'@1YC )7@EU%F7*.5D0)X/:$0_.CB10-0HM!]T9ETFK% 9"+L"+V%&L'.^YNP;2GI&KW=+PLX=25:8XN=.5^@PM P).3/M6G=ZMA[I&V
MY[@#)"FIF#.U?%G3QD0H4.,?%^-P;AR?@919K9OZ_*I YI(.
M#D\;H.4:0!S2M'!2%WVP#J4G[!X!^+@!8(_2\T:X0T-5+XS+]F@7 G2EK/[,
MM,YSM#H(XOAH'U/MPJ[ESG12K'Q>0XMCZFMK4EU,B('"VJERX9J:W
M4.(N+:6C3PM*H5_(UU;J-6]3M!.RLN7Y&+:M":O?FD*9Z
M,QP>@91R%+<1,HWN#7RI[K"VUGFMH[(SB$Y. -M[\6O8*PKO2(:TBW*6>R@E
MA%_J\K3#LGF9 E2X>(+=O#D%, V&AT%IBS4JNP2E3VQX.M;,MJSRV$Q+WZ^6
MLPBB) 482TJ1J_F(@TXNG$TJ]/(%R53O9*?6[R1F*:XR3)'R7$M\D3C_P\W.
M@ADHLM2GI9E\N(5T$>7&$?4'[- 7&PT/J?,IT%_0')P*+"WO3'B#4>PW<)Z&A%G
M%[;9TLWA4KP7!R7>JMM]A[BRXZBYAA>QSHUZ-#5L)"B7*Y2P
M^T.R#;5 "1U"E0%!%INCZO<<2R@Q)A+ XN1,25+AJE8'6@:;Z!?)S7-&VKB3
M+X@X<9*ZW_0&P_CH\(A)Z&D_[O6']'VZ@::_I <>$C2<>B^Z#5),J.#3C .V
MT#%2I^Y;LR\D49?).A!$T#D/83VTMK/A67QR>F@7M\F=?6Q=(%:GDW7I6K?4
M;&&PU_(>Z(B29E";/;%^]^S,"20=='N'^L_M6Z[!1\R$SVR28O,EFY,Y/&5D5>MVCXTZ_>W**5J'^83P8H#4LP6UU!D.V'/2Z)_W.L'MZ
MU#GHZ/IG\#?_WSN.;$ZIR"!@ E)8\]!;A0]#^.#)\2E92& 19QW$AL[P&/#W
MZ% _P^&CC7$]M,^=#F#<8 #CA@,8!^SY\*SS(BX@8O^"#W5\@&,@2)XW'G _/CDY\=XFIX$MYJ(N4J5,6!':7QM'>@Y\QPJZI4A)/C<
MF#RSO5;V)7O#-O@K2K_Z1[!5'2H5F69^R (:*VL$!I^C@3)?VRBSE=FYE,8MU8;02H:/:&1LH7M7AV3JVCRE<:
M.&3JRU#&DRDG$Q/U,*#VRXM3=])$M"!L#(;J<4"XT"C,2@(:6XQ%:%PV4%.7MA 0QZ2:JC2.4&J!4"EI<-Q21BKH(""GM5N4"??_D&%=:9$;.9('Z0LG>9Z[]+Q[3 :7WU[??7NZGQT?1^=?QS? Q;=C?7;ES??WHUN_P!/
MWP.&O;NY^["EQ3JWTYIS:4.WFH=5 FU10RMB Z7PNH_3<3A]P[TDFR*W%:"5
M?WNS:MT'+FQL9097 S UV9[=H1(+;Z*JV*!BZFPI"8O0>X:)KINU#<8G$2A_
M.*#L$R604NTL6VZ6=C3K#)QY<:M449/0B(U(@TOR!+\Y'J 1BRUL/S9? [WJ'$V U(LXDU8<1Z8W8YE9]R'EN@CC(TESQ3
MO[[K/PV%8N-NJ,)T_6TZ,R 0LR+4'KC \KIP=(=Q'XZ.?95'1_'1R4 <0,Z9
M!VW%?I1@_31;DU%W,OE0W.*36X9SS\VAW&=)Q_T:#?%Y0K_W&S9Z'_W&G#'2
M0*^H;S<:M*)TPE'JG_R%0.CE&0_E Y*23P_AH(A\#8;\#A.#HY$16X16QI:E/3X^ 4)S0
MWV>'?=CM4-[5WDECA#X\'\!"SV!O0PX./D$",ZQS^EM1!EM]L9[W%2TY=^E:
MZRO]#$)IKQ?=7EZ/45ZX?3^Z'F_C.A?IG(+&S]VX%URT,1UBL750M[@+AS7J
M2A=QCE@B1B,,*J.*RU0158+'5LDSQJ1JT5?6];;J]<[,2JO1N:*M@U*JU"LJ
MC!=)[44(\1!M522U"!R;1UO6MV%7=+<(@;:]-,H9=,"RTYS:_?X7MX= XNDZ?HC]B*=60Y++@PG@^R8.+V0>U!I<#
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M'$XJ;<( RL]W&Q*"UHD&+L"QS3=H"-("(H4W2PW
M*_>T&4K4T((((@4RK!OIQ3Z:L%>AGIE)JY.#1NF7C[H]*GUOL,]L-*HS5R>%
M^I([TS3?2OE[F#),I4[
M#'CJ#N^2-,5NUG !OA7_W 0]T!(P]AL
MRF+GFGCP;8Y<$IM78&&4!4%%)"7WM>)3,I_ W;FL*Z;:@5C3@5(BO-QQFLR+
M>2;7$-E>,QRZ8CDVYN*;8M3S>"%*6?B4FWZXP;I*^.T6$EG$/%EFJD!3S-IK
MK2IU593">*D^B^TK)U>ES21M*[RX%F4RBB7S=/W\/;F$E.&\6Q1_^ZNXB7),
MP$5DTR,W0>-XY7''+H\BJ5/RB3BP 5]7Q"5'[P+$5U3;1O,Y-\?+J1,0-VJ$
M^3=!SZ;I#DSRL;,EEY?A61H,90>N%[AS>,00,6O2)CK4)-T)[GLD09[K:1MJ "W!ZX*"DN-EW0\&$
MR]*X+[S3 F>*<*< ",YQTB@//U2(_/WXB3BB@"6GVH$D(]C*"*9.G(;=4(8C
M90>[<*>.;F[=T"8DJ1V?@9&G50,VU4!2J
M*JQ>G!V"!G,LC,+!XD*IK?.S]0QP^<>G
MF$ L5KE!/#P\_,)%-_GT%Q0_^<]#O9-7K8Z3PX
M!;N(7U,5PBD.(#U>6_N1>PTJS.=-U)GI=]ZJCT2UE8W!:@2TS:JRV
M(:328A%/CP5%N5#E&?S1EBKTB]$0-[35)+YGUSOVD*4HF"=4B;QH&#>5O9;_
M*(_,RD/%X+Z=Z!$A98EWQ+-GYF.=(1S+ ]/.6MPA&W_K$H3
M^ZDV3EL:"6/BF(7*.793G;XESY82\.HH'"C>N&M:>K_;"<\0C8*U(:.][ZXN
M]_U4<[K&TDYC+]L7NXD3Q"(1F2AY4-,.CHHPG83X0J0[E"<#Y"JP_4[]'DDL
M5('?EP5X!0D*"E0J(@IR)N "@<,F7*78NS#64V5>JC3@!LTQ -!ZAK6\ZJ7#
M@&ZS9M^"%_?M",/ISX5&,W]1W1\+RM^V%_LQEAVGBR!*T9.J*"[email protected]"_$GDU?9]GBXA*;A_3DL\7LY-QISU7CA&V%
M.((WI00*:#94DH(*=:'FFDZY_H@T>S*59]&J@VU23)D49/ P5K(#;$]'^81T
MYG5"]VN&%(3GK^QWTCHIYN@#.VEMHV2^
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M0=\UP0?Z#IMH;--B3HDB129V-,J$FA]AHW!.7H&_,1&B55%B1Y9,2%[email protected][
M^1XNVN%^M?+0#,+
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M :!J0I1W73B2Z-'2:8EK5D*D@Z58(*
M ,%/CM[)U PN%H_$M<.14,"V-VKY:1IIQUK:Q[NL3GU -59(WH/V<:E?S7= 
M>3-NEOLN^TR7&%$7+QQ56JF_?]KMO#3$^PEU4I[$N]%.55I;G1X9C,L?#@^0;=!E]/$O9DDLD;3,@IL
MHN@=1+?DB&E(KF?(HH)OF_\F7GDQ!CM[C,F"R<7G,#F,X&"[/1+LC!J;)9@IS7^1T3-V&0G\1?JA%O)MHRH
M]IRJN":^>.D#1^?CI+&S*KERH#))Y2:7:])$OP"5YC9(GCY =[ZV<_&G.\U/9/"Q'6(D_2(6'5&,P,W,=LLT:<@C62*G952*?%IL IJR#ZEOZ77+=VH?2RQ1$D#EW8T^X<:_Z
MC"L-Q:8D7D+HZ5142!P_3Z:B^*N2(\4$\H+2]3D#V# X6-)#F2PY7XN..'[I
MVZB'EQD)?J%/&W3U4R9#L'#:X#3H(S%5%37>8P;.>W+>,OW;S2UT")1S^SRA
M>X.B=<6)/PMZ7>0V"HRS4[;)&%ZKDQTD"P?W)/B+8_3OW9>]XA&RELQU\%$K
MT(4QQ#KB%'O&/?.SR.V8V5FID&L[2;9D0JJ9+U"E]8=-)?43402=%,6/GMA3
MGPC5"S)B>[4>&@*0E,](XO0T>M&+I\>JFXKJ6!'5/J/8NU!U^&9+
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MN)67F\[FUM*L7W1#&LS5Z?II2RUWJO5:Y(6S"E5Y@O;2)O5T&A%R=-WC'O!/Q%XHM0A9O,J6IX\(JHNKW5VJ)G
MB)#!=Z2FYCSX0>K&P1R!W()X)Y//!&P*!J9D+BJL(;*2MKAA^<58)H%$D5A*
MMBN5Z4L2\?VVQE9SFI3C7=DH//=64,R"Z5K&M4+J"Q3CM*\A.;
MDBOLRJ*8L'0.4UKXT7IDUT70DKIL6 OF>@Q1MO+
M.]6N)8M-)3GMFTHC,M VTN@)C&!K+;W@GVW+):>,;#DX/C)LI+EY@'\[;;*HSF$=
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M7]'>?;$"XG\Z[.]_W:2*5)O?-FBUC2B0UJ*A/Y\^&ZO>:V?J'X:@NM;BC'9MK+RHCQ.F>*&"0: _5UP.ENHGS
M1-+PU"WEDLX3EDY1"4>Z,>U] TU=23+2=;W$Q9\9)4\()5TG^T&P3X!VF@=I
M2C%WT!_L@+DFQ%JX@Y&11"]XI,@,YDVW?"W8D.;Q>L^0
MBP)5/8*R:=-":@>:O2E&R08)A(^$NN6@4<'X8(E@)8:"<:^!='4P /LQ&\2Q7O
M(BO\P<']VKLU)[W2':R."EI&R+ -7>;8@97\I\#GEHK/?B_R< [)/96I;4G+
MDHZESK4(EREL=W'71KK9+XUT?VFD^TLCW?_81KHMW;-"E-_)Y)7W
M1VY[FDO;> -0_KK(#\POC>K5O[0]^J7MT2]MC_X_;GOT0:W'47W%*)2"7C?[\@?3$1NEU=[%VK2.SUIO:6O_\'EUI5U@B
ML%G&W5 GMVJ)U K14B>OK+_Q(FS@C8_CBVCO35 >@"VXU[OM*]MVA4T$1+R?
M6V_5?W[_0DQ?XXMJY[\W=OZMKSA&[R8]X._;$T\J+]U
MQ":)QN3)YZV3G[0/:\O_?/45V-U0\.JIQ]/'=+994$/8<#;7-I2Y#*3,Q([1
MUA9^JH\>GG7/3G\3Y@Q>C1.%??1/C8)$P7.Y]=M]ARH,F>)$MJJ0A&.U$9S!
M2??PL+'J2QU'$9?UIS]+*:$&LAZV+<3?<^G&JIK&:!)&P";+D/FDD674^KG7
MH.<+%JL=*%T -UA\"=6Y"6&'9Y^H/W2-$ U6TC 4- GAR^I\8\Q/UTL;B]]5
MGV[F/;F=UC_F7EF!L6NP>S6QZ7ER68/1)[EA],=R^(Y@]";Z*G+^V103^D4-8MNIAML DD7&V_C>!1$T?Y1VYTS
M/:?F)B-9 VG($I9B#4A0RO#L&S2W]19?H<^$+')>Q6.@M5N@?F$#LR5R>I6Z
M#>QA=!CRXTVU8G50\V!=9V*#J'G+VOY4&GRN#-KJ-MU/T+^E0OL-J)-A[:V?RQCT6
M5U>OIZ:0_DFK!#W0%_F]Z+CUK3:KGV?G8K UEX>N'VG
M.XS??>,[F-[BR#%[A2[,F=X7N#EM-^$G?3< P*'>O4/]:/OM^TG?W ([W>N1
M?O:H];,O6BIW0*X=YMB.)+M,$-[I[G0K=#;'AGZ>M0)I6,>;P'NM;3N_A(6:
M">^+MA8:0$+"70&]W),O6$.@M>469CLR1:9L%TK1:1I%*:3)8NB$KAO-%W\6
MT_.K]8PVD5Z_MHMH'WKW9KKN1H=BBFP(4*SB?H^U_]U%:JKH.W*#?B9[[,)L
M?D<;HTT7^ZC/6#GE!$PLGL 0_Y7W,.73NP 8ZGN5-T&'+FH/:&=N@9(8&=;@SR$.ABCE;//UW_YWNX'EO6F+:RZ@7>MV
MH:!,$[*7.RW;  [XJ:;-$N>ER 7>'UH*0[:]SJ]^A:'\C6TY[=V:S,@&:K4;
M+=C8(/6+PSR4I4(L7$0=>E!$"0W2SHW4UR9DX!TU&J/8!A9 -J2&D2F@TN (
MW:,VL]X.#,6]M#!'VC*Y-RXG7N-1X2B:G^IX Q3S_ZV\IMIM&$;%G,
MTZKB+?HO?%55ZV_^#U!+ 0(4 Q0    ( +*%L$CG?S$WN0$  )T7   3    
M          "  0    !;0V]N=&5N=%]4>7!E&UL4$L! A0#%     @ 
MLH6P2$AU!>[%    *P(   L              ( !Z@$  %]R96QS+RYR96QS
M4$L! A0#%     @ LH6P2 QUTFF. 0  J18  !H              ( !V ( 
M 'AL+U]R96QS+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 
M   ( +*%L$C..)7U1@(  'H*   -              "  4&UL4$L! A0#%     @ LH6P2-E+5TVV P  J P   \             
M ( !N!$  'AL+W=O
M&   >&PO=V]R:W-H965T&UL4$L! A0#%     @ LH6P2&5!
M69N7 @  ;@H  !@              ( !!AT  'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#%     @ LH6P2$1J;I>N!   ^!8  !@     
M         ( !5B<  'AL+W=O&PO=V]R:W-H965T&UL4$L!
M A0#%     @ LH6P2)))DI2C 0  L0,  !@              ( !ZR\  'AL
M+W=O&UL4$L! A0#%     @ LH6P2,.9VKFC 0  L0,  !D              ( !
MGS,  'AL+W=O&PO=V]R:W-H965TC'U8I $  +$#   9        
M      "  5,W  !X;"]W;W)K&UL4$L! A0#%   
M  @ LH6P2+ST0+>A 0  L0,  !D              ( !+CD  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ LH6P2/"*V-)J @  4@D  !D     
M         ( !2D0  'AL+W=O&PO=V]R
M:W-H965T&UL
M4$L! A0#%     @ LH6P2&2WK!*E 0  L0,  !D              ( !I$H 
M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ 
MLH6P2$0L9"^B 0  L0,  !D              ( !JU   'AL+W=O&PO=V]R:W-H965T  !X;"]W;W)K&UL4$L! A0#%     @ LH6P2#W"CNJA 0  M@,  !D         
M     ( !E6$  'AL+W=O&PO=V]R:W-H
M965T\6_P(   \-   9
M              "  9!E  !X;"]W;W)K&UL4$L!
M A0#%     @ LH6P2,/F)%$$ P  " T  !D              ( !QF@  'AL
M+W=O&PO=V]R:W-H965T



/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em; 
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}







  3.4.0.3
  
  html
  98
  198
  1
  false
  36
  0
  false
  8
  
    
      false
      false
      R1.htm
      100000 - Document - Document and Entity Information
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DocumentDocumentAndEntityInformation
      Document and Entity Information
      Cover
      1
    
    
      false
      false
      R2.htm
      100010 - Statement - Condensed Consolidated Balance Sheets
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets
      Condensed Consolidated Balance Sheets
      Statements
      2
    
    
      false
      false
      R3.htm
      100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical
      Condensed Consolidated Balance Sheets (Parenthetical)
      Statements
      3
    
    
      false
      false
      R4.htm
      100030 - Statement - Condensed Consolidated Statements of Operations
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations
      Condensed Consolidated Statements of Operations
      Statements
      4
    
    
      false
      false
      R5.htm
      100040 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementOfChangesInStockholdersEquity
      Condensed Consolidated Statement of Changes in Stockholders' Equity
      Statements
      5
    
    
      false
      false
      R6.htm
      100050 - Statement - Condensed Consolidated Statements of Cash Flows
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows
      Condensed Consolidated Statements of Cash Flows
      Statements
      6
    
    
      false
      false
      R7.htm
      100060 - Disclosure - Organization, Business and Basis of Presentation
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureOrganizationBusinessAndBasisOfPresentation
      Organization, Business and Basis of Presentation
      Notes
      7
    
    
      false
      false
      R8.htm
      100070 - Disclosure - Summary of Accounting Policies
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureSummaryOfAccountingPolicies
      Summary of Accounting Policies
      Notes
      8
    
    
      false
      false
      R9.htm
      100080 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureBasicAndDilutedNetIncomeLossPerCommonShare
      Basic and Diluted Net Income (Loss) Per Common Share
      Notes
      9
    
    
      false
      false
      R10.htm
      100090 - Disclosure - Accounts Receivable
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureAccountsReceivable
      Accounts Receivable
      Notes
      10
    
    
      false
      false
      R11.htm
      100100 - Disclosure - Consolidation of Variable Interest Entity
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureConsolidationOfVariableInterestEntity
      Consolidation of Variable Interest Entity
      Notes
      11
    
    
      false
      false
      R12.htm
      100110 - Disclosure - Investment in Unconsolidated Subsidiaries
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureInvestmentInUnconsolidatedSubsidiaries
      Investment in Unconsolidated Subsidiaries
      Notes
      12
    
    
      false
      false
      R13.htm
      100120 - Disclosure - Stock Option Plans
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureStockOptionPlans
      Stock Option Plans
      Notes
      13
    
    
      false
      false
      R14.htm
      100130 - Disclosure - Concentration of Credit Risk
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureConcentrationOfCreditRisk
      Concentration of Credit Risk
      Notes
      14
    
    
      false
      false
      R15.htm
      100140 - Disclosure - Advances on Contracts
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureAdvancesOnContracts
      Advances on Contracts
      Notes
      15
    
    
      false
      false
      R16.htm
      100150 - Disclosure - Income Taxes
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureIncomeTaxes
      Income Taxes
      Notes
      16
    
    
      false
      false
      R17.htm
      100160 - Disclosure - Significant Customers & Geographical Information
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureSignificantCustomersGeographicalInformation
      Significant Customers & Geographical Information
      Notes
      17
    
    
      false
      false
      R18.htm
      100170 - Disclosure - Pension Plans
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosurePensionPlans
      Pension Plans
      Notes
      18
    
    
      false
      false
      R19.htm
      100180 - Disclosure - Commitments and Other
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureCommitmentsAndOther
      Commitments and Other
      Notes
      19
    
    
      false
      false
      R20.htm
      100190 - Disclosure - Summary of Accounting Policies (Policies)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureSummaryOfAccountingPoliciesPolicies
      Summary of Accounting Policies (Policies)
      Policies
      http://www.milesci.com/20160331/taxonomy/role/DisclosureSummaryOfAccountingPolicies
      20
    
    
      false
      false
      R21.htm
      100200 - Disclosure - Consolidation of Variable Interest Entity (Tables)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureConsolidationOfVariableInterestEntityTables
      Consolidation of Variable Interest Entity (Tables)
      Tables
      http://www.milesci.com/20160331/taxonomy/role/DisclosureConsolidationOfVariableInterestEntity
      21
    
    
      false
      false
      R22.htm
      100210 - Disclosure - Stock Option Plans (Tables)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureStockOptionPlansTables
      Stock Option Plans (Tables)
      Tables
      http://www.milesci.com/20160331/taxonomy/role/DisclosureStockOptionPlans
      22
    
    
      false
      false
      R23.htm
      100220 - Disclosure - Significant Customers & Geographical Information (Tables)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureSignificantCustomersGeographicalInformationTables
      Significant Customers & Geographical Information (Tables)
      Tables
      http://www.milesci.com/20160331/taxonomy/role/DisclosureSignificantCustomersGeographicalInformation
      23
    
    
      false
      false
      R24.htm
      100230 - Disclosure - Organization, Business and Basis of Presentation - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureOrganizationBusinessAndBasisOfPresentationAdditionalInformationDetail
      Organization, Business and Basis of Presentation - Additional Information (Detail)
      Details
      24
    
    
      false
      false
      R25.htm
      100240 - Disclosure - Summary of Accounting Policies - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureSummaryOfAccountingPoliciesAdditionalInformationDetail
      Summary of Accounting Policies - Additional Information (Detail)
      Details
      25
    
    
      false
      false
      R26.htm
      100250 - Disclosure - Accounts Receivable - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureAccountsReceivableAdditionalInformationDetail
      Accounts Receivable - Additional Information (Detail)
      Details
      26
    
    
      false
      false
      R27.htm
      100260 - Disclosure - Consolidation of Variable Interest Entity - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureConsolidationOfVariableInterestEntityAdditionalInformationDetail
      Consolidation of Variable Interest Entity - Additional Information (Detail)
      Details
      27
    
    
      false
      false
      R28.htm
      100270 - Disclosure - Consolidation of Variable Interest Entity - Pro Forma Financial Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureConsolidationOfVariableInterestEntityProFormaFinancialInformationDetail
      Consolidation of Variable Interest Entity - Pro Forma Financial Information (Detail)
      Details
      28
    
    
      false
      false
      R29.htm
      100280 - Disclosure - Investment in Unconsolidated Subsidiaries - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureInvestmentInUnconsolidatedSubsidiariesAdditionalInformationDetail
      Investment in Unconsolidated Subsidiaries - Additional Information (Detail)
      Details
      29
    
    
      false
      false
      R30.htm
      100290 - Disclosure - Stock Option Plans - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureStockOptionPlansAdditionalInformationDetail
      Stock Option Plans - Additional Information (Detail)
      Details
      30
    
    
      false
      false
      R31.htm
      100300 - Disclosure - Stock Option Plans - Summary of Option Activity for Employees and Non-Employees (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureStockOptionPlansSummaryOfOptionActivityForEmployeesAndNonEmployeesDetail
      Stock Option Plans - Summary of Option Activity for Employees and Non-Employees (Detail)
      Details
      31
    
    
      false
      false
      R32.htm
      100310 - Disclosure - Advances on Contracts - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureAdvancesOnContractsAdditionalInformationDetail
      Advances on Contracts - Additional Information (Detail)
      Details
      32
    
    
      false
      false
      R33.htm
      100320 - Disclosure - Income Taxes - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail
      Income Taxes - Additional Information (Detail)
      Details
      33
    
    
      false
      false
      R34.htm
      100330 - Disclosure - Significant Customers & Geographical Information - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureSignificantCustomersGeographicalInformationAdditionalInformationDetail
      Significant Customers & Geographical Information - Additional Information (Detail)
      Details
      34
    
    
      false
      false
      R35.htm
      100340 - Disclosure - Significant Customers & Geographical Information - Sales by Product and by Geographical Region (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureSignificantCustomersGeographicalInformationSalesByProductAndByGeographicalRegionDetail
      Significant Customers & Geographical Information - Sales by Product and by Geographical Region (Detail)
      Details
      35
    
    
      false
      false
      R36.htm
      100350 - Disclosure - Commitments and Other - Additional Information (Detail)
      Sheet
      http://www.milesci.com/20160331/taxonomy/role/DisclosureCommitmentsAndOtherAdditionalInformationDetail
      Commitments and Other - Additional Information (Detail)
      Details
      36
    
    
      false
      false
      All Reports
      Book
      All Reports
    
  
  
    mlss-20160331.xml
    mlss-20160331.xsd
    mlss-20160331_cal.xml
    mlss-20160331_def.xml
    mlss-20160331_lab.xml
    mlss-20160331_pre.xml
  
  
  
  true
  true







begin 644 0001564590-16-019566-xbrl.zip
M4$L#!!0    ( +*%L$B\B:?(;Z(  -2N"0 1    ;6QSF>Z^J=3&%>%/5W6=1?O1X3I7M8]P]9]\OO824
M0'8+B='#+O:OOQ&9*2D% @0&6YCLM?<4!BDS,MX1&1GYT__Z/G7((_4#YKD_
MOS.JM7>$NI9G,W?\\[LH.#,#B[%W) A-US8=SZ4_OYO3X-W_^N7O?_OI_SD[
M(_?W%Z1OA>R17K# "_;JO5[N)'
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M9@7Y+_"?U%= 3@GADNI\"JP)G9KW=$0XOWY"NO_\+F#3F8-\SK\S?V#O(#C%9?*C6%;DLI P^^=WO_T13$P?M#__'GZ9
M4A/U_2_BZY\^QG_SUS[B>TLC2+WSV^!B:13YTR?X;_S82^HZTW!E*T8. \[Z9C++__T48%]Q=IG,- 2
M O'+0IA#=*%I]KE-7J8G_OY)>6 7@!:/G(C7\M
MA%DP[,%_1N'22/#])_QA]2"6YX;TNQCG_(_49_F#ZQ"C9OR16.QX<, &"^G8Z#W@9?HBN
MWB_"QT/5^M/']-OD0>K:RF,-4+\XM*T\]--'9?"?/DHD%,%(RVB_.B*$PQ7^
MDKBZ[9\^QM\]=WUE('1V?8)^^UE?RZB7:WU O/J^UB>]P0& ;D<.O1U=_B<"
M*+[1<.+9U]Q)0DVV_"VE-^:4]K^[email protected];^BNAQ#(7=J1Q0.LKVS*0FI_9>:0
M.?"R#$J^T>F0^B^'5]0!=(QK4!4V_3YSF,5" 0VQ&3P@8E6)D$_/P(BRPIB]SCAG M=!H@6'!;ABHDQJ:S*7VI>F[S!T')TCK?!2\)2+?>"Z.XWN. PN,,V(G2.IUB'A+!'_P
M>=7*_%2M=,[ZCX6\^T\]2?IKA?%2"J.4<>D".YR\.)2?BS6#O%A<+>[Y,\]?2,(W:YT2RB2LYM/"C#L4@\0S0,Z'\B'.L1_N=A/LOHFX6?5?9J&:V7ZQBS,Y_E
M+V_+4_%Y2#BNJI*7.0DHFO6T"NA2T=.GC+HT/.B2=BE;;Q"BZ
M /,5&*745;H+9XR;M7:C=NH,@%3(@(C;5->M%T%MRJ;XYS$^)0HSBG01,?0RJ:,372,LH7,:UA)
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MHW#B^2Q[D=\%_!:$S#KW(C<\GBL?\Q>U72"2N_0C\51V)&JY"^<7A_'L6_/5EOGQ.<08+H?[2HPM69]6>9KI%=31AR3-WZI96_#P[LX9&
MVQZV7$O)(]%#K\6RY59DFF5+K&4W-Q)I&K5:>9FK5/U#LLV):MS#W2.IJ ,^
ML'T''O/\P3?=P+2XH_YEKOZ2: KURYA7C\7*%5_J%HID-4*.Q+SLE0'*;3/>
M  .\C$O\A;K69&KZ?V6<#-.A0/Y'ZD;T5\^S@QNZ4*!7P%,YCX(0PH=-GLHW
M\T_/CY\-$N:+O[G%T]U'EM;9FXNP 87/E>!UA9:"W0)
M!5I;:&UQ#R"@QRT4VLIIJZ6%HC268KO,9IGY](4R"^7:+=DNCZ7)5[*]CNVR
M%F^>?)NCAJ.2OH4859.O9-*W1?U1[!K&]V/]2KVQ;\XFV-&9OV:)XL/?!D<4
M[I2K9FDE;HN!) GPZ;?!6XM;#L:F1Q* :#8]BDAB)9O^TW3M&:/6XCD9K4P5
M+EU$TIMFTA+JTF+J'I33-J";7ILQGU
M-/3IB3'J*]XW]*;48\G)_(K7CKXIY5)R,I?0/]HA(2(?N/'&OZZ?",>R2J33/N&]&XVZ=-3EGAEBI_QKJ]C39MH3:=I>T
MRBGKVY+E5TY9X^Z/=4]#YYXJZY8Q1WC4*O18"%_&K.%1*Z!C(?PK2#RV+JHU
MXKM87X*(6V&DB4LM=%_IOD7A@85XL=>U:[-'9D=9,;A@/K5"SS\Z%9B[JBU[
M3&;6_M8TX)9D/Q(%>"1D/YS^LRG[=.%9/%&*1[8X_:\X_6NU=T0^>T]'R^IQ
M4;*-VMG_^>GCXH#I-'WXRL:OKQQSK,YC;#?/R'0"*B;*#+F\H#N^[$N!#'7&
M^G8SJA*U
MY,K8Z?0/OFDS=SR83X>>HT[9VF[*;U\' S%I9L1THDLN/?=TS(+0-]T0NWRK
M\[6WG._ZZ^7@X?;[email protected]]O'JZOKL_)]V 457=RO'3Z<\CW\^P1 ['=[>#X"R^.F'=^(L(N&(.]<_AA['G9Y;?
MVV[RP=1T8"1R3V>>'P+MR;DWG9GN7,5&9K(E4GC3J>?RJX0&$].GP6T4XHD0
M9"0%,&.CAFL9P$J/*+H[T>KMGM!2HUX&P&[ ;%/P6*#8ZO48778_M@>7YJ?0Q
MU0(9&\U!86RVNA"?I> M3EH29N\BW)F:0)=Q&\U(8
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M+>  -NJ=#1#(,./.G*/3O&RG&AN36,5QTFVW&ZWZ6,D#ZR#:RU+V9U4@QFIT5:.]\U(PR<:$TX1I'P"/N6/J6BP3
M=#4!E.\!^^0RY^=W(8Q;B"CYP(N]H4\P7&:KZJD1[Q 9'__OMZ_HAD[-,]&'
MQH+Y/NX$M[$5W)("AX0;HIX1!3K8/*^YF-EKKC-3BY44YXX9!+[]85U;\X
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M&9?7KN5$N$M\A[O?GML/0Y\-HQ ]XP\Y#CR2MY;]6:=NH]UJMNOK
M"+\+L(=&P/Z,7,\ !/0.C  EQH%88+U4[\\*+N>!-L&Q.]3[,X#+N:/MH-ZV
M5J&]SB#*07\W?8;4CJG+RS\ G"]S'@DP,,)\'^%V) I#U)@@]]WYG0^(\+$Y
M.;?@IGI7^S;.9;VG)CI>H+2COOU9V"I8G-$N$"67EJ>:K5HG
M)W&SM\J5=H%(N[0L4JO-8M?H"V[VE985NM]5K
M&T567[!PI+W.K2L[+S2;1G.G0I6BR%GG\I6=59J-5KVY"W(*;K:WUSF-9><<
MH]9IUAIJOG//I0CM=PUK+_C*)^UN+NB4P\V%JSE;PV:$\
M9>7:_2EFK_Z'?[_2B*C+W%^2L=7M=6I97;T7: ^/@_WE&5OM=K/3.30.UA3O
M*1.J ZNKW5_JL=UN].K*%LSV<.US7?M+3K:;[4:W6'%GH75E]_;O3/_6YT4&
M-L\]W5&?GRM3UM(MX+/MO?YB\4Q3QT?D:M5:^HIHF)K>RX^"GAL>R_;
M>"U\B$.&_2B<>#[['VJK>'B-NIQ59R71K&4LV_IE[+KDUZC8>;$E7P=!E%UN
M@4SABU&XLW&M OY=UEGD",A+D75_Z\P_GMPMD/(K$5%7GF_>8L4%\G@E(N_J
M$]UIS5,1,[6M:[6;B2D U+-6L:TC]?*K6&,O>MM6/FW0];5$\#ZD-(<>7Y5U$8^10'Q\2 NK9M,RJKUF886#VOI,CV
M#O4+(F7;U,PJI/3:C:9ZJ/7 ."G8S*2W;4IFIZ=/7-J;-DLK& :
MNMUKJ"4$>3!L!^4FVYGM6E?LG$&G4ZO7MH+RW O"VQ'_;> YM@K@=IW)"A[,
M:W>-7L;,9Z8O#-LF@[D#\GKPI%H9L!:T7WTO".Y\;\0R--VNF5G1 _"&H5;9
M*U,7@FF3J=D!54:WT:FUV@5@&E!>;?HK=:EO.I@KMJ?,Y9W+0O9(9N9)-AV0GQO6ZM:SQO)6CK3=_"DL(+4 V.Q_/S.0O8
MKE%;L04T&\VFLO>[%I8=P=YDEG;!.\K@3E#?SBB2PAW+7Q4#:FSN^;8#KQO-
M9JNC8'@)@"[email protected]") NT/%J"W/7S7KN5-Z5?0,RJ$![!19[UF([-WD@/"5C >
MP%:==?!HQQ8@)GOS2^*RJ3_;3E*^T.(K,_=RP:5H-2- 7SY$86QNT+:+2:BK
M .;#L#VDF_JV[2(P=:.V+:@WGNME.2*'[MLU BTH.NI)^I50[ #LIJ9OST9L
M06!3^;KRO:DX+!_!*U( /3?X0D<>A,_\N0?S.PT6SUR!T-ZZ^4\+EO[-]:GI
MX)869VI+@"[2*/CVI0.+1_?B]8?M\ F"LO$>E&$KK[5X'*^T.
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MG3T/2:M5L.UM87LRK5O3J]C"]MT_5I]NM[KW9JF7NHU7L=
MY/%-,BX4#]X7*M0\__G!NYS.'&].L?W-%\^-LD6S:WM>/]M>[7CH0N[Y%5W.
M,S&PKY#@(*+8J/6Z[>;+(N0 FYH-;-)?V]LRA#.S:1W[_'Q]K+%N6II>W?9BK3 ?E:@M-LM
M44?A[A;ID/T!R7^GP=0K[.;$46MTPFD56
MHG;K5%:RMIGVSF?4.UV%P=29B\%T@&J_5J=G% %)[7EY.UILCJD">8A^")U6
M0[V,8"TLN\)]@(H]
S_6\!N'F0IG!_W[5O9_Q\AV!>"-#45,TY_! Y>!H/
M'OR=NK;GRZ1-9FT'J.EK-D6Z:7\ 'Q(!!R@>!%>ZWMS_^F-FV;:4>FU_Y[WG
MU/=QU %<^V[V /3!Z\W7-H ^-)*><13A>2A"WXA>4/'OM;O<@US%T &2<$U0
MWZUL0?Y&D)ZWB,/TMF@NG!5[]B)NPPGUT\=53EW;&'K')=3;W9[17+>$18 V
M+2"^[X9E83_ H=FS1JO7;776 :\ LR/<&UR7W4K,V]UN;RWS+\$='SS*/(=[
M..*:H0;S6PW*X]WH'Z"4+3F@:QLE[QIQX+4F]77,5P3(0FHL
MZ:VRO+ #M/NHUYN-7F.C*EL JJA1D5?LJ&LX1!N0>J/3;:U=Q ) A0BQ\ XV
MNUJZ#$9=V2&.$@(S-XS-Y"D"ZD'6?)ACAXU>IWV ->,5E&8PN?.]1V93^\O\
MMP!/F::\;87L4=SQD],60%GVYH[)NY"Z >9-/3;Z/' /M?1#')1L=PU#->W[
M7#FP!W?F(7R45@C,T6@$#&*&JF+:U+5Y)^5:JV72@&MA66/0RPHH5/P=#+]H98P\)C,7\Q:[8 6&R &[L;[0R.[FY5?0N328S
M/28W@K,!^@(7MHN!-6[LMYP#]UNI-=8M^V^6(;"1>A"X>
MMY$#\V\>5-=Q@,9IK5H;%[(%0(5,?XY67F_ZZX?H3Z/9K6TT_06A/=3*
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MRSR 6[1PZS37FW[!VX4< /LK1 JG'326IM@@L6
M6(X71#Y]@.5\<6!B9:5;MEC_Y;^<\+/-'O]K''[^^]_^AG_-2!#.'?KS.QSC
MS'38V/V$YT_8:/YY:OICYIX-O3#TII]JLS#^)O1F_$_^#G-M /13[*I1_1"848B'WR'R[F]_[5_<_W_]1^N;V\JY,MO@^N;
MR\& ]&\NR)?^X'I ;J_(W?WEX/+F@3]#6]YCD/1
M;:#.G/R7.9U]_@=$9K7<09*?C<\5]5DO\E?]% 7*+\3SU=^>J/+;!_)D@COE
M6IX_\WR3-^-Q23B!^5$:B#"[I1V,@#X%8KEP'"VN+\ 
MQC+)#$(P6#,JG@K!1G\11#%G<>T?/N+"(!,:PKLV=0 A/@1;;A#Z$8IB!6#Q
MO6@\X3!% 8<(60 +@!;
MX(AQ;1;,O(#O9("9MF>,6K1*<(P4&L(" HSX%Y5X0A; >S'FH,# Q^4P @?9
M%!\J"B;JL.@"1EH)9\&!<*WDSHEICP,)UGOHD_<#L=('SPLGI"]P'C#S XX=
M1+/LT"A4W=:/GPE0(\34Q5.S)#XE!M. D8!
M?DVYM[K[HI;QMP7%=T((YY*L+,"2,B@ O3D71,PBP:?CR#%]4%L0X:"F%*)P
MYY@!RO @\L<49?V?)O/)/2H($0>EO]QYH =#_'3N.9X/:A!F2'Z]H*!D0_AA
M#'_<^N$$%0FS L[*)G%Y?R'4 AYN$*'86FSF *,%B](:B$7Q6YZ$3OO-Q;Z^
M0K6) >$'#YB<-#N$[S3Q(@=SZ'NFG:_@8MUI=#X'B!8[LN1$TW2WVR;#.< :
M3IAOG\W )YMSAP'WQ-7'_.J.!M&HYUK$9F
M=$.YQ %1D4J=5JT"#A7QE(Y6HE@9GS#!Z71-;CK)%; /N'4DME[(9DA5$6@!
M=8$TKCD%S>-Q2T NN$Q7A%E^KQA%Y5?5.E;Y'^XPF'U./\&R!G06\G2X7!O7
M#"H4:%6GU.= N#"[F9I1Y;$*2!.>#<$5XLH#A)4#S%I01?;V1IJ?6&48 B%SP
MS#'13*N8 %UN)0Y_C/\\2*IO6OA0%T:N"11")&0P,HHC'EAP'/*L(A],"-K;Y#:2BRH9%C@65X@!S\+O*#(K-#',
MW0=I 5/#BCSN=&?F:/DT3FQ/5AZ*#F2JKI$>9&SU0C\
M'WB4VS&I>8;S_4*/3JX#'F(NFKF-"K:C3##Q(K!A0PHPFQP&>.?/R+6$ID'T
M(U"Y[^*:Q7K16E*0! 01'Y]3TR<4^!4%QQ+*K"%42RO&))\LEROZKAO!3/<4
M5%E( (PK0#,Q:F?_^^W;-,2>-P.M#SQS9*:5S+GG0
M*S!1G(!CS;0%!<:';L#XE@!.(0! +1[Y/GY'A:?R@;A NB" X I-W A<+O3+
M1'ICLZY/08+(APD9$8H +Z*+N:$M]/$$V0^K\?D3:%F]-!\?,Q4$:Q0\(5C5
MA'.<*SCLC?/$@X(;GTL$TCL/)4+>%M$+3@&JKYB6 #7('3K>W,F1FDQ!OH+X
MIPF#H:;F'-4#_3X#9UK.#5'G:3&MNP!W"V[:%WT-GPGL#IP<^?/_'D^R*0$"P<;PTBQ
ML^DJ %)Y?27X/'EZ.1<]0^HP@%IF*Q(:NR"!-N:J\ PNU_1 &[X,\4@FD%(+L)TR1R5)'J 
M]3Y2=/!<'%(^*O  W(9GNV0\)5^(:665%,@20&@HE_&_3)U46?6 [H
M5NX"Q[J>SI@=^7*1#$E_AN5Q%B9,,NQN 9\-*5'3H(I'"G-,*2U@P(>1/:;A
MFDQL[(MBYL3&4!.G2@0BQB>R0[R$933RQ8C!8J^0DP?\9KRF)8S%#U$28RE!
MFT $%ZCXN27I3RBLIGI7\VM%$<$%;E^AYL ,\B@FB$;P!>."B3A (?7YRQ+A
M,G!@7%Z!;FS&5^,-P4)*<>79(@'@=]!53]1YC*U[;K) 9OG:M>*?MK;5V^T5
MI7::6T\%U&1B_DEN62D7PNYY2VWAD#PL#.F%E5I).'8'WFX?KF5W)W^_7Z_/IRL.@/
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MF6FE<>70=/B17(5-:'*U8DQL2Y7-ZE:^Z\\^R%RYDAVA_&0@ID5FU)\RD9.-7_:D(R*RX4H.%5T-3. JF6$PXGRK=M%_
MB69BWQ#GEP#(.1D_"N/YW$$@C@DA/S=2$Q/SJ-3'33%+%((DZ3-T"]2]8H$ 
ML)8$UKY4#S"<<\!S[>M#ON'E '*SSBVS]X0Y((_8#(N7I-NCI)(!NU,/TZ"I
MI<8M'?#J+!65_V7.O !SC ">-P7++PNJ.&[C/;X:':F)V>
M8OF+0!@+.?W3M+Q@@((46B3*BD(HA46#&/WHUJYP!461#,.M8? ";0]>PBU$
M990"Y6L@:Y[S* ()?!-X),+I)8/SM0=+K!SSA^2I)]SEE2B*7#Z,S]O=\@K_
M@/$MD[_X=@L_:# 7*=2_Z#S=QP2I'0M,Z$\O.R+^R+^1^P$
MF'*W%]6PL<[
MBV)?C1=&FWY2#QGZU SC[6#\8L7RYTM\I8/J4H0J.J@^GJ"ZH8/J34'U>5P*
MSC\HAV)U3+V-1>1UF;R[ M8*3& ^!\L@ )VV#%U%@<)"?(B]/0C3
M&*^6,L-(Y+E'V>) L"D.EMR#F1G*LB6:TFDQ%M-FHA3"I\W$\9B)IC83F\Q$
MW'"1I'V-7]A Y%?//?!LT+7WS_&!%?1]V#)KR=)%,-B79/C S<:I%3&D!BKTI6BVL=#/_@I!.
MMLI"* 1X 8%W'*S5[RM;L:,8QL#$+6,,J>R(QCD:E[D4GK+-N9P=,TIXZG?,
M4ZD^%1N/&.#SS4<\4JHB1HXMX4]*YX?S?9W7VGMEW&F:WE+JL])87FUX-T'3
M>B'#6TH^+5@N)8S"/87@0!Q5_+?I S@R_:T#M(+V-]D*$35-\-$]LVE\D,'G
MZ(V-E6H9JR0F0?R,Z%OQ)*G 35]<)U4A%-@TXGE#<7YC9O+*?;[?P\\DY]9A
MA;PCB1R0US;/N99+XAN?$Y.?08^K^[email protected]
M3@^]-!9-QY(;H6GK6'*335.N:M$V;.5Q\O1N'5F:RTLRY/EO#,!&S&7!!)3X
MV//L(#Z)*:Z!)-A<)A [5F !Q(ZFP[?O^:8KC/!^Q/P UUPAXA.6Z$QYT^\/
MA/?YP7.951)#,B?_BFC[7AD] F-'!@V? AB-3QN/C0#%G?G
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MX&?<3L;.3=QI)=[HQC?H*'((=@E/O GA/U6DR^>C/1?I_1$F_+'H'UN&YRWD9DQ\4N=YPYAP$4+T1I*J;KL4JI$4ICN70.?2,T/9U#
MWYQ#CZ\5)/*DT!FY$SV3M=E:P582/S)IG;5:_$RKZ)0A^@%#3"G,"+:AL[BJ
MMCU+MFE+ M%L0PPQ ;G%\[+@5,0=BUUYE@TBV>1%9=@Q&C1W*KJ?>?S=.#J#
MX'LF=ZA%%WK>Z@%/TXXG8!Y\WB-6MLI.2ZKF-"ZKFO%.>'9%GEP*PDR_.G':
M:J9@94AE).N'_+#6,RSQ*$DVB EXS+NPZ)&;PBA[68AV;K+9J1ND&141V:;)G]SJ 'D8$POT (-(@3B,%R!PQ^5N
M"=R \XG88H_QZ U#<R%+-XH8;,1
MGBZ2Y7M>VND\PW4)7/!Z*)OVY4XMDQ!B5'R!#SQ;>EDDL+*PW*F6IPO=*B0=[CVDFZ5RB;+MCG8J$?B2R_ ,>!
M!?%6F-)=6T[#_0I'P"K[!>0["/R^@R#9J!IZWE^9S9'%@;!*A'J,")-_1<3_V-?F>XIKQK%'3593GUI#;I
M1V327ZKQ:CE9M9!)OY?=U.]%,Q;>GU*;\7Q^BG$E0F1Y $ <=6.9=C9H1D"C
MQX9/UCLZ8/>$P<9N8-Z4\BL0U;-[<=&$+2]3#29R1X771P9!TH,+CY/'/T+D
MF=9/)&^(4X*86+BZ_8+G$NC$@QAYA4GC<6>R@*3%/H 3@P(^ IXMC\VVK"X-
M,V<(LK<[>'$WER<>3B?@)D#9B !7[O\,DI_Q9*.:(,MB:&E%%7%7%68VU,L?
M%&K *A*TJ.!C%2O')'@E-.E=8]'8M1E&[4S65*#9E^=BM]T4/',$%.&PQ6U^A& HU[PH
MAU]DPZ3T\DH$2IRK"= OX_XE8'',MP'CXS9XI8Q )YYGD94],KF5C"T2=VF/
M6>TFE=+V:#?IB-PDW65VHYN$YFD6EVC^$_Z'MQ$]Q\T3[2YMU21.1,(!-\D)
M1B<1 ?,[LK)A07 O.\,._+CIDX\SNW
M/AA+B4N(\:]XCUFFZN2^;W(PG[JFN(073P;&%6,^+R!3JOXD[D1Z3SF5R=/A
MRO)B^QG?ZVOR:X<3R.*[KG_G6]8\2>
M7)&M8G,0@EXW?;"67SSX)W/MY%5_\"5S7R4+@@B[ D7,3BZAC[=+_73OGW_/
M^QB T<:=Y6B&5[E3=ZU@)]MX)<"\6(G' <0#83Q
MYV?)92HQ5,)\)C F?I)R&9DG2Z]2('E=.^X?!B&=!9^( 8OE5=BC>7PW"W^P
M0NK*+VJUFG)C>X4T/J1%8O)NCN2>3+$_7"'-#]RMD#5WN8^@R6U]6-Y3%TO$
M[$$@R;?H9%%W@E#9O'Q 7(*^>%V(:XH#JL(9J6"V.\ZDHW3Q$R!BSSS.!;W[G7,A]3?A^M[';@BQ\J8@=\+2$S^U3<:5+LG#+ 52.Q(4P\JB-
MR8_C)!6-,D=I,%G#DR=_ J2E,P"S_48^+= + ^
MO,1.7!:'7F;DK[B;9L'GV]W\U,NI,&^\1T'2#9P; +(<24%>$2%/"@78-@7)
M&P2\RXNHRAAE_&EY.(13:%E+<0IB/4GV%8P/TH8IO/##E0TV*O+F*5& &N!!
M,UEGR_>T1!,.E.KTE3C:6E"56*;[3/EJB^YI6>G"9B^Q@"FW_6+AC+QY2][ 
M%+^ 6W:)K(@3-#S*@U7).R2!G^/S:YA*15##S%<8U0$68[@3W%5)/Z=0ED.-
M-!?[<[)-3&X8A#UM%NX?P]-^;_S>0I=2:5\0]X_>#.P\-UF_<.G9=/' E[KY=HBDH; V>?JEJ\.
MCUVZV+A6]C $X9#9%) ! -?SQR:85GGF3MQH*8VM4-JKK@5SF1=([2 <&SZ3VAK!50\#O/';\K@[CSIK__+7RH*Q)Q1K75:J%1PRO@IQ6<_P>UZS&J12Q/O5ZN(DU$4OHR[.P:A2
M-Q V+BG_!6TP"#WK+Z+^G*,K.D:W@*Z0\5(2+*5^:1PVB1-EZ(U[, I.++8.
M+&7Z2OJ4N%Z4"3\1T#FBO%L3L#EZ>H(9%Q@F=B%%J7E>.'8>AW*AJ#17CF+S
MJSFIG75;>7& (YOL!7$$S_4@UUZ)&E'[ E3)K^+>V?C:TKB?8 '_X23D>B$%
M*--[/WV,@K.Q:KBUYTD7]\:3_5"N"3+]8#?8N/[@G C#4V]#?",8;2.$V$'.="S9+PP.=/&URF:&BE#543#'3.(F]T [CB%HIF,XY,&S5CNS?T'8:.P@D^<&@HJ
MRN$M?A=]DML; IC47R1)NJ/^MG-# WYN<,4)-7&,,;XMT/.SV;;DXO5H2N/<
M?I("5TF22V*5%3(TX^/'9!.DP23Y8D-L540X:U#FQS'7(MOA]11G\?[Z@=O ;IGY_?_G;S,"#WE^>7
MU[_WOWR]W-MF4?LURT:6)7&U$Z8O8I47L:9[/*MD<9.09>.OWY$H\#,_9P5K
MO^3[^!?)UG:N;#9U/+9"7)OD_/9FPQK5\[P. UZ([[8
MM)XQ\-RQ580?8:,![,?$>T6"-HYD.1*X?_"^",0P]'&B@-_QZ.I71AY^!8/@KE\7FG#$XJKL86N-99M,*RBP@X;
MR98&J.HE(ASL(K-39W<1"ZF$4"]8R:%$ZKKD%J$K^Z3UA
MO[=*'(ZN<.D^%\DUG.$641&>*0MS>B*$P8.C;\!
MAX@"#]M8/"#C-"S%%U5\_'E,OP83%'9Y+V":A5X$.YXYB(*9W!_@<9MESAAV
M.?9-#!DABO/PED(0>=&GU:=G_ R>+;/&Z<5 @DQ*J50._LU@W4XQ,*U3.CV F/82=M[?KR_YO51'T6R)PW)YK(@>;R'Y,L"T2>@19'
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ML9PF%%RU[,G(HTWX)$1QN'DUI%DWA2T);
M--R=,#F5QM[UG_4V9^H?\L_SY%DSP7)[0Y5TMC-(.
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MPB#NL$8DQ%_<)!Y;!3J,"Z
MVR7;^'?6;N(7KZO%"C:V /P#%H >]7<):<2B#T&=^*LO*5H%P>JU:GT#P?Y1
MX__E$4N1*L&IFX5J,_GXVC_%LQ9LUK#_CE0B6E)-?PL[.I K_+E0 XS#D5/V
ME2DN:,MM4@XD>V4B7A%)_*@JR2+Z\OSJJG9U?D")E"KT[9/GP>/;8"* WE&@
M#DX-(Z_%T D0YX?2$J3'#58QHBCVR<<)WYIYJE.ME(MNY;,,OJU]%)_Y7]O76R581MUW+7SFIURL<>&E;AZOM-1H5H]G5
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MQ_4&25R)56*/3N<3WTI8I=.%FX\IU(U=J39:I2?.LRRDWH0K#R&/+EK4FW!Z$^Z8"*(CPJ,U<.V-Y"\I<=\\6O*N3E>N&CF&*E4=!Q_K1J>.= \2Z>H:4QWLZF!WG1\ 
MH6YB]1N_N,%J+C",!T=G8EQ7XU
MF;MLL\XGS#7W8J]T$>LQVS1=Q%HVDO;:E7:GJ:M8CX!4>L_R:*TBC^3 ,";[
ME=MMR^GBU36R&\X:&Q 'C6=IX0UO*
M$PHGM;%\OK$T*HUZN])HZICS&,A5TOW!5[&83:-:*[_%_$J#X!.)[28QP]!G
MPR@TAPXEH4?"B9)Y??/(R"V*A7,/W^*U8$(R+Y@K'4"&K?8PWNPVK?8Q]
M%AMU*LU&6]?8'@&QCC FM[T(K6F]NF\/H]4\@I8,*UV+I/1V+P[&4> BU[\8
M6 R 92-F'7WM\3K&/VFWXH?24G4W;^(9E'WSWD2WW:WT:MV2YBM6&J.3E,N"
MWL1';K22IVSVN):O_XP"T.=S%35&?9;'Z2IRVM5VYT=US<8LW!"42$!^^A@%
M9V/3G'WZ'1<)H,8= "_!L(3S"Q988((CGS[ ?%\8\P^^=W5W\ Y>I&ZQW!P!A^NJ>CG]^=X[>U;JO5[C;^J->,
M=LVH&>)#HV&\^P4AE@#__6]%<;>:T3)\]6.&.8:>8R\B,S:9'KF]\O!P_?+F\>X"/!Q>+KF?6FPT>S&?4M,Z!BN-]NSF]O!K=?
MKR_Z#Y<79/#;E\'UQ77__OIRP*F.(R4LD.,WK>?$]D9&?&5L]NU'T[4HN;4B
MQ_2%>P1_#OJ+6,S1!ZFX_ /8[G,&74M4*/#^^D\O08Q#8NX1R/4,\?VRZ *6-_KV\/!=_9FX0^A&_1C>AM&A:":J2JG
M^12GVGN"T>NM'_&%< )C"6"KI!^(KR@[email protected]@#HA7;#&D%$!"7WTQ,;"! 
M7:[M> @C%A@J( [GN9-7R47D8]80X&M5\N$S8^S^T.E6.KTN;\8#3/$7Y1 /&&P*BF7)Y/9^9<
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M$H;R^A7LU/R85@53\-=PO5[D+V" J\P@
M&@;,9K 88,9TLZ\1#V1PSY\*<)+YDYW.@#@XZ:Y%QVBV^#HC>0/>!
MR@:OGZ,AQGF0(CW%$5*2@:&#.%]J6[$
M7+=J1^NW8\3[PB8A%YO@:]BHE&M22S W(S[2F?D/J*H0[R[+XY=E!5+-5]?>
M$RSQARZP0*-9R[ZF0(2,JH(0ZV3F2ETI%  +,JZ3:5E>A(^#$%'VR#/ORWQV
M>O1%G3)&OU?HR= +02W[$*^X8"Q0[!+-.?8\.Q#\( U9"##S#T@"+E3PV*)R
MG<#_S!@@'2*9?P*%(=BI -L(3R&16;(P6.%H8+A@4Z"1+XWS
MV$?[(U%B!H$',0AZ(7R5*99CT
MJQ':%\D9 ^2,Q1VMI:1E\>QC-FN9/G [0L>)N@%?RSUU$(ISE.$!.AM?T+^Z
M,^=\V-Q49ENG,E>D,MM;)B\'(:+V=L;9Y@[8(%A.PFUG;/+QUCY"6V,I3!I?
M%H=.FLD3/ @)<9B+BC4 "?? :'#1XJHW8.!'!]1_Q  2,,ZD7HL3).B^@Y3"
M+P@IE[XA#RN\F9#O9#CYLA1I!,-"F57>K)(KZ1<7\XC7KQL]J4:STJJUA,?;
MK5>,>I//S^TNG\G^/&
M*O!B&$*%%PX^7KT-_]\4L/6:O4JG6TN!BUQE'6L!!-XXDW#%L J?+!<[ NV!
MR+/)"02)0%ESID0E#']CS)52K%[M]?B*A;YN5(U:_.?Z)6?PLR\9Y"Y@V82P
M#W'0=(I)! Q5A1XR<>7H$* ;'?-;0#!)*64"%97P_,!U&]/$QR\4'%9$Q!O;
MSB%UO*=/>]-TJRS$JV%X80\\_O:F!?T3.=F19@-?E;[EOS
MO^6...89J)_L?\O-:\MS'',6T$_QA\]$;'#W:FIWI]>I^JKWJL\K*U"1,IS5D740U78)252F2HB"! .0 4M L?J[5RU;:A5KVG&*E+R)ID/J
MITK:&Z6?A5_^VL_L$NHW" &O?  F5I,A=[A[O
M*&&';S2SRL*_,=H<0W;T9).W_E6E)A&I6GT2M"':9T8:BDK)V6TJ2H+
M);2I.EK2:5-5V%156]I*E8PF1R!@VDJ5A1+:2ATMZ;25*DK,>K6S:Q\G JFXJ_PH.A6KK^
M*COTVI$H2V&6UF#'1YEF4=*\=3>@T2Q#UW0M0LVZ7Z8+;\IB9O2._^E21CL SW0 M/"<
MKO!H U,62F@9*2MEM('1!J:+2!*0LEM(R4E3+:P&@#4TZ"'('P: -3%DIH&2DK9;2!
MT0:FG 0Y N'1!J8LE- R4E;*: .C#4PY":*/E)6<0)E;W;Z9OC4A#7VI6RE(
MC-WVMU*H]DL+:FT$)65,MK0E(426D;*2AEM:-(+U7JE
MI9*6G[)21MN8LE!"RTA9*:-M3'(=6D_;F)+1Y CD1]N8LE!"RTA9*:-M3-SZ
MM]VNU%JUTA)*B]!>=]+TP;,]$4@V9S2'#MW33IHNKBF+^='U :=+&>T8)#MI
M1JM3Z74;I265%J*R4D8;FK)00LM(62FC#4VRD];0-J9D-#D"^=$VIBR4T#)2
M5LIH&Y/LI#6UC2D938Y ?K2-*0LEM(R4E3+:QB0[::U*H[9KP<9;%R&!^ACS
MZXCTNAMI'T/LMGC6D[^,PI"-IIOYN4,CGY4<8)(60GJH2=^#6K\PVC7
MBG\Z$"K:U7;GM;'1)T$T!1CGQ!L1;Q8RSR6F%;)'%LX)#  /NV=T.G.\.058
M(H#<)^&$DID#,Q#3M8DU,=TQ_&9'/D@]_S&<^)22*I._I9+E
M?TN-;B$R_41_BP'.0!$ZYBR@G^(/GXG0QKV:ZEB^].Y]LE7?:/_X62XVIF+@
M.003G$4L>CI2"#UHYO2SLVJ[VN
MUHZKB/EO/AJU4YW8?Z2^.59;WI\82N([LE.4W/G,HN2'+@7/XQ3>M,#(=\I6-3I<5WO\W-?W@0SGL
M3?&81+L')2"7=@^T>W#\Q.R/QSX=FZ$2"UV#<6!NP*R3-0LR:4A^-YVH1%&A
M-@][W+(O4Q=9W%![^Q3*M)']E^E&N(==_CZR^5;^C='F")HOI/H/49QKP+7B
M*R?IFIGMRV>2[ZU7!'8KC9V/-NG.&JD:F62!ME0;SD=U
M= NHDM'D"&1,&ZJR4$(;JJ,EG394VQRRJN[NU$E*4Z2ZNPXZ.,V!_4+L!S
M7  M/Z\E8(T1U"M
MH=5:62FCM]!23(Q A;6;*
M0@DM(V6EC#8S*;F:U5:WM(32(E16RF@S4Q9*:!DI*V6TF=&GSTI+$'WZK.P4
MDJ?/S*%#][29IFMLRF)\=(W Z5)&;Z8I2=V]M(\A;NHD3]GL<2T/_QD%(1O--W-Q!D<_JCAY+:3\
MPVC7%*0472(NJ#[+DUMUB>UJN_/:JWR84#(RF8]2%U'BC4@(WWBSD'EN0)[,
M@%!8V=0,J4T\E_]HPQ_XX!CF"$D4@"3Q[[\XIO47&5@3SP&HQ1!G,Y]9^,#4
MLZE351@M^=0/<#"^/YBB/-XHK)!O#$8+81$P,@.LL1&SB$\M;^P"SFSR@U$Q
M.BU"O\^H&U#XQ>&PAAXLTSVCTYGCS6FZHG!BAN011J1V5:%PWJ>=J&X6< 1!32YZ@^^D/[@G+1JK;-6[= GL H:R_*N*?!.6>+]^@_XE8."?,#4(_F@(J@D4R!008
MSH*7F$U]$U\GL!HR]CR;CQ-0_Y'AE,  E#T"G8?S? XQ?]EH4W@LDR7#"FPO<]YDH'"G),I-8/(I_:'*EF6
M.].=JR@+&/""F8LT"1=393.S.BZ)9^LD$6:S^:,FC#7E#PC1X/3-*H%U]'MB
M\'SD""A@A2A953*(K(FZ.H T7CH2F"^6F#/@-@ *M0E7*;/(1XX*D2EP_G'$
M.'M6R/LQ=0'#CC.O"%J9OL, ( DH?YM#S,&+2 2RV.#CCX\X<&M(/')66.6,A* 742#"4U$9\M6R4SZ$3
MTX;1&+X;3#B'\D4O0E9=,,G2V/[T,0K.QJ8Y^W3! LOQ$+FWHW, "B;FO'@O
M-.&Y%X3!8 +R\ 59Y,Z<<\H]@+KXXH"8_O+WOQ'R4SS8N04"4$Z'P6
M=L1SF,WUXXBY(,S,=++FAZL\4-$@L%X@=(2EBH P;J"W6$A\$ >A[H,0- FH
M/!\6SQ\ "0;-Y)MV8G1B$R6JGU!%F/:C-)9/*](JB,7/(!06,P*JO71!^K@?//7_F23O'DF\=L%/ABF5,0/VY7LC5
MH0_?6J@1P:X *T$9+G,(QI(^\L6CFI6OQ\3!MP-@6QP>385"&ECN
M52Z1(:*#269>B&"A$8%9AW]2*\P'&ED@G^ P](R_CZA:0^P@?V#;HV(]/E+1
M1]?!016-V$YL;$"MR$$+*>PTZ<
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M_0#!EP5BC=H+AQN:#E:E3:S19_
M"/^$7XQZ=T%PB;(&'ETY$)B"AA0A5*R5,D%N&ON:KAN!$HX"T$\QQ+!,(ZXTKF&\*)3RGY!F]. D)=-.BK;"TLGR=:S.\$\UG,03<5,\0\
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MKFSZ:&7^@+D\$0OAC0^CBP D2'I@VFH$FFT31]6R2\$:8J
MN8N].C+RO2G,SR.RV8QGSY\H@/1#N]&NU%H]H:[;1J?2KM53IAQES,1TM9E8
M%9&M3@R9"FIXK#V&*7AXR8F[F0ZQ"6 !CT'%OA_/SU?P30RH)P#5C&'47H0\
MNQ!F#?HQ_T9&@ 9,!6#820),PT] %0E>S44-KL8)/%C2PM.<>(]<#:_ JO=$
M.0UKE7JM+@C:;+4JK4Y#&".5^'F./'\E\]7J^'J_VCHWF71 ;ZQLB:RK/#%;
M],-6[B*%3YZ2Q7IO@^OD,V!2L-NRU8T?.>T;K1\3T4&71 H$
M"= W &[.2=LD"@)@F)I_PE\I))E9S:GHQUB V-9E<4
M&* CE),LJI+-"&NI"-L/ECH"2T;W5;#4:1N5IM&0<72G5FDUVANPM*' X73+
M'S9& 9R6N/,;$Y=O31AP!)\.I:>V37&I
M55F\7HL,N?WZ^1UZZ=1QL,8-#&_RMZR*XW_+$CRT6M1/"N[$ &=\WV(6T$_Q
MA\]$E,^U:VH9\$MW7! P-#N\T%(N-L8MWP@DXD'"V00J[79*4$1YKJ[4^G3%P>K7[T:D]68ICNY(
M>:JVN\\4)ZU M0(]'6ICJJ44DJL5Z'X=SX-WKI2^Z&$HM+3Y]SR2/8,^%[??
M+@D++SP)I?B@K0:2!TO8'5]MN
M&WANIZRT.E7A*ET\;M(H*ZVT%)65,CK**0LEM(R4E3+:TJCA3J->
MJ;7K9:65EJ)R;N;LZ]S&VXN!;K%A8HFS!T4JAK7(E9)Z"Y4*SZ?@6S=NC6:E
MT>F5I0Z\J)K4TO?ZY,H>N#FT8=/DT:;MM*FG3=N6)'UO-"K-]FM?\JYM6Q%:
M?2CGEM6KQ'#EI]:#%^)% WA-2\BL$B=&]G(X]"0%;16T6M5E\!JF[[4ZEU:Z50LMJHWC<>X&'
M+GU\&Q0J3794GT\^+M+M]WRR)I\NV->4T;62I:*$MDY'2SIMG8Z:?-HZE7-O
M[G5B*A71K]N>\/KFX?+^AM\OUO]:UK24%IZR4D:7^!\5N;[email protected]"R6T
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MMBKUFFX8> S4*LU>@@X)2TT>;1:U6=1F\5EFL5>K5]K-7M5DLF]X]N:W!
MMT&VTF10M;E\>^1]>;NI2:S3KII<.GPL-WFT/3Q-\FI[^%9(K.WAR\6-L/:7
MWH.TO6CH4%*OGIZ1%'N0=[YG1U9(!J93ZK-UVZK2#&%/6I6^M63K,RC[UI.M
MC4JKW:LT.F5-MJ[4MBLMGC#AC*(.1'%0&(@?5PR1E_^CAU
M@N"3C*)X$-5W[0&P%!LQ"Y9Y'@4P._7QZ]^I:WM^<,$"R_&"R*-]X1"]8#/]W3T<_OSO';6K?5:G<;?]1K1KMFU SQH=$PWOV":Y)+
M^OO?5NJ)/V$Q;#3?K"GR,*O>#[" ZLV*8G?.NKE]N"2$; X8,X2TRL!C\ADQ)
M)F9 3'(!7.12FYS#<#X;1EB%3.X4T HK)^AFJ+3F>/-*2PA
M]#AG\7-)[ CW/?,I>!9)@A>Z3P8A &$A#Y"NA1:T*>
MJ$_YT$$JE%6RBN@OHS.>*^A9=7'N3:&$
MW,)48TKZC[1"OK)'$#I\M<+!_A>,2.E4VO46
M"1 <2D:4!Y2K@O6"4(,G^7 ,!30K_/0%4$Y%^F&Z'6;1@54J\!>*B^
MR116/H%Q43'B4#\8]4H+H@S2!P]5'#EQYI5\ -%">*B12 #X;.
MH^DR$^9V;0")!!,VF^'P^!9WG,DHK,#C6@#'_\UE*'>#$'1B
M$'MP$LD"P8A-%<%\XO#)(R,^$/@\.-;YA+GF:B]O@VC6CX([D39H!Y@X01C[
MOM.,I/K4X;^B-A6X,MUY_*@Y]!XS? 16T/(BQP8FAQ] OP(9,.\*SO8C&C1"
M1R/0>ZA\\ZB:.%"=S\"B0^8PL #  8+[*>>B@$(\H(H$6 PGG' #8CKB/"08
M/ \XD7)_GK/2''0SF T^@@M(7;W(> 5# #; ) $+)M1>8>>>^*,N%8SJ4POP
M(5B,3\>-F^%"3/P]_;-7V-#X1'9!EO&*DRB(8!_4^$E+A\S-ZVL5_[]\H8
M6%K]FU:EUZ[T#,$9;%:X0'WQ3'!B04@NP,=&RR+]]4B24PQ8._XB+@$VA3P!U'2.R&I4LP)1""H42 0$T 
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M"N_B[NTP%0??@KDWI^_ A^/?_)I%S]_4D*V&=;/0CJ \Z@:,^Q_]0&H*\@Y89 ]H'/"((SI&5D4_UXM;3L<\?9X>Q47;
M%_CD3.9&.*UM(YSPER%3A)"9YHDX/ %%IO3\\JP.[V&>AX$:F$3VMTP'XG_+
M)263@)S \^QQQ%ZF'T"7%8E"];IZS,*22@GY0'&;8/*SJ4/+$[]*VQR[798E
M$\-61]3GYW(=ASI'V]\X?/PUG<%Q1V,*9HH79#"5 >PDUND\)%0EBU_U!?1;
MQQU+(ZS R8S5M%,RX 5.@#M9T$%B>S7TU7W#6 O\.ZL5\1"@.OB9
M2V9FDE_Q#FQ?L5H_?KQ>\)3L&O4Y-1"70'*.+PI/'LA #RD2@)O/J*V)H-^B
M3 R>WA6Z(_2O"'\GP!ZBQ0=S56(I2!=87!?\T1.17VN+'#0^G0?;PT40*2Z/CN1@.^K>O)1NIW;]U=Q/*[6=Q1K+$MWF-TFL#Y)6[_A\Q/VJHM,D161\B_CG>3UI.DL6%57Q@*B38SGOWUX
M]P*EH.T;J6!#HYRYW!!_[KZ0Z4E1@E$[E]OS_TW2- PTY+D%G]T<2,V)<;T#
MY>.3$,2H&P5)K+J!0.L CBX%I*)P)>-Q$/+$A.>N'(!\IPC*8>@4-!K#L\$T
MYU)U:&/6#PME(B"H0W8:Z?&X%S9[>*HA8%HAS!VG7M#['B8REV2.0G _7U/@
M ^1Z"%7_L<=!A"%:&%XP
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M?HG^!YGJ53,\5^"*K*_L+$28<^5U@PO7DB4JDD&#S[
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MA'LT8?L)2WUBONLS+)"W)_+MZ,%S4=!PUS5<+"H.@UA$IS&K7"6,?+84+Q#BL).LLE)3UA)'5(3
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MC" )\YX ^#2?Q0:S0Q_;^/(@N,SZ':6,@$1]0,&"H[\'10AH)[]
MW?!:&"4>1N"_(&+
MNAP8O^=>!$Z (AIJY@!F K.GO+@?^W4-11=.0,5Q0R<982<(K!SP,74/&[;+
M_@"&8X3M@(*@;E.ACL%1]FCK9
M(428X@GVV8^O_#[>.L:K%[M4K#HI7:<@S$CIJHS2U26E:X72=9, RT0#N&;<
MN-^Y)8S2.V-GI'LM6%H9A0I"B-=W1'%-9-Z!FI*,$H_K#'TL=W!<48!NO%7^
MRIH%\YJXT3C!RT4C/UX*@94[,/ ++DY3'>@I5<-D_@/>P0:)!TK+4ZYT"#4K
M;;\M3CG@<13>+11K3U K$&U#19U==OK*R,:4>#\K>Q-A")'\H#3)5)057J_(
M16Y_97)A6?$Y';>(L045K"]1H'/C8@^'C]@+;\;%86U];M+925L]W<+:B%L*
M8*P<38\"&*L#&"D/,V25X87QA3RUOR^G78>S6]4'ON(4M@?\38]Z0$_
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M=C9&?(A(034&]E,0HROZF5%P6PZ] +(YI$RE?+:M1@#(.-L0I5'JHC
MBN_ED5)X#;94%E7' [/\ -"Q/UJ:*
MQ%K']G%"?H":;A+:POUF9T-Z#.T1[X\M(*ZM>C?6;H8N#PLN>G6V7)7.'$MH
MD?<:7ZD3K]1NIY1A[F_#L=^&;]UH'$2V=SOX&/B/_!;QC"7>J*V/#"3]6 NM
M@_3CZNC'9IT4Y)4* <%0L'%/EARU$CV1OY5&6T$=4G[C!Z!Q[QQ&
M$PO-XU='Q#91,HIJRE=<4 G[*IK0+&_R;5&3[]-@]*[email protected]?;SV7:BF=
M1#(Q0^%BI(26Z;[>B"XA<:!O1R#$7JH
MG$(E\/0Y4GC:979>'$C:K(,BMM1(?P3;/\_.R>X0-;$:0(:?Y<=P4@?$!ATUF"FT(WHUK7D\'(\
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M,I30//<[S9F0GEN9QY"U*6&^S;,0>1ERFL(9\HQ.)0U7TDYX>Y42, 5
MS(KEN"B I."*UJ_J$'B.""SY_S%A_ZMHY@U?, M%=$>5_G3^LU1G>..V0>+W
M^5]INS29-3SV$I[$,G+])$H/*\/RI[[PLQ<3C.>-?0K;$NF;\S6_ J
M*U[_$@8^?'284F:\1#^B)JCKL,[YC7FX&"+]:#5Y2#\2^M$A^J#JNU1+9D\T0LH&I@&"9/EI1R#27HX'+^P9C247]2,T3Q4#\.V7N2)FO)P
ML.QD<9'B4#.:+[@J)/->YUZ":D+KQ6Q:B)@B.F8B"=^T8LC\(8ZJSS-@O"#B
M]4/%\\I\6Y3F"P6JAM&/-+*"NXN7D8FTA10F6&6\](MGW^2DX^@HC7-AX5TE
MC_ WKKV67'NPE&:6CZA$XR\%O91=8*FX5)?P:#EYB*0H-)/39(,T5T&L/>QG
M+W-WN9KZP&!+\FHPD2_Q%MC'Z $^X$!@.)V:&"Z\"7-%^L%8T)L?>AMS_1B^
MW^S9;0$+GRI2![1#82>$3)PIETW<\8"4 W$BG:S7LWE-7Y95G)(\6]3SV@+_
MSM*N2@_,<]E3EC_M1GQQ*%V3QBK3%(N%5P;:>,0/S ]/T16GU:)FG(0+#L?+
M^>N6XJ>A)\/\'#P)2%>LW B(Y4D$>5*/+#>,L*\4PAM%O V62"P:%&P 66'&
M$9KE4AQ!3(DJWH(V3=Y1BN?2F2P".L5I6Y[CS&*;H4X:[.;TDM
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MFSF6>&ER% D&)[0=?-PW?HPTER8US#6T_.%46RE
M4K$/TFUJ-:P2VY1A(;:?*K^*UB\=G4-^FI':P>^_"6 X<&5NKE+T/=LRA.Q9^5"S;YN\T'.O3(VHC87N33>BX/OTW/3TX:K)?2'L]C7JT(IZP9)2C7!
MGQM2V?J4FZU."#@:^YGEA)PAW1?"GZIB+)>1C!/Q9LE1,L+]^3]9% 2[^($+
MV?D+8$$G8^$_P[44)0^1VW=MWO%&)!/C"LUO^L2P -WC-^3?ONLGTH1_SFS,
MGC+X7$58$Q8Z0X=H+!YY4+>=F62['[Y#L74%=M12UL@^Q'W%Q)"/N+R7HC3C!QSI2LR4=&
MDOFD4GU*H;U0UH+$ZXO=*UI,.4-T1_53%]H.R4S>+<,I0#D8V6%@ZX-DM&^]\>(1; QC*/V_X?]D;
MY!@N,$#+B9!^\97O_?IEIZ5\>8^4$E^) 72ZEYWFCZ_D3%/:O
MYH2I5J(B_\P&6#SH!+\X<@"Q7'P5Z ]4 #P:SS)HQ*3W@4[ZU9N)E;IZ4ZV&C\_]9?K6DC'#W2=SB;0BU0?8PL"B<8,_EXK#
M[@].F=Y0?J/-1NOWM/=T J_,3OQ)99)E^.7US4W]YGJ/.U*RT-.'YS[ QI4R
MC+7AAMH[&N:\3)ZN,VD[[3T_T>J4-+Y)U.-N>9=7,
M9I29)QGU)
MQD-9> >$^-1%IUGKMCJU7JMU9,A)>)Z"[4B>RSOF83>EFO$H$BU$Z] ^9C7@
M>3<\(BK[6DPG&^AC?Y3@L+3]](2NI( DX2=\I.VN5>NT.MK"23Y2,A*K ]O"
M3E%;2KQ#FHUD%5;=*B2C;W5K)0LD'YE\5ZA32UGLCKN%P@B6,_--;H
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MZ_I+S(\LBEX:J=PT[#@.W8[QLX9^U6O$O;5'=3)O8 MF3UR:Z
M[6ZM5^]JZJ]8*(S.M])5XK0O
MVYT?U3F;XWB%42('\O-/273Q:-OCE^]XP/@3BX=!_T,>-;Z'U[SQ N?OU__X
MP3!^3J^^!_PQ'H:,&2,8PS R
M&-S3-S[QHTHMLV8@86N&&QGCD$4P%/CQ@7G!MY?&(O5J72I/K]?ZS&(]',WS
M;?%/6$^OIJ:H[D^A;@H>^,NS.JQ1YGG(Y8"JV=^2?_*_)6=VD(9AQH
MY=GCB+U,/[PR!*/MU=4J@^-8'XW>Y7;N365%B.GO0C9KL$9TB!E)>7S9UA B
MG21R2[1CEBL''T RN'[D.FD#=)O$46S[2(2:\1_;3S ^+:/'VB8\+Y+P)X9-!5+/
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M9VA8=*B;%M!4($^#N)JNR)!*D/5F[K2[-:O9U!8JVD2Z(D."1A[JN\^+5W)?R51[ XFJ]>R2J/V9;OSHTJ6(]#ERHB2$8QQ8@0#
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MR7J.8'Y.1@\LS!EU,,@_WW(!&>FQ+F*A_:BV6S\SDJ3G,^E_;#_!&+;^/4SG2_D3PZ8"A?\Y_T,2SQ7@Q/CTA*Y9"%]N"=^I
M9Z-U:];&9374U>%\-QE)*EV0($E56>BL@K. )-6*VIP.M1_2#),*[#$25+H@
M08*JLM"1H%JGP.=RXV8X)*C.=X^1H-(%"1)4E86.!-4!SD4D*56QJ.(ANKF>
M1U3Q/5P8J[GL1XG1DQ*A2W86L;#J(2/B@Z0";*,"T/XYW_U#,D87)&B/Z(J,
ML$-)QI",T1"0"NP?DC&Z($%[1%=D2,:0C-$6D KL'Y(QNB!!>T179$C&D(S1
M%A JPM,=H7??QVZX<;B,XCDC"Y(T![1%1DR/W.X
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M@U^>7>.W]6ZKU>Y:?V+DK6[63?'!LLQGKW%"&\1"$?08,$Q<#\SQD
M9L#NLK\E^^-_2U[KP(M9F'%6\8 +8%&>/8[8R_3#*T/PR79=U?<.'5H78VAV
MN$25DTUI&P6>VS?$A09?.&. S8]7B%DQ_UW(60V8UFI%"! !N@!([6?'%+J@:>),)T14:8!83$\9$@<559Z$A)*[T=/7O
MV^(RKR3.=8^0@*D"2LUFM]9KDX#1#)9SCR=5PKKYM^WWQRYSV*;D'=-4*
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M[C_.JH$K9TC\!&S6IN
MVO^6^BB=Y>ZC[A!:PT.B[231(]&VKN56K[4ZU"*P"E#I'KRB7H%+>@5^\&,6
M^G;L!K[M:>PEHWVZHUZM0PL IH:1-+()-0:WA(+))8)+&X
ME5CLU1NU=G/3M$<2B[KQW;,+#9X&;-IX4$E;!#&Y70DN,A_UAH?D
MX7G"2_+P5" F>7@XNQ'F?N@89#]('CQF-"[/3TB*&.27,.@G3FS7;S)P#6:)K/# ?&#$_\R@:_/+O&;^O=5JO=M?[L,_[2]=W[L
MQI.K[V[T)[[K=WCF6YBO[7WPG2  TIB%\>2+!\L0L'H'XQIC
MZ\Q?(S9(O(_N@*GCL):,0S[RJ^T_,DYC^<4GUW='R2@GZ\QH6W_\_-,: ]IJ
M!LU-9F!_7S&#SC8S^# :VVZ(5]P./@;^XT?WB?6OHHC%T;^9U[\)0KA3G4-K
MK=6P9/VZ4=!LF)U?[]X^>UW/9U!J0,4YO&4#%L(JN[>_BPL_NO:#Z\'J9]%G
M%JNC;Z\:_6:#7C&"C8?;63[<><,63_QV.U@_AMFOV7L
MLSUBF?#YY )?CD$1^ 2LV>$B2.4O4Q1I%N@Q3D(&E+AL]GK=G!REIUJD$ J(
MV\%=#&(XO^1VD-UW-8A9>(^ZB^V@+%,)M4SH[I]0Z1N2AXC]-\%G/<'_[B?C
M O.>^EDE!'+BC$7 /YRAR&
M+/?+0L(OTP>J1OC7\;? $)J4$0R,[+6&?*\!.K.!?_-KBI?<.2X\VAVXSEQL
MUJ"NHHFIB'YE,/:$W83!Z(Z%3Z[#(O@9M7C@.\%OJ+Z#(LN+EV!(0L%4@2JA
M,.T.J'>@W51_W7;Z.V# )90T3:C6JF_-@.??=I>,P$(#
M ZQ_X_JV[[BX 9'P<@US7%2:+5,*]\@20,&=0TEW!&9[/Y7*D^L -$I_DE.W
ME:JH,[*_OE#R-SH]TZQ;J^A=BG#;(W =1* =<^M*16&9XG 8;9;75ZK=9V:$P14!&$FSSMCGF>ZS^^
M9\#U; ](<=4?N;X;Q2A\G]B[[V/F1\4]L\QV.0F8&C"33JLCY>L>J;HE=E]9
MQ.S0&5ZA7^R)>0%W6\B'JX@M,^A. C&S:;6[K2T 6TK*+6&Z'7--UG^XN^5@I"A\(4_'L=W;H
MPX\%6$_>>7 X6(M$WBFRB_$[>;?#A=7J=.KFSO";A](V1O1G%N1_$
MA6F!"&\VMW-"%.BWY:8I/.LJCD/W(>$I,O?!9W0^^7$8<',Z%:P%P$[>&]%L
M=<"ZW6(GK4_?_0'ZA:>)J?B=O&_BHMON]NK=_0 HZ+E]"*=S"#_$5?\)YL9N
MG<2S0QX*=-C=U=HQG,9*!^K*&(X<270?7 T& +4=%XAQ".M_%3%:9J/L"NMT
M.VIBP9S)E5D@*E?M'-34OA["HE?3^-I679WY17NQJ2820%EC=MP]"T=?DM 9VA$#!@\<'R^4
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M3<9NHV6I&L,J0I71H7[U0RDLN!?+$9Z;/$WJ.RLACJG;;[(2
M+\Q.L]U9J75M0)4I8H_&7C!A3*XY7@WW!EAJ'UUCS(^X?^K*\P+A0,,,9"=X
M]/&-HGP-=TAT;8_=6(QCEO0ES(*K;W;8G\Y7SX:&F>.WXV(IX$:[VVJVZJI%
MN9^Y'YS )>R']0F\B2>TVS ;31WI^SD0^[7/Z1#Q[D+J[_@BV"I_L#@?@DKA
M$E;))DMX#;G4:-?7)NTFLSX"<4M8-ILLW_(9U,U>IUL_'=J*O7,3A/(KO,Y4
M"-XK82UMS9!??VG\89J?&IVW!R#LW!GK0NT2=M?6W/GU%^L/\U-;$UHO8/1A
MB'727?+$GW'##$8A91DIU_N<$9ZR2LX19M@$YIV,QBQH+F$VSQX.U
M>YOK;DGY'BZ,P8X6J/'* I68):R\7:IFBZAJ-44 =8^S/N *+6'J[4!96+A"
M._ >-?M#\Q7Z[CN8+6Z$1N$L*4M8;?LDI=GJ]+K6[D@Y,]>]K0,<8.Q/
M++0?F7PQXSYIE,J"L!?[;3$7+HF&
M&E4\(&&.OB4.8^N5W1(]W;=$>997%H"]V(.; F#MA_VO"<##ZI<^K(WZ5S:R
M74RWY1F"MA,GMH=1E48.AE7?BZV86R]<4J"MV/MDFF^G2'W86:NMOW:J?Y8<
M@$KUO=B,,Q9Z\P^SSHW&XTU:J[6^%].RA%_D:(M]5P-8S-@6#UX]V_<)9'X&X
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M7QR\V7=XP3$\["ZV8W;E]S\&HN!^MCN19:[HU;\) 9J=0H+^FH/;VP-5TD\#$)7'M4B?WT+OT6QZUSC
MB@DG:UA:"R:]>-P;S*]1PLS9<'Z;'H]0=GYI5=/M@^<^94P&X#!8@6F
M[*[N1G^_F%,Y=.<;)%)2E*9=9&SK6VU:ZKL>W9.:]#DQ(J_+%H
MLL;^;YN==KVQFB8S3>$YVQ\&7I^%T;_A'_XW#$<6V<@F)RK!=G)L4-.LUY?N
M@[1XN-Z:T\F^W*#G%UR!WC%;1'2=A-@J!=@C2&9'_*'.NJD+>
M**$NSN$N;YCO#$=V^'>!Q6"+==GRGA<5?F93Y7LE^-1U$L4@FU;QJ4_V7T&8
M7AME:*3?W&*SI'63Q;(./87"[L5DW(S@)8(452?X8OUP <$[^R1XB3!&!0E^
M_RW8?(5;K7T2O(3R776"K[O"S>XZ!.?JA BHW ZR$2DDMDKH_UJ1>*W""97J
MSUZGO==GZ%&65IO9%$>EU>+EM6=:K7?RY^'&M4REWQ^]IE6QO,)_JM;(LDKH
MW^NI+*7UQE:]52BE7S#8M6=40E5>3RJN)W3+GR+1
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M6U]Z[6Y5M+K-3J%)P]:4V$:5VQ4E-CP^"IM3[Y 494ZXWZD\V]VRL!I6#V\$ DZW&=B&1>.DAZ6MY!I,XC/X[B-'-TTA#YS-OGFJ6S.P(3YUUA:_T
M+9!.#3@L/8Q\3EY@H]ZH7]3-"TN)\\U[Q:+$'+P4R)@=L"IS!_ ;F+$ZL&5*
MTL;J2ZO1F)=VLWQ4E)6V&E9CBN#30UASE'M(4S.M
MKMJ)L,0H99IH=!.$7X((-C4F+?)<4N:S@1L7%L0RI0"33K Z7GXH[5O$:@ME
M):\&X0PF]\P9^H$7/*I)5$N/25U*<6M^EE3.ZW<_[HVH,O5L
MKES]7]?OWP[F$V1C 3@_(EQ?GQYE1JSV^< 2X0]1E+#^VR2$&\26$ZEH2OUP
MFM7.^L7#N:[AI\2+[4+G>*O,X9WW;HR-IC_X???)[2=%Q2:=V38M]411Z*YG
M6=ST7X.)[<63.9N^A.MC9Q18JMVU&XH;HSC>LG,IX;I8:"
M[;]9%/$=<\,*>>ME3E,\ #+M;J>EV!/3 RX_G1(NA .  R9P02#-3N?GG[X_
MA-[K_P]02P,$%     @ LH6P2'&"HLRN#P  J)\  !$   !M;'-S+3(P,38P
M,S,Q+GAS9.T=:W/;-O+[S=Q_P.E#)YFK7E:?L2",I:;]U(!*2
M,"$!%2 =J[_^%N!;I$12CYAMFO_SLVVA)R(DY>RJT6UU
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MH(B"%=&#(D0#>X"YSQ#J["[\Q0V:+LB\[
M>E'-,RS#7IY3\%][&KI[<7'1UJTA0ZX0$&VV<>2W9DA.GHUE-I)[email protected]@
M,]H&S B$?H/;577#C(&_H/W-"!<(?"U:=F8-NF^JK9/0-96\\2
MN&69?&YSC/8!+ 2&WXN%R&OV8B$8;*KO\VV]9H_.\OUM1D+5Z842N/NVD,#I
M2'H(#YQ]/)2-^)11B!5-(S. M8GER##R-Z.1MXVEW;/%L;A1WY1D)A63B_.R
M&:;50S.*6CO]U2D8Z4IZ-*&WR'IM12E2(B73:59Z'(!-3#V7[W\SB
M]N@]2#7U4^G^-Q-5GP',&'=TK_JS^F:UHFS._8_PA9KL+@6WR!0"'J+F56-*
M[)4%2YT'G0VIID_C^]S,HJT VTG<"5C:,$\Q,6P?9!>F@2W#M?9 C#C;CN=_&QACPT:!
MGL9DCG2F>HF%H6!WY[/ME> K(AP*LUDL'=8$EH+,KQIJ2=8,S/@[2-@"NP4@
MJ0Z2QM-&WU"*SV1 P:&.(G$3 6F+R>\1ML)NU&Q[U9 P8"QRRMR^_3)*!>N7
M56K28;)U.@AA%96<$ AUG:9'U1S5<6%P%)6W,U8E"WU* 956O@P
MNA>.Y0Y^YHS;:X_%(.@&?_O,O&7 V/H>9A)A:Z8:>NH8 _COAB5B_][1_'])X[#X_^A5IP V[J6<,.921AT#0^26]2$[\UK;*E5
M]V1)B"-CQBR#E6?3KK)I2!"I^J1/$\6)(I\J\LC6ICVF:4<8UBW.DC@4-+6?
MG9,D\HQ^MI?1T:M$+Z]K)SC0"<)6.9P/84K3(A8?Z%O0\XS?*VC\B#SB<-YWL%"44?Z0YJH^=G\.&&
M^% L,*-_:BFN74D9D1(2]&LL*1@MOLR(9_3[H.>9_:W.\$/*\"%._'L4D-<9
MO^Y F3W>16WX$H:?N+:-Q7HX[QNZD$[98@1#RX"E;::E=\'GF?:'E&E]:LJ"
M$3T4$*P-6<*0:B@8,.8&U'(A+'XDSCT#1/+ I1P1<<-MF[/)$M+G3+N60,\S
M\[N4F35Q/6!]\@CH(Z\#]$IU\1I!)\CK!>EN:N.7,+X_>.28&(0^X9F5;>0,
ML#QC7J2,&1!!$97:5B5L%24OP,YP_AD+JG1XSQP"\CE>$2O3?,4P<2=K[7.Z J,;UGGR#4Q?)A=R:I24')6R;9@JAYENZF
M+!T15NNE)&D4IUU;NDP.I=:=PY5B9F1AMB5QV@3*L]Y9.EM2))!' VDBM9G*
M!5X#I!!^^+P1Q*3.F,HOVX+M%N@\P_6R FQ$2Z]2-36DR-4F+)/GF$^J&BR'
M#%0*^C2<[,&6!9=GMC?I3,>G@L!H(9W:7J7F0)7B3_'SUHDN:L^SSWG&;*87
M$!J]-DN9"8LN&)U3 S/GQI4.*%'(#X0O!%XMU;[*E@W>;^\](<'4=!+X++JTYHAL5H)WG3>DR81EO @:0Y@"%
M+-1N]6U.*)2-2X=3S7.E="6S\+F&.C"=M#Q2.N4M@9_G%1GUT'0AI3;_*7+JIF.DYLU>2W!"P@
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MQG2%?\*34KAB-<((7]#H//[2T"/BJG=S@CMQ F?%N TQ#S@>(9M4 *
M__[H1V+/U$DV3];2:)[8WM72ER:W,64O*G?T9N2=X+;*^RESP1C1!177!*Q'
M'BGC0MO2*V>"<9.HWNT$C\19(D6BKF@2Z$C?EU^1>2I>8G['EDBD/*FMW
M7%QS!K-W&#*+P_]EQN6&2-[ *JFB)L:?AOHT*BF<4>:E#51W7OS!!F4(E
MZ+I@+#V#@ %[email protected]'VH;5#74D=P / S8287$R*>J!%9]$C$*N/R)IGE3/8P
MRTHR(-[?*0_JK%,>5%D?,7/G\!=6*R(VB9?$JXQ&"N0_"='NV< E*K4;$W79
ML3G"^C92+UU1UO>V)BB1VY13AD)EU)3C..KRI[X!Z1MH4XFV[6X%?U05A/ZK
M2*_C@Q<5PJVG>&Q(S \[X2HC<=ZP2!^-FY)GY]H" 0-I=X(D9@TG^/YEY\#=
M,2LM7U'P*LKJ5QAUQ1$FK*S*:3B/R:@^E5+"X72JJ)U"U>%IIM?OA5I%'81'
MZ56@EKIP%UM4>KEM$,0#XXAM.I=+:!>&.]/*.XT"?@4O'2AF56&!BQ47&>N@'*"J+89T
M-/+N/!EIPHDPE6R(&R;H^87#<'#P*#:MI%_12(W&TF@5&XE9_ =<)\9> <#*
MCK:,O8B'F]SMB@BD:B,-1I&Z:0@OR' ^)D^$>6N\H 8 S6I;B9A3OGMM=#@=
M7S.@EI5'ZT5GU>R:ON>YJIJ?=;!]0BP+//4#841@"V:3OFE31J6^Q^F)W#ZK
M%5.TP#YI%Y59D>6L0?=1@OI!62R,I=H< %>S^$KA^+(?HMTO*%V#+4%E"JCM5,,T:*'3!)7^1TK$!;L[F]M@)'@3U3=EW;'12CU
M(2K>0K R2CSYE+W=JSS:MU@P:/PF?KS98V6L/N*12#7!P!TY#WS=D\WSN"/B9(/PFYP,LC%EAK"841^
MF"_F(AR ([:C-,P)"FACZ GM#W*;NI3+J8$Y5V
MGUG;?+.D*'3%]L_#TDMTWBQU1F W3/4%2IP#V-Y>V>W_^#:W'GK^KP?_ G^\
MT1 /810FXP4L=UXT
M9_D%,W-%B;&9QJ>_KYK:]5ZN?S)Y8PF2T5(U[ON"X.%\.)_#,G^RPD8X_64T
M1 $?)@3\LOXR4!B<^5/4JU,B'# G28K8M#Y>DJ,)>,67ZP;J3+ $4D?,PGXINK;D%"/U?]1
M9@[GAVBN&-6**2WV!M7 5>FL-SR\O"]V;Z&\?09V*:SFDN5]_RU-'"LY'95D
M(M_^QJ_UOF]+8PEK_Y_^#U!+ P04    " "RA;!(Q^MJT_\+  #HK@  %0  
M &ULV\?'
M]F/G_(_7L6\](\8Q)1>U5L.N68BXU,/DZ:(6\KK#78QK?_S^TW_._UNO6X-!
MU^JX 7Y&72KQAR C#"ZCH!LJ*?,^O(;GVLV\?UUH<'
MNWW6/CX[:C5.;/OXP\G);[9]9MM+ K[%3EA+/R"@T6[8C?;28WW'_>X\(:O7
M77KL^O3JTZ=.N],];E]=?[1;)^W3]M71::=]?=3J'-VTZS;\G!P??SP1'UL?
M[0_+EM/)E.&G46#]XOX:F6P-&N)?EQ*"?!]-K?]9]Y1P>'(\<3WQA>/3=
MB*'A16WL@B9T&UDNY'P=]%+FCK&/H%5'#7!>M"D>;*;+
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MVU=%;&/)#H/2J@3-AC_ O!1FN=/[@+K?
MI<>>K-*:#1Z@P,$$>=<.(S"Z<< M'(M,'WE=-,0NED*]B#3MR:Z'Q33%\?N0
M=_?(E3/!@>/#9'I,202L7,J[79KN#"?1)9_,K)75/FZB(8*NYJG9FUE-&,=6.
MTJ"_K+2CN%C-+BZI!#MVZWW;92V<65INZS WI<-A[EP^?%Q;:TNOG:/)P
M/(ZDU6%2-9Z7'S(ZEC%O9@95K"K*0-A%K67;+;MAVS5KPG 4/2]J1S4KY. (
MG<2#;O- E!6-$\S:1F%6\OBW$=EEE#Z\HY23
MH248'1N.49:_F1ETXO+'-^CR^B0G\??3&_2WR)PT0>#D#2)09)DA0>#T#2*0
MM5*T\!A\+NQQ_0!<5IE'Y">AZ_EFRZQ\6>*O66E;OK_;MC@3C\W*VO(]SMF43APU*UW+WJ1<
MSDR+<0D2_\U*UK;ZOYD9DKAM5H:VU>UU)L_"U2.)U,P$5]/LJL1-PS*NK0UY
M(_,M<=O$M&J#VX7(BXGWBCG7>7.%75H!DW;Q5WXWO(.L(])=!J5VL^ #Y-;F
M&*Q[\XL'=\//E'K\'J:Z*T5U;V#"H T#&/3Z$$5:)1E@V>6ULSHX@D@@
MDH\NJ/9IE$?/^K$DX$]1B;KI
MG7%'(T\SA7)$X?7"FLW]S"CG,#T;RK&!4L4JH(?'<^,>@5B(5)@#^3*T&Q\K
M4FC0:T4UFPKS-CIO?S%*"D9O$%)5QXO5WD(#5>IZR\6U-PZAZL%YG6%T";%+
MLB/FBJC$=('2#22>\2YX".@E><8E&E*&%O8AOKI?!R$Z+:4$4G.E9E4*<>G@
MR+NUGC6+;PICKK/^*S)$=P1&06)(V>0Y!>'Z3V) J)(-U,NEJJP/9:SWO!20
M[03-!M14(M=6)Q5:OQ*7ZQ V73/Z%:TL1)K*YLH&37+H-(VD5>WXG8NGYCS-
M-%K8GFLE8S*AQ#([A%"XCVD*W3*I-)7"MF]_2C7KITH%#
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MA[S+Z5Q&\96&X>69M6DKR>G33M!XB,?J()B,*:]@-$LAZ@&XC"FO9R
MAW8?,2QF".DH>_TZNY<'/HQ@U$,#B$37PR%RI7*#TE3N=5V[;.!H>4W&5(Y>
M]9 6#D>F7MM6/:2%ASI3>8 E)1-4)C\RC398[E1S6BJZ9FLJ&*VE:NNWL
MCF%7P)6/2GJGPE0.7?FX;-MX,I5Q5QY29>Y'FDKI*[_=R9[34>8&OB7$"K 5
ME*Y9^U$ *^FJMA\%KA192>FVM[>%E");3>G"N+>%W*Y<1:5;YWX4"+-YK0ED
M$HG;CP+9&KTY0>L],=N!])[ J+B0J.6C3NI=3(.5[LX_7X=Z+/L7POS!MRS L/IH4
MG<:2V=[>6=5>W@R\V;[9:33=,"S4R%+.U)3M>$^F+LU5.%_L>&EQ0IY6&ZH 
M1.E6SC*U'6"O7SJZ*#P>6
MU/1B"?-7_%78YE<5'U(4V!LHQ4VJ J[-%W5>K5_4J1]M?9>]+.-NFS86\OGVJ&FGZN X
M[1AS%TS&!$LS9H0'B&6*'+O[B;8L4OEY4UCZZ'#T^_\!4$L#!!0    ( +*%
ML$BDT3WYUR8  *6C @ 5    ;6QS&UL[5UM<]PX
MJOP'Q5>5NJN4K)%DV;)KG=3HQ3Y59(\BR;N73UL4B9E!ED/,\D76W*\/
M0'((SO -#1(@AIJK5.R5A49W$VAT T]W__)?+POWX!GY 2;>YS?';T=O#I!G
M$P=[L\]OHN#0"FR,W_S7?_[KO_SR;X>'!_?W5P=C.\3/Z H'MDN"R$=_??CV
MMX-_7-S?'MQB[X\G*T '5\2.%L@+#PX/YF&X_'1T]//GS[=3[%F>C2WWK>\[
M;VVR.#HX/%Q3OO21%5(F#JZL$!W$__MT<#(Z?G\X.CL\?OO;IY/CM
M^6AT]N[\_#]&HT^C48[ KXD0![G_40)O3]^.WI[F?NW.LO^P9NC@YBKW:]7IY\')]>GQR/3[Z<'H[H_\[/SMZ?L[\>OQ^]
MRW-.EBL?S^;AP5_MO\4L']R_9?]W13P/N2Y:'?S[P0/Q OJ;BZ7EK=X>C%WW
MX)X-"0[N48#\9^2\32FZ:QW2#^,%G]_D]/?RY+MOB3\[.AF-3H_6O_@F^^.V?I^O?/3[ZQ[?;!WN.%M8A]H*0?@0^BI$I&W?\\>/'H_A?LU^ETSMA
M]KMY;LZ.DG^DOQK@3T$\U2VQXP\J(,)!Y6^P_SI<_]HA^]'A\(K#!5H\(1_(Y^90A4S.*0G?CI[08:8;&*NE!%*&1;E=N$%P
MR(S;Z#39?G]Y1/2WJ+&^C6W$-C-,K 5V$3T_8E._'GH4<[0Y=HL585*A]4(\
MLE@E-!]"2I"=.I?$L$LE1<'8A5/_:OE1@C"<-EHQ0S?HY >@\BYMGR/+L-@;%/7/V*VW;FBAL_&
MH 4B0DVQ0&/'B8VUY=Y9V+GQ+JTE#BV7^NX+XL6*A0@D0DVQ0+FYP NJ.%8Q
MLW>4%O)]Y,CQ6SIHI$Z"J!K
MI9*,ZDUKVR2B$]]9*W8XTOGI3_P(.3D_XC*B"\,#?1006?4B=B)0?^SG5=G^
M8^ABO*@KF>U=1T6? *6N=$MQ&FBJ7E9!4(B_&I91.D(Q8Y-PCOQD+N:HPY=[
M!0'%;']AH2H-RY\1=59"RYMA9O<2+A"(_R9*RAT)LD1^N+JC\6](URA;ETMV
M. '%J*>C6(AD,WU#X9Q0)3[3B"D^7B'\5Y+0LC%ES/SF0/7^YI(ZYMQ$-F4P.VZ.4Z'
MC;]'-L+/S",!:;D*FKAAI7341VJ6,&X8@1U&DL9?ZR"@!:VY?G5QN@#\IFGNGD[\"U]N0'$Z'5D5*]\UPJ"
MR32>\BI]& ,L\\+HWT]VCF4--SGKIY3R'%WM;BY"WZT%@B^:>DH:UKPN4=3O!7N.
MG,A%DVEY!%'%'GB[M)I'L1)^M7S,/)SU>]6U%U)F[GR\L/S5!?+B)PGZ5_A1
M J6LPU1C.F=L#2;31_?G,\.GDW>CL:O3E8^CC& GQ^0_=]%%".R#)Y*:7D8@34)P9O
M0"_AM1L3^OPF0+-%$JVF_^Z2 #F?WX3^1HS6K1Y*P5.U>ME<@J3MSN&:^]"L
M.45** $0EJF@E>DA\L<&5]%'$U2T<7[TKR%#]+.)ERQ3CM3QW+2_:IRJ3"VG
MQ[VII4/STLZ5SI1Q=F+"'JHS,YW$)@02-7+E")Q>O1H8O;HQ1#/-ID4P+B>R
M-R1<#>\'84JJ+[&XI,:[(\WW>=LG:N&*E$MKNF?14EA#1!5T$LIOE?,+N.ZJ
M/I/T?7_GOH"D8H'6]E,*%\YH@USQ=E00K/"FE]_%84>X',
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MU>U!+%5*:$C\)F[Y>CS=I>NLN8W5G,YYZC$-M6!M;L
MJJ99*7'#"YQM\JRQ4M/#G,X,0O*6#M=7"2B9<1*%K!PH,Q@0WNOI*!;B*O7%
M&0"'K@8K,4"^14,PMDA^P^'\AG+RC)UHPZ-;%UK]0OPO41CYZ"8(HK04JK#D
M"B;7_]11Z4$ N4W21$FK(%UL%5&*_=73R<7>XP5SU_\9
M'R<0(66HJR\SP6\4ECZR<3PO_;N+XM/2V^"G\NT6HH;NYE2M'-4:ERB=L$^?U.&V=N=S=\<"6"F!YJ_*9(5
MT2?@47.>@-DOO%WF"8R,OD(6S!. N0B9[,<]IOET)GMG#B+/I#W;?;7(A \\
M9_9T]Q4@&B1F0K\;0,)04ZC/A34Z#TQ>V/7EC!&9C"H%W;A+XWEA [!<0A>A
M/%-L *:J]A:;ITL-P#Y5/C=P*0=@F!2\)/&4L@'8L_HW1IY?-@!C5OH4S'/*
MA(U7#W"$[%]II#6A/G.\C+MHKU9/V#P80@6_:N^B?D.LARCUT)_IA#/T/6(K
M<3*]PF[$6&KS- C
MK[H.:@HP77MCZ?R0+U-)0C/KX"5504 SVS)EN:MI*&;^.PIO/&I\T2T)0!?J
M6P-ULMEU_T<)XNI[J$QQ"/TD^5%0<\D5,/'*$Y1V%NJ8@:4-\Q8,_Z%NJ =-(X1)"C_A1G9)'DJHHN:.TV)
M@K*/UDM:IR$I< CLEE)!0NMBK=9]QA\*5*Z'7MA2?531
MT"5AFQT8C*/T&X..I&HB&OK_)*I*YI4Y4*MI*&<^K3\*UWAAJ.H61IN?%WK6
MEP[7Q7*J(SF&^6#%[+(+.\NW68VO*_2,7!*_)$HLC09"RC%=L>_YE9X0ON6R
M!U.'.CB8Q0+-G'<(-QO#%..(@_"R?0K(4[P0%P@^'UK
MJ.IE8KDHN*?+TXM0/"NP?UOY>.G&.9=SZH3+=L?9&#R\WCU-C']##DNCHI9=
MEL4BA7WWG7WWG3TF='"84!&,V% QH=T4W>^SB*+9=>7-+B0C6U>^>#2"&N3L
MGL#@0OHG1J.+9=6PX5-R60> +R[WW$UHL=(A)F4KF.+2#0"1M!'1[IIP!;PUP0!L!E3F78XC
M%".,>*># :R+/(J,5_X?@ F4@/GQ1@$[;!PK$)N\&\  8JYJ_"RO^F_TWFP$
M$=<(F\*<>0E\HRUU&TDS)#J7=8<-4[L\ E[OWTC;U$D21FXI --%>#< (ZV;
M)NU49PWQ=@$[D>4VF5[.689F<..5E1#.ORRWRWH3FLC@++AZ_H>6M1"+^$@N
M4)*IG*SS1W)-/PQ9(59PY8)XD2!2$4JQ);-QSGR7O-805%U=S_F_* T8'TE%
MBX=8DT]6L)EX?8_HP@QPB!Z0_XQM5D, $^<>V626[*6T8X#X9N8MB8+T2/*2^4
M/2"V"/Q^LJ.,ZX,M;TT?2)<-+B>TAXGO8>+[TL&U6\2P\L%H:D5NV"!KK=4H
M(+U+K+(1A81A-9-;R6R(Q*+@YJKSK++HY(Z531:6LL1]XYDO.Y"=("!B@W/-
MQ1W&NJV*A;BKE@0AZ1@>EF/:(0#$\W,_*A%GB96IU]
M5=P61C[;0P..;OO@CDQOZ2ZDE/+:R:;WNA9JYZ#\<8W#D7=X)0!?9SG$UN@$
M5+C,=:_G'%JYPQ^Z%C-[+KSA>ZX??6D%\R\N^=EU^>@"78-Q,QOLR@ [DA6_
M7NE!WO;! !VUA#2\V%$M3/P[RP_3_QC;B>6F\W]'[(MU<^--B;](^@E(E  6)JGZP8UI
MWG/8'\RE>[;<^+XMO+1\?T6]-C B1Y!@+V(E;@AU6ED$BZY0\N?U2^K$TK_$
M:+I[:B6NIU,$^Z*=3:F^N#+CD1YBSYA:VXO5CX#EOGS!GN79E*6Q'>+G>'^5
M)56!=GG+F=277;815XTTFV4-%YH-B!J$O
M[%/AO=-F"GW?9^P\LPY6=*U,I]2%IHQ)?IHR0D:;\0[/-_",_2@F*V6B_'P3
MGDE]L?NM/3@)Y\A?]]ZERY>=9JPJD6W[T48@"=%"JVFTJV"+K7:"%HCU\T7Y
M@@,?EZ(4M0MVYZ.EA9UUM\*T; ==1L_9NQD\"C[+CG@E16X?A+'C&?8^0?8^0?3[R:\M'WB=_[4KREPC0
M=*C)7]V MOM$I9H-VCXU&M2JH$>(V1!-;3U"3G<@':FK'B&G1J&7EVG-'FK&M5%)^0>2<.HXU0UXK8P 5P'1CM)\GI0!+RP5,I7Y6M$(/R
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MSV N%V\(8TKL\! M%C3PFTQ3U$#I$L[U5%07DIBFS:Y*XA-_EW!$KT;R2ENK3+8FEAG_D5D^DM\6:W^!DY"2=_
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M9'J/GI&7)&RL"R?0?V83T.5&6K;E:3^1ZHI[%JM$%N.#OELL,7MJ_ORFDH;SGY%* _(U;-CQ4!@-^:51#0R_8C911>\+62
MB(8[2K4"],$^N YM%8E]]>)]]>(=K5[[QFU[%?JOPI?C5MQ'M0W3-7DUM9
M+VX)7O6XQ[M&L=W?@<2&R"N2%-84]%2+6]C-9CXNM#5?95< H)X+/7[=5BX3
MX(YF1_H$M'0AP3=S7"UF%W'[email protected]^_&+D^VP[Y71T@<]+I N;5A.>J.Y\
M\H4]LJ1%%S2]5(G/N@,/5@+" "_ERI=O\KZ*_XF3';,QO>XAGI(/S"=>K;^@N)X2%WL]/)$!!"C_=,1:#(=
MJZ:L7ORUY7OTPZA='_430T7GU"9>.3<7B$Z-?G@^LES&4[SL[*2?$.^B&S$#\C+=]=F <#8[:O/MV:^?J%;'QE0&JB*]XE2MAFP::53:1OM7*"!M8W 'V-3Z1KQ0
M[D3I[@:B3YP9:D>5Z[;=;'O8XAZVN(@UK@(%)QBB
M9AIZ;S8*5+N&-NXR,BU]&#!ZL),+,*XIHS,%6F#FE%ZI9NH[-QJIK%E]#1?S
M7&D]YNT8I[22YQNNJ $:>P5O>IF^/@[0['?UULN5M+?X->_]7$W[O5<-^\B:
MX8[V.ZXE0(BK[,
MSMOL=5=6[KV3 >^]#C(LN)Z&NB]UI>YDFCS=[U)0:AA7G/"]A>+<22[#
M!/9J::2D6)GFW^$J($SP05ZC+3N50*.R-K_ 6R62BE*#,
ML7+;C\A?W$6^/;<"=$D6"QP32Y;9':(!81#ZT0*2-0RDJOCC-W$#60W-M#2L
MY,)WOT^M![,5L)TI1&Z?<1FOZBOV-,4<%N+?^=A&R%MJ?$_D147
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M5U-5XABA4S/4-W9C\5G:\73[>S.N@TMKBPR8>H-O6XVVQJH,79&J@-]2.OY1:(I]:3]KWTJ]@KAJU=+'2!V;2#
MJ+K34"DPJ/4*>4WXJZ[V,*DT1X9AKNK %^46F*@_CHU 7PD!-GI1D2$*$KB;
M5.GW$"&'>$= ;:HU)1X <619ACNS234HJ_VKY48(!#=0R06X (,@+X6O^)7^1LA@0LFG
M&\]F/II9X19'PD]TRODP?#-.HC (+<])2A@"-:B!B=W9F%LV^1XQSX]*%!>)
MM.PPLER&ANUKQXJS)[656WS]>"=5'6U5?,(VN'[N#%^WN1TG*-*)SG4KQ9[A
MEK9Z+ZIS+;MBR7#5TO!CBG!(XQ46??3IRZMEM._/T!RI).R:&$.!.#-=T;6'
M4G]:AK#5MXK%75)3C(MGTRC'#2IUKIC2Z0U76<[2ZK=0)9/O
M,>Q[#/L>C"TH[1Z,O0=C[\'8>S"V(9@^L\'8>Z"QH?#9/=!8(=#X_6XK3.Y$
MZ#XLV966@4;JLS0NYN5_7N,*E;A[X25@C 9;F[D$!2[S,OV^W^NWB[OF3)_G
MKQ!!K^T!)-/R1[,+:?6CY2Y?\=::/AGU6-A[9S4-?)7.E'UB=*%M,XU'2^A%
MIOO3O>[5X8PR+1M>0ER=EG6#YC*-OZ:8N$]@:*;P\]?J4>O&,Z\U?MKGE>NN
MFNX::'ZFU^-7Y/OI21K)5/MJO8UNC$0A32E3[*MU,%JY<34W1*=9) XQ'ZP5U6.X:1K3?'&E!7M4"+29+Q-:1-V/5TB\MWU_1
M^>.L?@B HHZ*8J1(ID565\"SX]9*5'D/(3T>:*-'(VQ(I)=1YXKQ@G/ EANI:
M6WCFX2FV+2^\C(*02NH'7Q&9^=9RCNV-:*C#EDB=3MISG:UN9%&ZL5;%WW67D^^QF*R[]9B?_(;,L ,2A"X;K*H7YSXE+S6CP=_I' C&\\=)Y
M+Y/N<\(K2H:TZMXY:<_-R9.+9_%[email protected]%0?:^WU^-/ LPX+!DI._G$0Y*3
MYT8J_E0,U3Z9?K/^C_CKR>$7$Y5$-%RLJ!5 .?L;7_ 5\W3;0TK'^=XO0@S"IC ;HWFFFI
M%B;=EP5&X-NED13TB,KY.*N':+ET,?*!9U4="<6:S4\-7^7%T1JV:=\P++CA^*+5?Y?H)L20E7U09:NV0ZV9R,IW6:3I2UV8/XYF3X.LLZ%Z./X
MDJDA44L&_DP5A'X4HT& !KYDI.JXT2=.9(<,(I]V#@@D^L16$]'#_L1/YP6W
MCBT=KSH P1Y>1 NXT=L:J/HX8I@F.),;PW2P"#X0^2!MM6*NO1"'J]^P@W)W
MN&DP]L4GB^N7$/F>Y6:!Y<6J9%.UJ!O3*0.JJS\!>2V^JXA4AY*?1'?%F/;Z
M*"T4T^F2&"X&0<]F)J7VR3#80LTK?M$2;TM4?,$V^JV^[/0CE4>Q"<_RYJWD
M_LA"!9RL):.,.6,;&QT,N]MXR0MZ/
MC6CQ*^TWE3^LURJ@"&[@*NBQ>[2L!]5: X;(+V$QJD B>8>J!J+#Q>ZOQ)EY
M%J,,C<4[4_=8I''SO(:WT46'.ETL$MD1F9K.
MC8X6.U53?7I,II&/P[]H\A8PS7FM=N'"1.5F4<6B0^<9T
M\U^L\K]YCV98?5:E!!,[DV4)D4U_N@<(]%,Z'MQ2+IPC/]4&M(-)Z1:&0BB+ _?PS3U\L]/T-^+] *R,TF%"+ ;(?CLCST=V4@*"<7BZ_@_&
MW&F.N?3'O_]X$.$I_]NJ,9 )J"MO2R4:&E81T0"25RN AO:Y-';8GANZSVJ(
M:(/0IGL]=V2W@,-6$M-C\'+S%GU9<;M73D8W/%5$IE( :N5'>$U@TJ9E381V
MH6% T;H[[V:#1 0-OQ%(4J&K[VYD-D1B@=J[C4_0CO4],?H^OQNL[XG1G;;$92S>%W 1C7YQ$!>Q[#Z&PPF,?B^ 
M^I:E5U_\O=&4B]]+LEC@,-Y8]//%WZ>[,GERQ/N]J 7RK/X"=C*-&Y!^MU@#
ML#F>AEV(
M+$A;?2@^14$0K[ O"%9@OCA6=:(S65ENN+I^83TG0'<>VR.AM^'P)KWC,/3Q
M4Q0R3_&1L'5-8T'6.DOX'KW3.:$"<[N37Z=7V$)&,S\"RF1L
MM?X;4_,U?43VW",NF8G7%.QZ6G5B3[8YN$0^MPQ+9>+I2*CM@;M7F(XDI
M)';D]DCHE[IBAS*Z0![],[QS+2]M,[-NT".H]"8RJO67S,;:=-Z1@#IT2Y?$
M/TDY@MGC9F**Q;E%5L"*5=^SU>M*K(H* HK9YE6GV?0!FSR=.DUP3MB1["G3
M1%/'-^$-EZZL$%9^MWP\V+#ZR*)^SG1*([2'I66+-\XH&:F\0-=3@/Z,V!>C
M,91,D,^4"X084!F^%IHHZ:L;5&"$G6I5[(%73:MY5#?-2MT_B6Y9
M6R,5,_J(0Z;"&\_!S]B)+/(E&4KV)4KP%;B7.;7_H"8B,!/!IAH^A$%WH
MI'%'[A!ZHMXHU8G:?'08@2X0>JQ5I05#=-#\+B9[#)-J+\D$#(;*O=_.V36A
MQI4@UJB+X(&(QT)<,T:C'@2#0](.E%HP&&,O8MZ9W7%Y P>B(1O;;;SVF
M9])^&-Y!I@(EP>M&#,DR*$'4\((21IE?;>+JLJL1HB'Y5
M$>C(2XH,:1?(HU0S?0PJW/D-I+G_Q=QWP'GW9BPX]0OM^VQ/3MS47IYM*ONTDJRO1..BPF*1$DTY6,15^@S/TS+.4+DMX.=W'[X _W5Z>PVNT_S7AZB$X!S%VS7,*_ *
M/%75YOLW;W[[[;?7JS2/\CB-LM=%D;R.T?H->/6JIGQ6P*C"4H'SJ(* _O<]
M^/+MNV]>O?WZU;NO[M^^__[]U]]_^>[UMV_??OW5M]_^[[=OOW_[5B#P$WLK
M(/R'";Q^__KMZ_?"UVZB^-?H$8*K<^%K%]^=_?&/B_>+\Z_?GUU\\_;=M^^_
M>W_VY7>+]Q=?OEM\>?G^U5O\W[=??_W-M^3'=]^\_4J4'&UV1?KX5('/XR^H
MR.#V-?G_'Z+GZ"Z^A5FA.KB0F#,OV^I!]>HY@J54$NT/L-
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M/TB.0&S1_"X,:I[E!S:+^,$""M >?FVX#X=( 6$
MPL)[WXY'H;9NR\]I(UDYWG[5LO) T;?EYW*D46]"(2 8J8"H+44:&Y+;;WJ.%XUJ'B;,:@7$#-QN^$(8<HWR
MNPK%O]X]15CLY;:B55XXL-+=M7Q6-
M(3T0@]5.UJL8!;T,.,DJ*A\HJVWYZC&*-L13OGX#LZJL/R$N\[7@,OSCO]]5
MV"7)RG>YNJSK%F]0F>KNA>O1TU*0#FFK:FH8@N4*-"Q!S=/S3KB1!I$)G+WU
M%99-\#YZR)1BY;XGIYD5)6)_%&ZMZ!?*(0QCZ6(M,PL!CF!P/7#,'DB=V.E/
M49$2;E+3%(SLH'QD:DT&],F.,6Q3D<(,J'R(.@7(L@\#KP/A!2RW3E:
M1VFNX[AZ=(VTJ\-B-D?=G>RIU:?;&BD734'X2!19IXT.'+!/J^ 7QM[CK+J[
M*=)U5.Q.80ZQR"G^\0-L-O+9,XY%/S">'J--PVU.S:-C@!\
M-)HM;I9F\5/,-EF$$<-_[W%$GV U1-*KO)G+"0)P \_A9#L
M!NG&OM/XF*U/)K"T[\XZ!?4@S3 OE
M\"+9LJCX.EVGY(@SGHS3C&T(D(/LZJ&G&5W]\T::+)R<$VMD (T0@$L!&C&:
M7@#>SHJ9:AE-@?I(-"J.=%)U7I\-KB*"?;%LX)WZ3'3FP+I.8=-U^7)%-P&U
MH^9^(M-2]OOT'%0-$0X K=CN9Q!;(KV:D.V.R!$*$?6#/1,&_9)#/WL"EK^@
M89IU[VGS'%R'T$NV[P'0]].?$DR" EA,90H&/&>Z\@X6*2P7-Y@D+ J84!'T
M2TG(-P 91-=A^#+(I<];(("^K"^8P!C)Y:\*$M8E2:5;_M/
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MSBF'0(R\%W TADA X&8BK@+U64R6;'3GV"IWV%=TS+7[G!&:(@DW%16$NN,WB#3<%W$1I9/-!5/^8(<5J3B*XKC[7J;D1M[0 (W!8Q3[Z=CE?2(=, -5&=-6,,8 ,DI$RAHDZ6!1@C\#CUHG,
M3Z(U*JKTGZQ$&__M7[_YYOW)=U]^@P,E\NL';.I/X/V[$W;O(%E-_.LW7WUS
M\O[;;_DWSF%,ZYWJ+WWMT]L4%8_T=!&LDKG/,5: \@(MLWHA,9?7"0NFCUA5
M^HN)'@+FF>E]6JYR__X7%M@E3N+G=5GHDCEWVU.+VZOKJ_NK@#BX_GX.Y^>?8??UU>GU_(-*&\TAS7G,NZ\5Q\6V/?'>NK.F@?<1,05=3L^)F1-6LNU@;OA^UP.C
MZD'*L(6HBJRK!!KBX'K?.&LY!C17**FR?P(9!_0X
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ME/?/7='[LN<@+>G;S#W_WJ[=?U'RH$'J#H
M0?C9;[[]X\F[;[ZJOR+XE+0J9(C?=]^\/_GJZW>3N 558=)K?&C,.@(RM*QC
M8W/[[R))Z%U74783I@!P.>)7F
M(&9L_1YS4E88TL) L%VTU
MWSF]JT!K*:5"S4A#XX2=I+N% F#*Q*??:&@*Z0,7M%:XW]3L0,T/B"HZEZO(
MB=?<%S JM\7.+&R4/6V$_R&AB7A_Q_#.X2.!M$Y=.U55B?@_?N3
M]^_?\U#+IVL,J .-HQ4&]%U3;S"?.YPZ3)M,2Z59R]ZXVI)IFXO?Q2G,*W*W
M%IZ1X]?,W.O46K1!)3LD$EIF32VC9C63YCJ#-HNE?TASO.:M=O5E33IV?OBL
M$;+[9.S',*3"F?0V0%E&EL I9^33@GMQ1V/ !(0QM]V:>'/CEZ.#SK<#%6G*TS$(S3L0(VB?X?%_G,7^<^39LXR]!MI5W2)BG.T?:A6V^RP^:))W9L>8;/\I@X/
M!XFTFCU8H0(D7 !R<)A*X#49;:16- G:8U%AMJ\]S!K4O(&L(>C,9:AMKK'M
MSH!_SB -#/)D(9Q&[VU9H.6KUGB:5D):8>\Z5=Z*1GKK"2TW+KLM-QJ!/-? 
MVK4CY$IA+\!FLD-S$:4"C5BLV%;L)C'4"L1W&Q#A?429=886$^JV.TGT,'([
M7.RW#-FP]B*!]OT8T[1:+Y!!H(]*J]RA1WJ&B/H69?!0'GD3%GSTEE.$4.XXJK[?^<1C'X!65[>N(;0MBIF!9
M ,:6;1("S!A0SAZYHI6K4YVDIF)-#XS@?,[!"GA#NA.8=,82,><@!AN,H9]I5EOUI<
M'U"QL7A1(C?U=,%\RY:>DRV!'.K06; HPQ>V=%46!HZ!7U/Z?5TQ4.ZI[39-LY^74+
M2U@\P^02%9=;LGM)9";;X3JNXH"YD9ZMRS&3>XHG?7TZJ3LC0LZ5])(,A@\I
MM71 % \(\@$B(&@E[)RO!+60M+"%B0EJ.?U,PH:)D&$Z=F8$IRD0J=,'DO]0
M4M+0[&PG\^%>(0/S]-PYC\[I.B:#CC]('Y]^S(]1LF_]/0 OB.5
M(CQA@9WMX2S:]H@]K[.R)%;ZS=OWW$;))W^_RF.TAM>H+"\Q;JSSV19[QW(#
M"SH+E:=PA0JX?_IHD2?=1R?<1#>3(%JJG$4F.T:1H'A+R+$"GK_VO"FFUX21NN''FI6UQ!\W&Z8##1[G7.]-J8+I(B2[FC7
M=$_Y ),TCC),_ -MKZ@\G@U0T!^Q>HDY&9/:UC&<'>T;XVW,&=<%4H,I.-S%
M9(D<=/ +XR=UP@#>(!L0OE=V31<\>\+1BZGW=1Z>8  "'<<^1SD%X&TRV \<
M[0"6D""6NQ=E8\^OK$M]X%+# KOIQ!-AYK#RY\U:I4A(N:A5
M14YQW*- N"
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MXK*0FD4]!OO=%)7CC480"0#;_4UG#NJM4/Z1Y2C[JQC,$0/$#$"OI>>L_BY>H)%
M$SM[W]P95PI2!BM$!7#3%[G4QC_O,*]6V,R^=T_*OET>:O BUH1JLUDD=+32
MX)7%FP(]IR4Y.4G:L[?U_325Q,N2TYP,!P#6%^^A5?N71DS_!7#SFO%!4=V,
MQO#[,-DF/&@6:H#P!*WHH)4=,.'K092*#PYN:*()N0."_"(7]AK@JM^F'8[!
M6& ^\)_"'&IN9O:2F& H!]1<+!AO>D8?_X-)OSX.'+\'J8"PESH49E+'&H"S
M,:WS.HXS?WU3X-19[N4@9#3B'M$@ZRQ$=1EU!=97F0<=VQE&9ZWC*
MBU\J^Y3^,!7B*4K16#^_ID<>?XA2>L],,VK3#116#/SO*,TK\!,6>GO8:/!E
M("(QC&7>:Q;UB-W*"D1A>:44(]/*"YC ,_4'KO'2&8O%IPP;R]8$[$<:'V$E
MW62:P[J+DY)
MIYE5&GL[CSJLB3Z'L>4,+@U]%@.^X*%LW9G;Y&A]/PTC@/O(V0_K&PO?P()U
M>0#19I.E<6WIL= L4+RK^$#WF_8 [,'W@Q+-1Z49%"E>$-N�(P;][MO?:7 A)
M=UXV>K%#)TR2N6?H/: ^;DDWAN5*#IC.4*=)V,@OM7B\P)G>3'EH$H#'HJ@^
M)V2\R;'W/G?TZ7=\%)C47EZ;M$V5]G%YD4&)J1+'/7 8QN-1V+@7UO.>=NOZ
MGOY:M%GX/3J%[+(:>GO9/;I8;S*T@_ 2%:K=0DJ-\D2I6VD]YL4&>&KVTUQCSJS8)NV-D1QLK'U$Y_+VMK;
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M*@A/&%$'4D,J..BYT=D@[*6.4%\$%X@)*2
MD YR@2HD,].%^SNM]1U"^OCT:Y9=F?_>7C;\
M+O$\G>G89C?;^-;:T^L\9[9[))"8#=037K+D=?].ACD: B80?.O-.%8!PBC/
ME +[QY:WW+A'/;D-*M5#5,*$[*' O*3CQBWILE*F%;R#Q7,:PQMJ(K8GIB7Q4LP:8-SBU^G*NJS$G*7 HU GP7?LUR>,->ZIL=[XM]R.2G+!_
M4>N5B[QN.W-1'[V1+E4"6 7TB=KG%6K)&V&/>9$GRPWMT,B$QR8I3B9G^ _;
MC#08)*OBDHEY8;HF;?H[""F,G.:3.*$B.GR(F7#T6DO%/#"9/\&^U
MA/3[SU1&4'(A_26@[)H2LJ\YW8,5>' B>5)X#MF_)&)\)BZ')PW2V904+G^(
M\NT*_[LM-!*>^H3U+5Z7AQ/CKH4 "9>"3.T1EX-U96&2@+4@BC\3-M8XFH3Z
M5,.\RL^WD#3VO(5TX_PFPI,IGH-H T?B#W&5/J?D(V,3U6$QW5C5N;DUV\]K
MN_V"]+=-(#:RCSYQU]:)KV&=1^;2(<618
MX-$=L_DI*E(2"C;79.45#AK5PPU%<@;QA!)E-P$#9HWMC/%F]OC,N3<]$0&D
M_#W& GJ*1 :P&AV39(%#O>HJQ?!!V:K&"1D>BAR@Z>8L)%N&'BZZ:3?O+(5;
MTLL^)O8F1J">3T2JJ!!IP3K?^4=BWY<9^JV<>.Q10F?J:<<#DNX..=(1C/(*
M[VQCOX;D1QI[8'-L4A]A11C36U 2F)SN?BQ)__#FDM)V'I;=&&%B?+8XFO;I
MM,#<00:3&/**&K)X_VXG#OS>ZNR)D8VA/$XSV.F-BQ>O:EB;#"UN^$_?'K0DBHLS(^V^
M(([:BEI.>@T1#=>VQ.C(!1>A#4A.;:UO"]JJ(E^87:79,MSG]2
MALO5%5Z%YX_I0P8790GUKA ;HV0V1 T2=3")"?Q(FF&#EU2>VY H:@CI@1:L
M-C*)(O#JO&4&&#?3C7F6AUC=F4"I$Y[L:3WCK$NY70*R0^?XS2_ MR.]P_Z$UPS_*;X%S=
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M\65U6..KEE$,#KSJ^C@> U 8JKD4
MH!8#<#E8*I#J7YX)GG.-T.Z$6O!R.46;H>@>\;F\N%DZA.BH@WH<7SI((0U7
M9\I+"&';W*>7U3F!FVAG+[/5$+.<+.%T[2>3>XY^-,FM#6,:BSMC0<
MH"K*^'#P4:7&]7AK[F7C@ T5'*WNLU;M%FKK?8X(DE.RCD_G:'.T:26:S-V?
MSI&=T@[Q=(ZIG8R/&$8J.7J;4!E!&L&".YV#0QQ:]':)"IZ5OT>+U0I'.%&E
MM4@?(61VT](031
M);"NFZ\* ;_/A31/*):$5ZZ-3G7_QOHJGK3.(_
M(Q@&J9\>[R'!!.,W?CYI'N?!OHS7!-7N!F-6+?*$'"#9D*],\J(!JG;4U:LXJ>;(8H^;:WEYV(7VK /.@\^4_O>2X9M@9D24\CS??:3_/Z2V_&6)>
MT^>(<)GF41[/N3.BS=&FE6@R=[\SLJH%"GQGQ-1.QD<,(Y4FA%'*3!FG70)T\[UYG
M6X>Y7A=@JAI$NI &K*UZB=7)!=;L@,CO"*;D^:9B+\.MPR!]4X^U#[MC"=1U
M;<+:M.MMN@UQFIUE5*#9BSPA_Y DSW.4D700NSQN?^ORXA._PPG_0%NQW$85
MO%BMH%ZD;HVED9U8XNYFP!"/]]#!@Z10Z0^PE=7G@&';7) CQ1R_:712?=@*
MZ ^"6/4%CX<;^XUHH)8-$.$ DVY"SRXY/@L\[A;%#O.S>#'FX7W(9WWN *(*
M/#27)9/]!_KL,;UG>^/;X%M"<@:B[_WU1M)O&9==-6*# $.7X69
M1'O-K15 8#MWSH/D,K;M/MQ*9Q]NUE6>&UM";M7U8NRF7A4R
M:<"RH&66H/Y=$(\V81<$/# Q0490"SGIDF3G-U%UYDBS:ZBF70/M_ WK*83V
MU.5]=!MVG6ZZLTPMXL
M N[AI^H42_CK;&XEY3V_ATG$L#^KB!*>@--MF>:P9 T#3J,RI26)HJ1'ZU-#
M!F7+O7HU]H*,Q^)(W_D&J!B=J%%+T&[
MEUDT;$#-)Y!Y4T$O2!TNUU>6IH]YNDIC4F-\((G1O*5*T2PWI$3<179OO2;K
M,3R52 S/:RI/3X'(#,O@E54OPEJ6,D7-/TA?1 79EB";2'3U:^12 T2,%--+
MS[[CD @LIK'8>9IMR1%3X9ZYS\GU+U^0C2Q07TQ#Q/'I3N/Z0LHXAJ@;[B;Z!E[>,T]&];'R#GY*+UIE]5V[C WR7J*OI JD YCD.$
M[OHF4:ST<2/_DU"RZGD"_4#BU2'HD0(P 7IEY_K!\1M0@I$[ZQ790^0BOY(-
M+XW_G=R5]A.[*LW(6[5)F\VD>ESLSJ_LDCG&7#S_3U,+E#^H!0AD&##5-YJ(
MN..)17X:DJTW=Q:::8",/KW1 WM/65BHS!/08%\E&G3U5>TY0]
M@\)$#]2A:G/VF,4'NWU^?B2G>;A/XO7SW?:A3),T\GW]D8%>QZ<*NUXXMPY'
M)W^??MCR7J[$H@3>^NL,E55),P$/44FZDNV,"P*FAHK*(IZ*(1M/79%9N?43.U<&V"JV9
M8G>0TVXS7F4GAVC:S5023C1?T>$5R REIB2D!9SC^>6,O!6Y8I'Z(19GXAI(C9[9
M23@%TDYR#RU7DGLX*V"25H (X/70HX[BD F*@2LID^F'<#1AFJP
MF:A*SV +0XVTFTW&^L[6"C57TH*UP-[CEJ.F!I$)G(%KJ[/Y)-P>7+,V/LXP
MZUMD>R_0=S_P_.$9*QZYCSZU8X])<#9(QO0^K3Z*MENYD^H9S*@S_ 81EJDH
M!VE YC@DD_ W"L6&Z=BR)J'4C<%2K9Q
M=1>1HBS[9EA5D6Y..?8)Z@PG0OQA(C_>E\*D\G41D7"I1$*EKQ6 K%
MJ'$M&/W+,Q/-7YQFS3R0596X+G:'CT1AMW"#"MJ[U:1]12\-LQKI'G)VJZ(9
M$]!P"218&-4'4@7J6,>03C)<&"X:&< ?HO7F3^ 'B!Z+:/-$KGD1NU*8+B7"
M>'MNGO7(2:6A"4"L8$^VB"1@[GO-NL#!,%'JC\@W"O!N93F$.5^GD8AQS'F;=6PW9
MV1^RN23^MRXG:QG9@O<(-9IUE4D&*';[>%<.4 OB>_)9ITU=+>L;^@AS/DV2ODISB8:,8N,DQTNHZ&Z-MWGIXC
M)Y[/)NAKL<^1QM$\!HU)7:SWM!#C[//V@0FSD1I!F^WA7<]/34OP_0[P =X#
MH#!-J8,8NI(R03_R#OV>)K'[(DI@G4PY/+2N/X$I$C12F!)M;VT!YO(G/94A
M(_A"5P_W)\I1R,+)NB',.$7=57CLC8J$[U+]'!5%E)M$@2.$S+:/AVBZ6"JQ
MG;I;6&V+G$Y*-4NO^\A**D):L(6JCGI+GW,"M4IJ7G.Z!CG:FF.#WTT(V/II
M&!9NRZHSJ *F"$R#>61?JG;>(JNGRF2=$J V18L*4H$[3]/)7)?+V
M/><2!TTI.35Q B[33^0'&D(U GB^H5=/D<@4T2-06EN81IG2^HZ*+DD:OMZF
MHJLJUG6M^:\ C=1Y7MB
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MM2* DLK _HR%\#?4&.D7&>/8?@WZ
M-?[;5077I;(5&M'6-T8#-DYL4I0#/#0&2D9)(@H)?#>",/Y,GZ](P*8O_;Y0F>M8W2 'L(]&I&(9U%-I,@S10H0K%JRA1"ARA$#FD
M#:."?=_,ZJL.)))*&+]^1,]O$IB2'-)7Y Y-0L&].E(''6W.'T$4#&(2!9'8((OB%D'=AA(S^.5I'::YJ@=UG
MM$$3'W=P6,NKU4GA1'WO'0!TF8@:^(61-EQU_AR12@X\<&9DU[G8('9OT@>X
M?H"%BG&I4-&?70<).HF/"$>04)8@%7GZBX34=(/4(0M2#^) \#.KOZ)*P S!
M+XR1<= R@_B95/*6U^1W\+:JG11L$ED %>;X7MPTZK3PSO/GTT0M?]P22R5+
MP8$,VO&\&M=CJSHA12BP9IM-_,^2%]38.6)70=[ (D7J.5K)DX8[ R(1AWLZ
M,;OP-Z[D2*.AD'1S3SQ#>OE2KCQ0:A&(H4_*2SUTZ+:= W,0H^%&Z-I
M]_O%RX:BMJ)JP^7P:$N&*D93<+9AAS5IO9RG B4[MM8A.J=UA6E2E\^# B[1MB3X7!B
MAA_2/%UOU_J&N/>@$8X=&O:-D9,?3!G-99=RG-$@%J%@FJG!Z<8^HT^&]ME]
MT Q+D88#^V3DP[!/*J+SS+>2I/'K\@B?WZ 71@4E=JX F(1EYP.C[[2+Y8PE7V^PZ72DE8+3(
MV6U#V%)VL(=?5NDZJF "MI0+R-)GOR=V=/2ETB=R'[VP=<.=9; [).,)"-.Y
MN]OM-PS[*\R22U1@B71\2)'@U#YG_;0=U&&1%G49[6$6L1YF9%1.&V$"Z5BG
MH#]YB[HQ+$/7%?@M
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M5(U?]UW^"!@9>JM^@?T.&/KW>5O
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M]XX(E5>@>+YS2&)?XSN54!)O?HIZA(R;;;58[-
M# <&K#V1C;5]. I2-RW"&4MD)C=Z-2GX!')C?MI1MU
M),?+)":ZOZ%X#A-%<^E>MV&*B4"#-UPZ]8:5.;\/G2%R,'^+O;F5Y13B+\/F-F?'F9]FF<9MPW&H*8\?GX[AH
M]-HMLI\F/?7$Y&MZFNP ES" @W16+.C@R-UTA1VUML1@/?P,E=5R1=LIN_;R#JO9S$'@
M:M_;"7%2@[LI$![NJQ*4*)->CABRU\M,8*+G'X!^O.J>/ )0&R$G-F3=U(,9
M!WXH\*+NID"KM"++.]=CP0&[V0QDC[.E,8',^GQ,H P XW!L0T&?%4P<#J28
M'[?&)P\+HID (I?I\BCX:OM.-PZ-@OD7"\ADV^'2 BXN77EV!087'D"PUGX,(N#
MUZSF53CC:G_2;E3':I".TK?WE&_#M46XCU?1]AS[JM8^ *Z\Z8#')YEZC1,"L"4'+[J9&-I\;D#Z:.YK%AR3&T?=DL8/\@%%&=$&CW)C5P+;[\A=9NL8ZJF"R6*.MK7,CW;?_(<*OCM7>C$UT
M@^#L"?,%_XY2;#$_87FWAY8!VZH!A/G.]H>&$>\/II2K/#,0XA-%ASG%S]O/2TAV*:UB6
MWX/:1PZ.4%9/D)Q[EAY[?M%@.3(P(,I..AA_I&7%+;I7@:%K\^"O;%0^L+CV
MV-5=G&+6Z2J-Z=&T%PB(<^MBPIKE?A;),^8(E_$VBPJJBQC>+33/Z X3T5_5
M#M%S79-]K>9%GM1*UK_)?H#(%,P/Z?U^S'Q (8>VW@=4B.!G
M>[@O!-Q5;[+O";SN\#J 1)JH>EKD.!1\@F4:7>5E5=# 1#,"4Z2F'P4H$782
MDS'.>+& 66.#KWGCE6G-W%]PIJ<\I(]ET(KJG ^[7X"6R^10;<:WX+[-S8RR
M!"U/E9=R,L?Q&+*\1XO5*LW2J-+JYB%]W&AHE5!R%O:7M,X#KX)_A?2D"YG?
MZ,DX^+@#&RPK2>#[G.B&M((4, M+ ]D>^/<(-!S,9K-S1T^\9=H_SQ'A;K&PSQ
M4U3",[1>IS0%QO:/S6Q&DZJ^#6DQ<&)31 )Z#2S8JHX--*>HY1,TFXC1!TE0&NN=9W!0:=.CPUPU56&]%#L
MM1T[L5R_-7](\W2]7?_G-J(W6=X2T N8Z$1Z!L2-HA!M/@[.8)3EEEZ=VHQ_
MJ$A@X3,@-%,.-O=+4+,$C. 6L"J5 @#$TG2X]K-3[#0P\1]G65B#@
MXO2W? W&_8L .4%&+/!4O/9%N2CFD'*B(6HA(S((J[2
M9SR*7Z+B(\IK/J7FZ1 IDG13C<7PCSIC6QN13,+.]5B9_HTOV1F#\C=P<\^0Q@?:QYWM[%T0Z0,7SNQ-FSXAT,GZ*.CMJ@]'(YHWLL8T@-H1@<,
M_--R=0MC])B3>H(;6*0H(37EY5FT22M696!0[N-*A&G9*KO2V!^8VO:$12,!
MH(T-R^6U3^,-8*2;?U65,!D!518
M($@[9RF1$M0?$:V,@FQ_I[PG[B+^G;S!1U3]#5;MVUD?R\R$<&=_)O+8'\\H
M6[#-A='L8!S#0QVK@:T0S38SL0'J7SD$-?I2/$D%E@8#H][N&-C^24J^$?D>^^"& -[) O+7*5"SA+]L1$2
M/<,"1. WF#X^$>N-\._1(SWDA>5ZD4/DL,7.,6X.*/UW8YUSCK!UP$DV <4W
M"3L9QU.'RVU55E&>I/GCQZUNB8P#YO-F7OKDL&.$;)2[JZ*BX@,EHTX:LW#.
M)^ 4/J:T6Q^VRHQTESO*K-RH-=E(T@UKZR59CK447KU!(,@)F*!',3K]@+]8
ME5W+"WHN=222Q'\9)1B?*5]Y6Z%C&I"$;LC@J]6KH9=F+]9&)
M20JN\CJ,HL+.,SJ1XDS:*BTYWQ9X:&024)E+H4"TO/@$BS@M];)O)M3-;$6;
MT2Q#1\/-Z^!AKF(T'>&C4F?MV;1BF?$'3(#:,YD(G9KFLE_-0084>(VV@BGI
M44)N0+CXM$GY!;CU4#EG>*$@C)?)8U2N6<8/+@7)J!< $B&..PY1-SV+48FB
M*E^RF5F/6 2YZ2$G0?(VC)EPQ(904X(?/HB![KG
MSW])F'OQQ ,YY@P0?7=VZ[24N[+-S^G6XC3EA(]3:OLUOGN
M(7P+23LM/,*?H;PJHKC:1AFYF4QEU"+V!Y,2QCD3D!?QK3/XQ$''I/'BX%M^!<.G?M#'POX&%7P"HN5YF4:_Q1E6Z4<^3QR&"9\W(GD
M+K7#FS)WF@E&W>;-96\*Z)$)+^1^HEI^_!E_ ?!,WL!SIF<&JT5SFL(=U(;B8W0(3$(C*6FQ6464AV%G$
M=4'TE:HYD,+WVG9/("^#U\M+L_09FYMLBE2'+]*P'.9&]D;^XVB%Z[D;5#C]
MGWQU?+HX_FKVF=HZA=7(Z7A:-RFU:@KUS*6_7M+
ME9S^+I4:92>;335K8S6\#[Z=)Z6<89*3/1:YPY>!2+Z2 _1<^(*C"&HHD\@:5CZ,W\E
MI2!EL'IW)M5MXIZLV:?8 R=@Q18HK=^I'705,6 # DBA@2[&NQQQS JTO, O
ME)OT]FG_XF<&DCM9,#:ON=A63ZA(J]WB4ZIU^TD?!:,P5T[,J3GB!3133/SFH8EU!FYWZ.I[RECT-A%E ($?M#@
M&:-Y3![S@F65QF?D+NIB]P'J-AWO(6"$N926?4N_A E>_6?@%\9 .O7/9>7#
M^",E;$+#FAMWS0%P%H-XA[%44X@6"4= 60;\'L-AX\ KN)U6R76D>9QF*5T"
MW>&5$%SDR34>7[+F.] LJ%0E/6TN4./BH-!B35R([$Z6A"==-,)/)#_JM:K"
M5+&RF5L'VN-1XJ$C=KD#RIXVDZ("@/:;<)Y;YY8;2/+D^>,U*LNSJ"AV*U30
M.X=U_'"(BI&V^@DZV/N'V+5J?B"3W/VQ*-\IYQE-2.LGP_2Y
M.,E-MF+0.4<0!)!_V2>TZ4O!A*$GB+ T_O*7$U2/)H+O^C1._ 23;8:%NL@K
MO$#\.4W@58X=94VU=0N?8;Z%EQB*BT]X6,NC[&Q;5G@6*9^IXTV6C:(^)H6Z_A
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M)GMZLE).2N]FW<_3UQ86.Z.DS):>PU0=
MY  XPU 7.ZH:0YH8AJN=S%PQ<^6-3V$>/ZVCXE<+R>,]6K:2EQVRLZ3.&HY!
MY<_ZE#6<4):@%[!B!E/+#3^O^>5&"@M)Y@-:EE33)?M[]ID>90WZC R]@!4S
MX#.MP\R:AXXR6/*B@Q\02LJ/L#)(00]0,F!J&-2"$W_X$/T#%4VYC6Z@)7O:"/)#0N[6(#ZM>P!N
M-(Y&4-!R*Z;DA8*M&<.?C]$:+E>=]]./>P:(&,'=2^]E&O2X#I R-B'BS:V<
M<"%EC%UKGYC@KN]S_A@S=17C27*\-$;?N4OV&_+O+(=3[[K*'1C"P2MT%
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MR)%?Z]2,-X%)FW4$Q>'?69^@3H.[6QC#])E,G;PAN;"'F@"0V1>HE-;"[3
M0]=MHR+.M),B"ZK7T)CJI'V#!J$,64W9) VY\2+2K9*$\S] ]%A$FZ
M3Q;]KU&>;%*\PM1M,7GXH'X.?9^&DQ1ZRP0P+M[RY[U8HT$\0L%5=&4!U*FE
M:FZ$S93E5/.39?4$"[Z%][ :/E:KE:I3&\VT2Q4NJ_
M[TF#J[WWB;BYB/(!)6'D\8[U7LC1,"J.*RVN4?YX#XMU72AYAM;K
MM"(P:N\)C9(R&A]&J-H?L0E#0#B"IGBTY1G";I"JRI FB.&J)YN@&2=>"/AB$*!NML#^99TT']@:)16DB)G.6(UF&:B#!]
M5?6&MH$DC'1TJ+3ZL)% FDU?:JN0:2DEE_F13NFO)#D2F+B9("F>CQE]<">3
MU,V !;%J+SYM4E;S?QY5>F=/Y,^;F;B$E(,QB' AEZIS-B#!?+P.-T,:0"KP
M!(9V)@+=<@"4Q6F_7Y),H,[SY?(SFQ*NXA\G;
M=X@/**^>LAV(47EPHG%./]!6FO1V=!7TCD!!]<9F>W,ZY0H($\#Y LX8<,[S
MS1>+/&$\N23:$\8A ?,Q;)^6BT0'!ATRZMYGBE[L]Z<*.2ZAX=R9+,CQ:L:C
MMG&SG;]SN,+QZ2G,\;_5#7Z_FVA'XM8;6*0H4=X&'".COR>K5\*R*YP6#P&W_23,_
MZ!!Q4(C&Z+-ICH=L?DYA_)2C##WNE$,Y)[P-:L+LB^&F
MJJR1LXD5*P22>DLE*H7^++13&[ULX9D("[9$6A S<4')Y 55([#'ZC2'!HA<
M:[@WL)WL;7MBT&+J_TCS9+ERZFAJ;%WZF(H$@;H7HA7OOV)A:6?$HW(N+7O3
M]RMUK>JZU%V%XE^ORG(+D_-M@6FSN(UU;:1_7&YH\<3%)RQC6L)D455%^K"M
M2,W>/3K#?]IF592K+1/M\]1W)HOLG7@2%0&D5$"04 EY5H-U#RU!2;^!F)0X
M).1B@DB0DWA?W$KJSXE<6!ARIS-MS,V'3-Q,,
M,,EX,JSNA/&MZ
M"+9#QLDYY(:#=UOM11R-01(0NID$V,L]8/G/UY@F_AW_AG]XP#/87_X?4$L#
M!!0    ( +*%L$B=A+HS+2\  !6" P 5    ;6QS&UL[7WK<]RX/KJ1/;J2O)M\VJ)(S A9
M#C&'#]ES_OH )(?@#%]H$ !'($^E8J\L-AH_-!J-1C]^_?>?2__@&841)L%O
MKX[>'+XZ0(%+/!PL?GN51*^=R,7XU4$4.X'G^"1 O[U:H^C5O__;__Y?O_Z?
MUZ\/[NXN#D[=&#^C"QRY/HF2$/WS_==_.?C/L[N;@QL<_/7H1.C@@KC)$@7Q
MP>N#ISA>_?+V[8\?/][,<> $+G;\-V'HO7')\NW!Z]<;RN_W)\].;3X>'[=Y\^_>OAX2^'AR4"OV>S
M.BC]CQ)X<_+F\,U)Z==N'?7'PZ//IU\
M/CD__GQZ/,4'_^S^2\KR
MP=T;]G\7) B0[Z/UP?\]N"=!1']SN7*"]9N#4]\_N&.?1 =W*$+A,_+>Y!3]
M#89TI8+HMU'A\>GKS=_.*K[#=_8?\-^/6?E=__<9+^]M'G
MSY_?IO]:_&J$ZWZ1DCUZ^Y]?;^[=)[1T7N. 28W+!HCP+U'ZPQOBIHLJP-=!
MXV^P_WJ]^;77[$>OCXY?GQR]^1EYKRAD!P>_AL1'=VA^P/[\?G>]-=P2^XA*
M=2IO;'$.3TZ.WK)??/N EBN?2MM--E-CMG\^=IX%T&,8[7U\&[RBA
M/R&$:B>R"JED!G'ZBVS66[^+?L8H\)"WHDFX^:'O/"+_MU>BE-ZJ9_V*@AJ>4RE[!9^EP+DQD,P"W<\+%2!D_I %Z*@^\(:^J=C[0@]D!Y@ *5?=/(3O50
M9S_YL^VH/'UD.]^-13@!$"M8+-L#IZ&[-8H3NIL1Z%\KQL"V/9?_QMN5P[3^
M:_<)^X4=,0_)$L1>S@6I0Y>$'@KI+8?:J8=O#NE59T6%,Z24?GMU_.H@B2B3
M9,7(.3[[-S1']!SR;C*(&ME/>8_I90.EO_G"$-K9#QRBCQ-$I%67%5 =G4Q0
MD8Z3B8/U>0*K%JPM:Z. Z_C]!!>IM1P+B$XF9;Z!J-[HYTA-.GT;J]* =3[29WO[,!6EUF!VP<#.O[7M[L>3B4.W'M*
M#S%PS@E5,T&$//J7B/C8HS_WSAR?^P\^NB!?".!2^@Q
M1WS*RN(ZH(*/([email protected]/S%0>I;I"98O5;XZO8;T6T,_P0(B=*PG4Z].^.
MGPAYN-J^ULSP'8H='"#OT@D#*H;1J4O/J(0]V7D7:(Y=#!(0$6J:)W3J>3@[
MZVX=[%T'Y\X*QXY?.D$A$Q*AIGE"I;'  E7]5C.SMQOK0H[?VL^-ZQB(2UB$
MB@$!P3$S(=A92ZV'F&X]%+CT[(7*2B,9W9O6=4E"![YUUNQPI./3GX0)-5*Y
M'9%?L$"[%T)6_Q253&@X]LM0]E\,[email protected]%*HHJ
M-[ .,*N4[H^I:VG03S0N2T7V">F_,Z'C[Y"+\#.S2$#H5K\U9(#Q,2E$/CJZ
MKRI.],0N%_0/IMB>'3^];L3G3ABNZ74#?L$5(VA26XN;O1TMJ4A>W]W6>UR(N%W)T
MC1NY"+&("KC0=%'2+4#N$_(2'\WF]49W$WM@&>LUCF80?G="S(R"S1-/]OY\
M&^*E$Z[/4)!Z\>E?X;U[$EJ/F&Z0ZPF/5+.UKML9FQ!
M15F.OJF#X(&Q)J7]\R]-,3J;7VUR/&])A*%AZ3!Z0X2_2,V8-"^,Q8&?'5),
M^FX^#MT'6Z'KI?6(K"KGP'ZR%5BI,[-+8EM, !Z2>V@KI-W;O)^YN+W=CZV$
M4(7=3L2O(3Q,U;KH9^"=CLA>22V.] 5L[&9?P_:N?6,>=Q&7(
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M-B#A)"H!^%G](5$!5YO)7$28BNHRC)NY@)SUS#X*;7G(W,-Z34E-*[+2;FHS/(VO%1S#C
M$V;@*)N&=Z T/X:  # JHXY
M#I2U)27D@=JX87G=C9$?!YT>=UY)8>1:7NBIA1<*&+E:;WUCXT4"1J[+&Q]2
M.4(C5^(:WM=Y$8:1ZWZQAKS,XAHU3+6!.;RH@ %%/TAH6?&OT6P^HW? =&P5
M?8O;">]C2%D#QWK=]'\@O'AB]\9G.N "?4N89VPVO\!^PECJ$V8!)JWY1:*!
MGPHC9TZ$7043;2(,[8ZP0[Z>[&G@Y@Q=^=#DVRJ;JPN05Q_<\(YCJ%+
M4OX*JBXY +.@ONC.&9J3$'T/J,7ELZMB"H:;E=WE(U_Z>(F#W*>:B,7%:&9 
M>R>Z#>-7U(!5T)%1D*#\"C.R68)V0H6:&TT9P+LI1?0,4S9%0XP86?$'YV=>
MVRPK+ ]L0]A PJBP-F-?\(V+[\^L
MM6)0&5=A(XDA7^NZYB42N']D_W.Z[AYL]E91'ZP'F[UE]V1[L%7/:@Z6M;DE
MQAK6V=MP5A;"+>.:XS0EG]0GG]A< 5,D)*C^(CNF3J^M\%3\$AP9^^VO5F2V
M'$L\4E]](.*>U'<3W$Z"SD(>M3_RD,0.;_'4%K+Y08!'Z*M7TB]JT]6^[G!T
MU"OJ%X5.Y:F.1^2K4]9[6$M7#)NFIU<>6C]RQ=/RML[CZD>N@(P&9'#41Z_8
M&J*">$;#:!6F'#D!X9$
MY#KO8SC:HZ0AA8&W*U3OP7A14M65J RO.->)\]:\_$/B@5
MZ60BR?LGZ0@/M=?)^^PPT!P]*MA(H?_>GCP_]8P-QCFJZ5P$F
MJ61$0_"83YM-X7D@9R@3@TPD'L@EW61DC5C]RS,2)(*I,E"*/9E-RV.IY+6%
MH.Y2_=Y_)[E+ZH$T]/5,D7QTHNUZ17>("G6$8W2/PF?LLG)AF'AWR"6+(*62
MMVL4%R?]O.A6,@KTX:0)ARH=L$,U.@/.>SL=[7FWVRVBX>PW4=!N1=0>UG#^.PB9:V,'9[WF8Z/=Q. <#]+ 
M)U-LS'BCQU00RQX0%0*FC(.=X2/I5C[UA*9TOYWA\HX;[?V38?U\V@CNA9G(#
M32N[T5!S@3EDT07*_KS\F9L/]"]I0L,=58&7\SF"B:NR(?6WY6(\4MOR&=.C
MY&S]/6*I[5KZJ,>E8UXC# 9)Y?$^(N/!(T9OM\8Q'0(Y_)W>].B-F5IRBU10?9
M325KL;5$R>G>EZW&%9YOX!&' ::H1JG]?!,>
M27^;CIT].(N?4'CJNJPJ4T3%EYUFK!BNZX;)UBT9@D*O88Q#L,-6OXE6B VS
MHES@P,>E*$7C$[L-T[RCP2)C'48A?(Q2-ICOE6?^1\C&;][F]=E'2/)$+M J1BX6?I.J_
M,UDF@P7C!"[VT5891'HBBMGE,DI#S_@OMZC,/MS:%%YGP2..IQ3&U%UVZBX[
M%1)YH85$7F*Z>1%OTS/+O(;.7L2>M7IV:J:S:J/5]X7G'IFY;VS=@\*MY!0?U#E.]JYMF$',A1_/>8:\M4I>(D*A%056=
M M\[^54-9#4 A[='5:=XK8=Q*R:+(VAQ_T4Y!"6#]7A-#'4:TA)$^X9PZN@^
M:SVT]6' '$J+#2A=)WD1)<[+N4S6$$0&]@:Z]5^IQG?5-:./A34VLE
MR5*\G[.U?D?%F6QEGWI[AAZO(&6QS:4>W=X)GB-H+6U$IAL3@CG %E_/]$/<
MDD/.JZ19; @;1+BE^H"./M8C@!I4PL)H/VM;$%9#N0S^9#,K*:##*S2.S6:6
MK6ZT'8?24;BI@'=T83X*X.U; JP _[UZV_E%*0MEU>4XHNJUA06(5@H5%GBI
M#]AYB>7E0;4K"^P^*M^]+["XLF@Y4XZ:M>L5>/MJ"
MU9<+\$RXMC05!K_ D>N3* G1+%PX01Y0>)9$=#-'$=5U9TZ$H]G\MC3X!JK6
MRN!]" ]3&ER*8[WID65&>)UR)K6!5V9C-L]M2L?G)4P[\@*97J
MQ]:<2]J+89FD4T4##JDD3/YOD[=]J_P\=N
MJ9R6H'H5H#2T/FUC47-^.5X$>(Y=YFBNC"VE%D4IZBZ,4QE;JKQ-"Y5!PYJ[
M9T?@2V*7!F'6B$NUZ07VDQAY6S'?MRC,\Q:8,P^H4."$A]8O (XU5U').R;3
M0=/AI#1,"Q'=16!V1I91*$RZ[]@??_" [BW^E_4'ZDU N8]'Y59A'#@4@MJEUZ
MBN-U'7QGK4AYK\7D,<(>=D*XRP-&=&A-)G99.J>LXO@.
M1W_!;XCM=(;6=,T,:NZX6QZ7C=?3L!*CI]N%1,=EA@,U6E$8.]1ZD'QFZB T
MJ%M):(X$NC)VJ8]-/8M9L*EG ;6,6B@,K3+J6(/ZBEOK?4CXC47I33YD]3YD
M4>SMVN+9@^F#\U/"&5/Y1#&==QA]0601.JNGK(I]$2@-]87 *0^M-B L RV$
MVY!XB1O?.^SH";RZD8JBH;).644#Z>[X@A;LKGV'5JQ^;;"0ZO;22&/01(.N
MF1%E:V27$KI%023I<:W[=&@ULL63YDY_V5";(GBWA$H\W
M'ODQ-&N2LE^/:]EU9&C'+:U^@@(5B]_:)PBCK5S_=[$@J( CA@560! 9$?DWM4CTM>3'J
MDX%>4%*0H>2@;^A':>R0N$#/R"=IN;"\!'3&#,PQ+4!.]SWX":]66:^0OSF!Y[-BN=0$Z[$ZHA2U
MK]4S"A+$FE'0>VT:I@Y!VDO3^<,*12L8:O00/QCT,U'0J2C[\<0@,'PGX4)WK(&W0#0ZW E(>.TWU/I35^[ W[&JG'(:4)FHG,K32:>!.\RNH^X2\Q$>S.2^M4 Y2+C$5
MY:V/,L4G%^ZB8+2I^L<>:##UU3]4B(9E*D\\M4U.&\K2'UQ1@AD'9OZE65YG
MZ_QE@'4169?IWZ'%AC0\V4^*]I3?ISN_3VI9[-(WXAUT3CT/9],J;;4+%#O8
M!^H@I6,.K9?43 :HJXJ!>$>Q61)'['&3RGMZEA;MQ(25%(QHHW9J8%D[HNSJ5H0R?PA\.\D*PY&7.PA52WI!2_HN7C;AI9"ZL=5(1T?H3<-POR_-9#
MF,GG._87QO"[DI:G/_HS\UA<&+1P_HW_Z$PNM;NUG^B3O
MH5H97XG4Y72GMEKVM]62DPQN4UC7Z;W7%B0-*L#B.+HV34GJ=+3%L7&-AQ@1
M.TTM#G_KNZWD[2:+8^1Z&ZI$RI3F028VM*=M21=6=X7L-\C0=T9)[C7[P'.Y
M>G!^ECI0@WS;#11T.^_YL%D45VGP;PCFG>\B92Z'=3)DLQ7TF#1_J9A,'DFQN?Z@[@=\)%@C.Y-9G)E@4]?;4?*1B(Q4-
M9D'>'0%*4TJB]D ]T:6PW8$B+M>D=A]9[#!I5C6[4%3= M9Y3-J.!M)X3EGL
M)Q$%9-N^L-W' 5(GR9>)9*?+B&-HW>&J <,MQV$!W3L#AIK^YDR5,@WJ_.%2M(=V@\.8WDM_
MGJI*C.-KW]1F_U@162F43J9. Z@:;FBET'L>T(8O*&1M IT%FLWSY/8K*LSW
M*'S&+HKH/[,!Z-E$ZED15BO]!](=$.ZDB1@LY>*;$^=9'D&$Z:;,TSS8KD8>
MY?0A=(*([FJ\VQ.H(UQ<<@1S$R\OTNQ'0+7&$UZ=SF,54Q:D/4@Z9L$/9Q(R
M2P!1W6M99!0U)$N"'M%DJ$*?++XR[1B3 %UZB9MIV)MS8%1Q*PW=B">/$?I[
M0E&X9+6BX.]1#03,LOU &16/E!8@8IY]Z#-;(PEI"?Y*K;DT%/J
M$*%OSE)"%KHH#:SXFM@#2TVO<8;6_L)OP%"*4Q&%EU)$071%+7Y2EMPN !#;
MM< (7J.5J./6TA_;I\L(WK0%CVK2;5.,X+V[Q]9N,@NW=^VQE:AU6-7M,%7V
MHKVU-[MO3\U057:A?<^T?556W36>5Y[[8"M<^NR1VL@4^QZU>WC!.LN,U7KS
M.);61?FHP1+N_^60?IH@[8 4](K HPG&>Z&K!5;1\Q3'=S2E46]#'XOB
M $9><<5'?1&/N0+3 3JDZX4_"U3"_T!>W4C?4)P53KXA470:QR%^3.*T]!.Y
M3?>=L#-;T^A0K[QB-KZE!3)BNL!TZ,5F!<53T4RQ,X@C%C"-_JY9T& FI(:/
MQTZ,C,*E$P9T8?3*1_O T*ES:K.@GILS1(=&WX,0.3[C*14[^M'*"9@6F^.8
M?7WIXR5E-D;>Z9+%MPE#H(\!(RVKM]>A8GI !%^0H'GASAK?)U3 9JOL#"SIM71
M3$RRM7N0U@EWC&QB\O,G'K4)L0L+"+&S\C(N@OSL(=WMB\A
MW9K0L/K^LWF:MZ$;CJVA]A"*W$&J&X9BF*'#YJINXWT)FCY_
MHKC)1IMN?:P@;IM>N^FE>Y/"N#[/+N;]8[G;Z;Z,<%UQ9NA!H1W;?J--,-Q([_8E'6_V+#H;\(&_B]S88'YDH"CD2A"6B1/DR3+:VFF5HB%OF0$^6M5EYWPV7+U9"0P>#
M%RWRP"P-CJ-RU?&,PD?RTF5:7]H/1UZY+K$">?4Y9P7B&A[HK= 9"E(:.<:3
M*:)&IF7R;/DJJ-,M8[_["&2!%["?J/<#5H1?>Y$%#LQU\)W.?%,M 'FL9A3V
M,,5*9=MH9>,-75BA_T2&B WLLF"^D5@F>5K#H&9:>Y8ZG]PAGXU/MSFTZW8W
M+$:U(1WBN?0L/'N83WR#H7I01ECC76>D#A\C8)W2_B!B(-W;0,2')EW>]R[<%T!6QG"I&;
M2C.D4GW!'IF9N4/"VQ"[2&YO=% 9;"_D_5;_?^*D%8_N$(4M1"!5*4%\F/A_
M!7'^^L]?[YD:WRAZ(*?S.?8Q/2Y!1V[=YU/?EG&E(-[3^S"[F9'XZ32@])Y0
MA!VN;8"9:8+4-*\"M8J]Q$US5S:%_^!)9RU$S+ _"_-QH7ED]=^_P-S47$'-
MW,1WPGL7(_H?]Z= 5MJ)3#F04P[DE ,YY4 .EP,Y]66!@RB8 SGU95&> SGU
M91$R*T;0FD5MJMF1M2EY\EJPWHX?0?^:U@M0%:"Z*QJOXFYM=XSN6RZ!WS^CF.UEYM=2G(:D#[I ^K^A 8&<0C>"?]6 53
M(!Z,Q^).MY5&M;@5WE<@-N*+PK/D)F4) U@CEKLC[)[H_SNCI[;$B?"B(LLP0
MDCT4>*<_G-"+'EBJ1OG?F::E(OQ?**::@RP")NCTN,?$NR)A_B/V>T>@%VC#
MG.E^J]9(I9(\-#%@N[PEWI&P] )
M%BA-\%WS7[EUUJG)SI:^>M")A,8H& T:O,SK&5]WC'\Q-'#K['QH+#12'N4>T9.]!]4,#[?89_,R
MA_FU.#W04_X>2_Q)Q5OV'6G(&[,BE&I?[7M+R*@"-E5M8M*HCT80I%FONHGN
M VD$L9I:+0DB9"N-(,)3-\KB=C4/$QV!MUB#[MV^1HTA@K3NOED#2$5GJB\Q
MMF^0-.S#6O?%J!IU:=AW*GQ8? VL-904.A;K#F_5;M81- 0;<$7D7@V*-3FQ
M]W;VLM:DX77,:&*&\>C:OF+6%34M-XK*)J^2ENN^P^_:,+3V??75@
MYW;5Y<\5SHLU7P?9!OD#X<43VUG/*'06Z/(G"ET7YLY#E=8&;-7@=QB(,(N[\[?H) \18ZN=ASF9LE<10[@9?5
MF"VQ;E+R&IGXT\>'_K%$B2#!!:TP](7^1LQ"U3+Y/UTLPK0F+AP;,WQ,TM6+
MB9>CW78.MCO$7")T1FF-:,>-$\=G$>A#J3UQ]J2V>J6-IS:)O%93!H!5GJ-)_V V!Z29XC
MG-6I"KPA;YQZ&1UZ&;KOTQF[^WC3!W&V[T"WGOK#H0QA:VB(K=79>P]MZ5C_
MED!#>34,ON=PE9;=/%R5P6VQ"/;JU-RX_VR?9ES!M7V9.8FJ'WW/(]DM/[2]2TG T!=##
M@K4U> 8TMJ%?99ZOV GC:44@SBU>D=%>':5G-22N8D4^*%^1[+BX#+QI5<3?:XOU^&1OANY>KH5P $*Q0I^5URZ8
M#"S%<3B;M3H^_#3M)J.K!(Q)*Q;JV-KV7ONI]GH&;1;K=C*MVSX>5[MFWK'Z
M+.W)S%,6ZE^LDL6]T?2MD.FC&XMJ33(S6J=
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M:%);$P4%\BN< )?).@^8N%U8M^U$#57>\\>Z-Q I -ON
M+[SEB8%#4'_7!KP(\!R[3A"?)U%,40JC+X@L0F?UA-VM^Z>Z>[G:08>^MRN:
MC69?H.NRHR6B&@'A9Z9CP<6+&DE KPE9P/YL7J E?#^H^5+SQ>"YP]-
MI/("68ZZKW474 IB>OS]@3U4TFIWZ!D%";JBA_ E5;#3"W*%$;A\=9*"JL222;&^3U8K'Z,0J!O;2&A&MCPT7,KKOC;(\$/H
M!)'CIB$N9^OROT E'$)5MQK-!4"!K'>2,JV#6'D@!;JT3,:\&I4IS-A*!OZ0
M%<5ADH:  15-S9>ZKPLA\1(69Q1X>>/2""X +43,L#\+\W&AZU[_O6[+$0=X
MF2SA^F+G0]V:G 4RPIG<^LP$B^"SA']DK  K]/Y)#[::3=6C&*M2!G3#AA9,
M!=ZA%0F9&UWF+;V9QJ"1R%TSJRV3JG3M+'Z%-[/M2*TF&<'#?579[D)1?7BV
M]GF^[G DC2>UQ2_QQC==OWZSD:@13P3;7"5G2A<+JT]4$5\[email protected]=N;SL7X'W=WMD?
M;,1=PL7= &9E?]M;A:WE(8,(/+,8C9M[$1JP\Z&,0S9I0 W&S,X+Z[;>^V0C
MVL)/UJW [;ZS%\"=6-O#0#APH6S@M,19<,B45\+=%\B,[>RZ0)RMO7QD);XM
MT4LE<%JBJPJ,WEGK\.P.4"/-P7,<'VNO;'!\2I&-')_).NFKPWI$MQ;+\-[:
M;=P_P+CL7*T)D.886FO!*,%0.F2>MQJSMIJ\4B&52*HH(/YDK0="*<3M&3D%
MFI^M/=S4:82:M*RBUGQ53H:@G0ZA87CV"M)P.-7)[%3RC,*0)#E^L^
MA0[_-R?P5ICJ,&C<=/7#*69[BME6FJQ(@N\ R:C]3(C%"+EO%N3YK9O5"K_MID(WO)Q )?0%B*ZV6>E3G;'AHII"Q%C8>?5
MPZ%'"'DCL2D.,ZC"JTNTNTB=!.'$'8=KB\;!\UVJ6IU5G8$KY5Q4OX8\8S"1V+Z.>*<+)1A#A89!W'LI";]!^W6_$=XK:Z)VRG%[@$+F4W7+/MO2T2KL3?H\H
MDZG6^@],U=?\ ;E/ ?')0KPDJ.IA]4U[MLO!.0JI5@[N5\C%\[76N0/&UJT^
M*$N4(8D=N?LE=*4NT)S:4&_@
M322@&_ KNXC&A*78>%DHF@L,U6FAH+O(^=\3'*^_HOB)>*P=)SW;$$N?@TJC#"%T,0>6&IZC:.[3V%NT4HT*-SY4C.C#SAF$%X''G[&7N+X?^#X
M*4T'8+EM_(%D<,EP.P:1-3Q4J<0T$!CNIP9$ZG:2TE^(M^_Y8NV)J.Z+ 
MQ2CJUQ<12'C83&\9# A@$4<0Y".Z)TCGYAU!>$^[WFN#J$MACR#@1_9\),TG
M^@A"@B3V9S]S;@2Q,4KL:B)^3>#!6=8&T@C>N4CWY9"#96U4C;KK8CZ"X
M8Y=?I!VF:C3;D:URU>W_:H:J&K5EK14GL?V$G+(CJ $'\7639H_\"$(#@4BU
M/Y^,H&R;)%[B[V:\!I*UT99]9*[ZBLH!&Z$AU@J8P,LY+U,TG06ELZ K?H(7
M'[+6#2(K#+/2P$Z.
ML7++NRXMX$6@W!3U6]1S.IRL[DJ&SDXH-R\B-NW=:GH.+(:?UQ&;CO9&+$$I
M(!Q1 V9E;2K4KV_99![I5/_M?P!02P$"% ,4    " "RA;!(O(FGR&^B  #4
MK@D $0              @ $     ;6QSH@  ;6QS&UL4$L! A0#%     @ 
MLH6P2*31/?G7)@  I:," !4              ( !K;X  &UL&UL4$L%!@     &  8 B@$  )YE 0    $!
 
end